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The genetic causes of intellectual disability (ID) and autism spectrum disorder 
(ASD) are frequently associated with mutations in genes that encode synaptic 
proteins. A recent screen of ID patients has revealed that approximately 4% of 
individuals carry spontaneous autosomal-dominant de novo mutations in the 
SYNGAP1 gene. This gene encodes the synaptic GTPase activating protein 
(SYNGAP) a known regulator of Ras signalling. Investigations into the pathological 
consequences of Syngap1 haploinsufficiency (Syngap+/−) in mice have reported 
abnormalities in behaviour, synaptic plasticity and dendritic spine development. 
These are analogous to findings from the mouse model of fragile X syndrome (FXS; 
Fmr1-/y), the most common inherited form of ID.  
 
One of the prominent phenotypes reported in the mouse model of FXS is that a form 
of hippocampal long-term depression (LTD) mediated by the activation of Group 1 
(Gp1) metabotropic glutamate (mGlu) receptors is enhanced and independent of new 
protein synthesis (Huber et al. 2002; Nosyreva et al. 2006). The cause of these 
synaptic plasticity deficits together with other cognitive abnormalities observed in 
FXS are thought to arise, in part, from excessive protein synthesis, the consequence 
of altered mGlu5 receptor signalling via the Ras-ERK1/2 signalling pathway. 
Enhanced protein synthesis rates in Fmr1-/y mice can be corrected by either inhibiting 
mGlu5 receptors or reducing Ras and subsequent ERK1/2 activity (Osterweil et al. 
2013). 
 
In this thesis mGluR-dependent LTD was examined at Schaffer 
collateral/commissural inputs to CA1 pyramidal neurones in hippocampal slices 
obtained from Fmr1-/y, Syngap+/− and Fmr1-/ySyngap+/− double mutant mice. 
Extracellular field recordings reveal that acute application of the Gp1 mGluR agonist 
dihydroxyphenylglycine (DHPG) induces a form of mGluR-dependent LTD that is 
enhanced and independent of new protein synthesis in CA1 of Fmr1-/y mice. In 
Syngap+/− mice, the magnitude of mGluR-dependent LTD is also significantly 
increased relative to WT littermates and insensitive to protein synthesis inhibitors. 
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Furthermore, in the Fmr1-/ySyngap+/− double mutant, Syngap haploinsufficiency 
occludes the increase in mGluR-dependent LTD caused by the loss of FMRP.  
 
In addition, metabolic labelling studies reveal basal protein synthesis rates to be 
modestly enhanced in the hippocampus of Fmr1-/y mice compared to WT mice. 
Importantly this phenotype translates to the rat model of FXS. In Syngap+/- 
hippocampal slices, basal protein synthesis rates are also significantly elevated 
compared to WT counterparts. Interestingly, elevated basal protein synthesis rates in 
Syngap+/- mice could be corrected in the hippocampus by similarly pharmacological 
strategies employed in Fmr1-/y mice. 
  
The comparable neuropathophysiology we observe between Syngap+/− and Fmr1-/y 
mice suggests that SYNGAP and fragile X mental retardation protein (FMRP) may 
converge on similar biochemical pathways raising the intriguing possibility that 
therapeutic strategies used in the treatment of FXS may also be of benefit in treating 
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_______ Chapter 1_______ 
         Introduction 
 
ntellectual disability (ID), formerly known as mental retardation, is a 
complex and debilitating neurodevelopmental disorder characterised by 
impairments in general mental ability. The prevalence of ID in developed 
countries is estimated at 1-3% of the general population and represents the most 
frequent cause of severe handicap in children (Roeleveld & Zielhuis 1997; Chelly et 
al. 2006). In ICD-10 (International statistical Classification of Disease and related 
health problems-10), the World Health Organisation (WHO) defines ID as ‘arrested 
or incomplete development of the mind especially characterized by impairment of 
skills manifested during the development period, which contribute to the overall 
levels of intelligence such as cognition, language, motor and social abilities’ (WHO 
1992).    
I 
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1.1.1 Diagnosis of Intellectual Disability 
The diagnosis of ID is historically based on standardized intelligence testing and is 
considered as having an intellectual quotient (IQ) two standard deviations or more 
below the general population, which is equivalent to an IQ below 70. The severity of 
ID ranges from mild to severe and is subdivided by IQ score (Table 1.1). As all 
patients with ID display impaired adaptive behaviour, the American Psychiatric 
Association has recently revised their criteria for diagnosis of ID in DSM-5 
(Diagnostic and Statistical Manual of Mental Disorders). The severity of ID is now 
based on adaptive functioning rather than IQ and is assessed in three domains: 
conceptual, social and practical skills. This revision means the severity of ID is now 
based on how impairments in mental abilities affect functioning needed for everyday 
life. 
 
1.1.2 Symptoms of Intellectual Disability 
The onset of symptoms in ID patients begins early on in childhood and can occur 
with or without any other mental or physical disorders. However the core symptoms 
of ID are rarely observed in isolation and usually coexist with other psychiatric and 
medical conditions, including autism spectrum disorders (ASD), language disorders, 
epilepsy, motor control problems, attention-deficit, hyperactivity, anxiety, sleep 
disorders, gastrointestinal problems and abnormal responses to sensory stimuli 
(Huguet et al. 2013).  In fact, the prevalence of other mental disorders is at least 3-4 
times greater in the ID population compared to the general population (WHO 1992). 
For example, the incidence of epilepsy is estimated to affect approximately 1% of the 
general population (van Blarikom et al. 2006), yet in the ID population the 
prevalence rate of epilepsy varies from ~16-50% . There also appears to be variable 
penetrance and expressivity, with symptoms spanning a wide spectrum of severity. 
This has been attributed to interactions of other genes, environmental causes and 
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Table 1.1 Classification of intellectual disability. A diagnosis of intellectual disability (ID) is given 
when intellectual quotient (IQ) is  < 70, as determined from standardised intelligence tests. ID is 
subdivided in to severity classes based on IQ, ranging from mild to profound. 
 
1.1.3 Treatment of Intellectual Disability  
Although ID is highly prevalent within the population it is very difficult to treat at 
present due to the lack of disease altering therapies. Current strategies for treatment 
of ID depend on the use of a wide range of different drugs, such as antidepressants, 
anxiolytics and antipsychotics. These central nervous system (CNS) active 
compounds treat very specific behavioural problems rather than the core symptoms 
of ID patients and are administrated if the patient presents with comorbidities, such 
as epilepsy, anxiety, attention deficit and mood disorders (Berry-Kravis 2014). Thus 
the development of pharmacotherapies that modify the underlying cause of the 








Figure 1.1 Genetic and environmental causes of intellectual disability. The causes of intellectual 
disability (ID) are highly heterogeneous and include environmental, chromosomal and single gene 
mutations. Monogenic causes of ID are further divided in to syndromic and nonsyndromic forms of 
ID. Syndromic causes of ID are characterised by physical, metabolic and biological features and 
include Tuberous Sclerosis, Fragile X syndrome and Neurofibromatosis 1, which are caused by 
mutations in the TSC1/2, FMR1 and NF1 genes respectively. In contrast, the only clinical 
manifestation associated with non-syndromic causes of ID is cognitive dysfunction, examples of 
which include mutations in SYNGAP1 and NLG3 that encode the synaptic GTPase activating protein 
(SYNGAP) and NEUROLIGIN-3 that are crucial for normal synaptic functions.  
 
1.1.4 Causes of Intellectual Disability 
The causes of ID are highly heterogeneous and include both genetic and non-genetic 
factors (Figure 1.1). The latter of which are caused by environmental influences that 
act prenatally or during early infancy leading to brain damage and include: 
malnutrition over pregnancy, environmental neurotoxicity, premature birth, perinatal 
brain ischemia, fetal alcohol syndrome, pre- or post-natal infections (Chelly & 
Mandel 2001). Genetic causes of ID include chromosomal abnormalities 
(aneuploidies, micro deletion syndrome), and single-gene mutations (Chelly et al. 
2006). However an exact cause of ID has only been established in 50% of patients 
who present with moderate to severe ID and this will be far less in patients with 
milder forms of ID. Two monogenic causes of ID will be the focus of this thesis. 
 Syndromic  
(e.g. FMR1, TSC1/2 & NF1) 
      Non-Syndromic  
(e.g. SYNGAP1, NLG-3) 
Intellectual Disability  
Monogenic  Environmental	   Chromosomal	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1.1.5 Genetics of Intellectual Disability 
Over the past decade technological advances have enabled the identification of 
several hundred ID-related genes. For example, high-density microarrays have 
allowed the detection of copy number variants, whilst exome sequencing has led to 
the identification of single nucleotide mutations in ID patients. Inlow & Restifo 
(2004) estimated that there are around 282 human genes linked to ID, which since 
then is likely to have significantly increased. Genetic forms of ID can be subdivided 
in to two major categories: syndromic ID, characterised by the coexistence of 
clinical, radiological, metabolic and physical features (e.g. fragile X syndrome, 
tuberous sclerosis, Neurofibromatosis 1); and non-syndromic ID (NSID), where 
cognitive impairment is the only clinical manifestation of the disease (e.g. SYNGAP1 
haploinsufficiency).  
 
Epidemiological studies of ID patients have revealed a significant gender bias, with 
many more males affected with monogenic forms of ID than females (Leonard & 
Wen 2002). This has implied that a greater number of the genes influencing 
cognitive function are found on the X-chromosome compared to the autosomal 
chromosomes, where the distribution of ID genes correlates with relative gene 
composition (Inlow & Restifo 2004). Further investigation by Inlow & Restifo 
(2004) revealed that 16% of ID genes are located on the X-chromosome, showing a 
four-fold overrepresentation, considering only 4% of all known genes are located 
here. However, this could be due to X-linked mutations being easier to map and thus 
identify.  
 
The discovery of mutations in genes causing ID has led to the generation of 
genetically engineered animal models of the disorder. These models of ID 
recapitulate many of the behavioural, cognitive and physiological alterations reported 
in human patients. Furthermore they have allowed an in depth look at the 
pathophysiological mechanisms underlying the behavioural and cognitive 
abnormalities to this disorder in order to identify potential therapeutic targets. 
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1.1.6 ID genes encode proteins that belong to distinct functional networks  
The generation of mouse models of ID has revealed that ID-related genes encode 
proteins that fall in to distinct functional subclasses, such as chromatin-remodelling, 
transmembrane proteins, microtubule- and actin- associated proteins, transcription 
and translation proteins, regulators or effectors of Ras/Rho GTPase pathways, and 
synaptic plasticity proteins (Chelly et al. 2006). The loss or reduced expression of 
these proteins leads to defects in broad range of cellular functions that underlie 
intellectual performance and emotional behaviour associated with ID.  
 
The impact of altered signalling and synaptic function in the pathology of ID has 
been particularly emphasized by research into fragile X syndrome (FXS), the most 
common identifiable form of inherited ID that affects approximately 1 in 4000 males 
to 1 in 8000 females (Wijetunge et al. 2013). From investigations in the mouse 
model of FXS, it is now known that FMRP is an RNA-binding protein that functions 
to negatively regulate protein synthesis in the brain. It is now viewed that many 
symptoms associated with FXS arise from an increase in synaptic protein synthesis. 
Consequently this leads to abnormalities in synaptogenesis and synaptic plasticity 
during postnatal development, processes that underlie the cognitive impairments 
associated with FXS.  
 
Furthermore, these investigations have identified key pathophysiological 
mechanisms generating several therapeutic hypotheses and the development of 
targeted pharmacotherapies. Thus, the mouse model of FXS has become one of the 
most advanced animal models of ID. Here this thesis will explore the behavioural, 
cellular and molecular abnormalities that have so far been reported in FXS and detail 
how these investigations have not only advanced our knowledge about FXS but also 
guided our own investigations in to understanding the pathophysiology of a second 




1.2 Fragile X syndrome 
The term FXS was first coined by Moore et al. (1982) who identified a fragile site on 
the X chromosome of patients with mental retardation. Indications that the gene 
mutation responsible for FXS was X-linked was first described by Martin & Bell in 
1943 who observed that this type of ID was transmitted in an X-linked fashion, 
which explained why more males than females were affected by the disorder (Martin 
& Bell 1943).  
 
However it wasn’t until 1991 that the FXS gene, designated the FMR1 gene, was 
first identified at the fragile site at map position Xq27.3 on the long arm of the X 
chromosome (Verkerk et al. 1991). From Southern blot analysis it was found that the 
40 kb Fmr1 DNA fragment on the X chromosome exhibited significantly increased 
size variation, indicating that the FXS mutation may result from the presence of an 
insertion or amplification event (Verkerk et al. 1991). This coincided with the 
identification of an unusual number of CGG repeats, which exhibited length 
variation in the fragile X gene, and the presence of a hypermethylated CpG island. 
This led Verkerk et al. (1991) to speculate that the CGG repeat may influence local 
methylation and the expansion of this repeat may be responsible for the abnormal 
methylation status of the fragile X gene. 
 
1.2.1 Genetics of FXS 
Since these initial observations it is now known that the vast majority of FXS 
patients have a significant CGG expansion mutation of more than 200 units (Figure 
1.2). This expansion mutation lies in the promoter region of the FMR1 gene leading 
to hypermethylation of a near CpG site (Oberlé et al. 1991; Sutcliffe et al. 1992; 
Coffee et al. 1999). This results in little or no production of corresponding messenger 
RNA (mRNA) and consequently the loss or significant reduction of the fragile X 
mental retardation protein (FMRP), a RNA binding protein (Ashley et al. 1993). The 
severity of FXS appears to be negatively correlated with the level of FMRP 
expression (Tassone et al. 1999).  
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In unaffected individuals, the CGG repeat is polymorphic ranging from 5 to 54 
repeats (Fu et al. 1991). However, once the number of CGG units expands into the 
range of 55 to 200 units, individuals are said to carry the premutation of FXS, which 
is linked to fragile X-associated tremor/ataxia syndrome and fragile X-associated 
primary ovarian insufficiency (Willemsen et al. 2011). The premutation leads to a 
reduction in FMRP via an unusual mechanism that targets translation rather than 
transcription, leading to a sparse amount of FMRP even though there is an 
abundance of mRNA (Tassone et al. 2000). The instability of the CGG repeat 
expansion means that it can increase in size from one generation to the next, 
increasing in penetrance, making it more likely that it will progress from a 
premutation to the full mutation with successive generations (Sherman et al. 1985).  
 
Although the majority of FXS cases are the result of a mutant trinucleotide 
expansion of 200 units or above, there are reports of individuals carrying rare point 
mutations (I304N and R138Q) in the FMR1 gene that result in a severe FXS 
phenotype (De Boulle et al. 1993; Collins et al. 2010). Examination of the I304N 
mutation revealed that there is a usual number of CGG repeats along with a normal 
methylation status (De Boulle et al. 1993). However the mutation is located in the 
mRNA binding domain, disrupting FMRPs ability to bind and regulate mRNA 
translation at the polyribosome (Zang et al. 2009). This indicates that the binding of 











Figure 1.2 CCG expansions in the Fmr1 gene. (A) The CGG repeat is polymorphic and can expand 
from 5 to 54 repeats in the FMR1 allele leading to normal transcription and translation of FMRP. (B) 
Premutation alleles are caused by 55 or 200 CGG repeats that lead to excessive transcription of FMR1 
messenger RNA (mRNA) leading to fragile X associated tremor/ataxia syndrome (FXTAS) and 
fragile X-related primary ovarian insufficiency (FXPOI). (C) The full mutation is caused by more 
than 200 CGG repeats leading to transcriptional silencing and the loss of the fragile X mental 





1.2.2 Phenotypes reported in human patients with FXS 
The cognitive, behavioural and morphological symptoms of FXS are highly variable, 
but share a defining feature of ID. The severity of ID ranges from moderate to severe 
and IQ is found to decline further with age (Ashley et al. 1993; Bernardet & Crusio 
2006). Affected individuals usually present with language delay and can have 
additional behavioural symptoms that include hyperactivity, social anxiety, 
impulsivity, attention deficit hyperactivity disorder and autistic-like behaviours, such 
as shyness, poor eye contact and hypersensitivity to sensory stimuli (Hagerman et al. 
2009). The predominant physical feature observed in FXS is macroorchidism 
(observed in >80% of FXS males) with a variable presence of an elongated face, 
large and prominent ears, macrocephaly, prominent jaw and forehead, high-arched 
palate, and loose connective tissue leading to hyperextensible joints, flat feet and soft 
skin (Hagerman 2002; Hagerman et al. 2009). Additional medical problems, include 
childhood seizures, sleep disorders, strabismus, a susceptibility to ear and sinus 
infections and gastrointestinal problems (Hagerman & Hagerman 2002; Kravis & 
Potanos 2004). For female carriers of the full mutation, symptoms tend to be more 
variable and milder due the existence of one functional copy of the Fmr1 allele on 
the other X chromosome. This yields some FMRP leading to a somewhat moderating 
effect (Mazzocco 2000). 
1.2.3 FXS and Autism 
FXS was one of the first genetic causes of ID to be linked to ASD, which has highly 
variable behavioural manifestations that differ in severity. FXS remains the most 
prevalent inherited cause of this disorder, however it only accounts for ~4 % of all 
ASD cases (Wang et al. 2010), with a further 200 genes linked to autism (Berg & 
Geschwind 2012). ASD is also a neurodevelopmental disorder characterised by a 
triad of deficits including impaired social interaction and communication as well as 
restrictive and repetitive behaviours, and affects approximately 1% of the general 
population (Zoghbi & Bear 2012; Belmonte & Bourgeron 2006). It is estimated that 
the prevalence of autism in FXS individuals is between 18-36% (Rogers et al. 2001; 
Kaufmann et al. 2004). However, a large majority of FXS males (~60-90%) display 
the core behaviours that are commonly observed in individuals with ASD, this 
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includes avoidant eye gaze, hand flapping, repetitive behaviours and abnormal 
speech patterns (Harris et al. 2008). Approximately one-third of male patients with 
FXS meet the criteria for autism, and two-thirds for ASD (Wang et al. 2010). 
Interestingly, several mRNA targets of FMRP encode proteins that are associated 
with autism, such as postsynaptic density protein 95 (PSD-95), SH3 and multiple 
ankyrin repeat domains 3 (SHANK3), phosphatase and tensin homolog (PTEN), 
mitogen activated protein kinase 1 (MAPK1), synaptic GTPase activating protein 
(SYNGAP), NEUROXIN1 and NEUROLIGINs. This suggests there is a great 
degree of molecular overlap between ID and Autism and perhaps autism risk genes 
converge on a common pathophysiological axis (Wang et al. 2010). 
1.2.4 FXS and Epilepsy 
Within the FXS population there is also high incidence of epilepsy (10-20%), which 
appears to greater in male FXS patients than females (Berry-Kravis 2002). Previous 
reports in cohorts of male FXS patients carrying the full mutation describe a variety 
of seizure types (Musumeci et al. 1999; Musumeci et al. 1991; Berry-Kravis 2002). 
The most commonly reported in FXS cases is complex partial seizures, however 
generalized clonic-tonic and simple partial seizures are also frequently observed 
(Musumeci et al. 1999; Berry-Kravis 2002). These FXS patients present with 
abnormal epileptiform electroencephalography (EEG) patterns resembling 
centrotemporal spikes that are commonly associated with benign focal epilepsy 
(Musumeci et al. 1991; Musumeci et al. 1999; Berry-Kravis 2002). These abnormal 
spiking patterns begin during childhood and are considered benign, as they tend to 
disappear by adolescence. However if they do persist then seizure frequency tends to 
be low, isolated to a specific locus within the brain, and are well controlled by 
anticonvulsant medication (Musumeci et al. 1999). Whether or not the epileptiform 
discharges observed in FXS patients exacerbate the overall behavioural and cognitive 
impairments remains to be determined. Interestingly, there are reports of FXS 
patients without a co-diagnosis of epilepsy presenting with abnormal EEG patterns 
indicating that they may also be at high risk of developing seizures (Berry-Kravis 
2002). 
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1.2.5 Structure of the Fragile X Mental Retardation Protein 
Shortly after the Fmr1 gene was cloned, it was revealed that the protein product 
FMRP contained three RNA binding domains (Siomi et al. 1993). FMRP itself can 
be structurally divided into three main regions: an N-terminal region, containing two 
Tudor domains that function as a nuclear localization signal (NLS); a central region, 
which contains two K homology domains and a nuclear export signal (NES); and a 
C-terminal region, which contains the RGG RNA binding domains (Bagni & Oostra 
2013; Figure 1.3). The NLS and NES enable FMRP to shuttle between the nucleus 
and cytoplasmic space whilst the KH and RGG RNA binding domains contribute to 
FMRPs role as a regulator of mRNA translation through binding non-coding RNA 
structures, which include G-quartets and kissing complexes (Brown et al. 2001; 
Darnell et al. 2005)..  
1.2.6 FMRP in brain 
FMRP is widely expressed throughout the body with protein expression levels 
peaking at the end of the first postnatal week before gradually declining (Wang et al. 
2004). FMRP is abundantly expressed in the testes and mammalian brain where it is 
expressed at synapses that use the excitatory neurotransmitter glutamate (Devys et al. 
1993). Functionally FMRP belongs to the family of RNA bindings proteins (RBP), 
which shuttle between the nucleocytoplasmic space binding and transporting mRNA 
(Feng et al. 1997; Eberhart et al. 1996). There are several in vitro studies that suggest 
FMRP may play a role in transporting mRNA as it has been observed in RNA 
granules which transport mRNA from the soma to the dendrites (De Diego Otero et 
al. 2002). However, FMRP does not appear imperative for the localisation of the 
















Figure 1.3 FMRP and its functional domains. The N-terminal contains two Tudor domains (TD) 
and a Nuclear localisation signal (NLS) whilst the central region contains two K homology domains 
(KH1 and KH2), and a nuclear export signal (NES) and the C-terminal containing an RGG box, which 




At the synapse FMRP is found in complexes with its RNA targets on actively 
translating polyribosomes, suggesting it may play a role in regulating local protein 
synthesis at the synapse (Zalfa et al. 2007; Eberhart et al. 1996; Feng et al. 1997). 
Although FMRP is generally considered to negatively repress translation of its 
mRNA targets, there is evidence in regards to PSD-95 that FMRP modulates mRNA 
stability in the hippocampus (Zalfa et al. 2007). This may infer that FMRP has cell-
specific dual functionality in modulating large numbers of proteins. Co-
immunoprecipitation (Co-IP) studies have revealed that FMRP is associated with 
~4% of all mRNA in the brain, many of which are involved in neuronal function 
(Darnell et al. 2011). These include three of the most prevalent proteins found at the 
postsynaptic density (PSD): PSD-95, an adaptor protein associated with the N-
methyl-D-aspartate (NMDA) receptor; Ca2+/calmodulin-protein kinase II (CaMKII), 
which binds Ca2+ and is crucial for synaptic plasticity; and SynGAP, a GTPase 




The activity of FMRP at the synapse is controlled by its phosphorylation status, 
which is governed by two enzymes whose activity is dependent on Group 1 (Gp1) 
metabotropic glutamate (mGlu1/5) receptor stimulation. FMRP can bind to its mRNA 
targets once a conserved serine residue is phosphorylated by the ribosomal S6 kinase 
(S6K) 1 (Narayanan et al. 2007; Narayanan et al. 2008). The serine/threonine-protein 
phosphatase 2A (PP2A) is responsible for removing this phosphate group leading to 
the movement of FMRP from stalled to active polyribosomes repressing mRNA 
translation. The rapid dephosphorylation of FMRP in response to mGlu1/5 receptor 
activation enables translation to proceed, which is shortly curbed by S6K1 
phosphorylating FMRP once again. Thus, FMRP appears to form part of an 
intracellular signalling cascade that links mGlu1/5 receptor activation to new protein 
synthesis at the synapse. 
 
 
1.2.7 Fmr1 KO mouse model 
The generation of the Fmr1 knockout (KO) mouse in 1994 has been a valuable 
neurobiological tool in assessing the deficits associated with the loss of FMRP 
(Consortium 1994). In the ‘conventional’ mouse model of FXS, the Fmr1 gene is 
knocked out by the insertion of a neomycin cassette in to the promoter region of the 
Fmr1 gene. This is opposed to the hypermethylation and transcriptional silencing of 
this region that is observed in FXS patients. Nevertheless in both cases FMRP, the 
protein product of the Fmr1 gene, is lost. Thus, both human patients and the Fmr1 
KO mouse progress through development without any functional FMRP. There are 
several other animal models of FXS, including the conditional KO and a mutant 
carrying the point mutation at I340N (Mientjes et al. 2006; Zang et al. 2009). 
However the majority of studies have utilised the ‘conventional’ KO model, which 
has been shown to reproduce many of the neuropathological abnormalities observed 




1.2.8 Behavioural deficits associated with the mouse model of FXS  
The generation of the mouse model of FXS has enabled the examination of a large 
range of behavioural traits, which have revealed correlations between the human and 
mouse condition validating the Fmr1 KO mouse as model of FXS.  However, it 
appears that many of behavioural deficits in the Fmr1 KO mouse are more moderate 
than those observed in human patients and are not always consistently reported, 
which could be the result of strain variability from the effect of modifier genes. Also 
handling and housing, prior to testing may have adverse effects on the outcome of 
test. The availability of the Fmr1 KO rat will now allow a more extensive set of 
behavioural tasks to be examined (Hamilton et al. 2014). 
 
In terms of locomotive activity, Fmr1 KO mice appear to have increased exploratory 
activity in the open field with a reduced tendency to remain close to peripheral zones 
(Mineur et al. 2002; Spencer et al. 2011; Qin et al. 2011). This suggests that in 
comparison to wild type (WT) controls, Fmr1 KO mice are more hyperactive and 
have abnormal anxiety levels. There appears to be subtle impairments in the Morris 
water maze when the platform is hidden, with Fmr1 KO exhibiting increased escape 
latencies when the position of the platform is moved after learning the initial 
position, as well a reduced rate of learning trial to trial (Consortium 1994; Kooy et 
al. 1996). This suggests that Fmr1 KO mice may have less flexibility in learning than 
WT mice. In contrast, evidence from the radial maze appears to show that working 
memory is intact in the Fmr1 KO mice (Mineur et al. 2002). Inhibitory avoidance 
(IA), a hippocampus-dependent memory, was similar between Fmr1 KO and WT 
littermates. However when IA extinction (IAE) was examined, which requires new 
protein synthesis, they observed that IAE is exaggerated in the Fmr1 KO mouse 
(Dölen et al. 2007). 
 
The majority of sensory stimuli responses in Fmr1 KO have been found to be 
impaired, with the exception of nociception in response to heat (Bernardet & Crusio 
2006). It has been shown in vivo that Fmr1 KO mice have increased susceptibility to 
both partial and generalized seizures (Osterweil et al. 2010; Chen & Toth 2001; Qiu 
et al. 2009). Qiu et al. (2009) investigated seizure susceptibility in the limbic system 
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of Fmr1 KO mice, using amygdala kindling, which mimics epileptogenesis induced 
at a specific locus (i.e. partial seizure). In Fmr1 KO mice the rate of seizure 
progression is accelerated compared to WT littermates (Wang et al. 2013). It is also 
consistently reported that Fmr1 KO mice exhibit an increased susceptibility to 
audiogenic seizures (AGS), upon exposure to an >130 dB alarm sound (Osterweil et 
al. 2010; Yan et al. 2004; Musumeci et al. 2000). There also appear to be an 
increased startle response in Fmr1 KO mice upon exposure to low frequency 
auditory stimuli (Nielsen et al. 2002). These findings along with altered responses to 
IAE (Dölen et al. 2007), highlight the similarities in hypersensory responses 
observed in Fmr1 KO mice and FXS patients (Hagerman 2002).  
 
Fmr1 KO mice also exhibit greater prepulse inhibition indicating alterations in 
sensorimotor processing (Frankland et al. 2004). Furthermore deficits in social 
interaction have been reported in the Fmr1 KO mice exhibiting increased social 
anxiety in the mirror chamber test, reduced social dominance in the tube test to 
unfamiliar test mates (Spencer et al. 2011), and deficits in ultrasonic vocalizations in 




1.2.9 Immature spine phenotype observed in FXS patients and Fmr1 KO mice 
One of the hallmark phenotypes consistently reported in the autopsy of FXS patient 
is the overabundance of dendritic spines with a thin, tortuous, and immature 
morphology (Fiala et al. 1998; Hinton et al. 1991; Wisniewski et al. 1991; Rudelli et 
al. 1985). This abnormal spine phenotype is observed in various cortical regions, 
which were qualitatively analysed by rapid Golgi staining. Only Irwin et al. (2001) 
observed an increase in spine density in the visual and temporal cortices of the 
fragile X human brain, which was isolated to the most distal dendritic segments of 
layer 5 pyramidal neurones (Figure 1.4). These findings indicate: firstly, that there 
appears to be a failure in synapse maturation during the development of the fragile X 
brain that persists throughout the entire lifespan; and secondly, that synaptic pruning 
may be aberrant leading to an increase in spine density in the Fmr1 KO brain. 
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Abnormalities in spine morphology are recapitulated in the adult neocortex of Fmr1 
KO mice (Comery et al. 1997; Galvez & Greenough 2005; McKinney et al. 2005; 
Dölen et al. 2007; Hayashi et al. 2007) as well as in other brain regions including the 
hippocampus  and cerebellum (Grossman et al. 2006). This suggests that FMRP may 
play a role in regulating spinogenesis in multiple brain regions. FMRP is localised to 
dendrites and spines regulating local protein synthesis upon mGlu1/5 receptor 
activation, which is important for spine development (Bagni & Greenough 2005; 
Grossman et al. 2006). Stimulation of mGlu1/5 receptors can induce dendritic spine 
elongation in vitro, reminiscent of the phenotype observed in the neocortex of Fmr1 
KO mice (de Vrij et al. 2008; Vanderklish & Edelman 2002). Furthermore, 
abnormalities in dendritic spine morphology can be corrected by either the genetic 
reduction of mGlu5 receptor or negative allosteric modulator (NAM)s of this receptor 
(de Vrij et al. 2008; Yan et al. 2005). Thus, in the Fmr1 KO brain where FMRP is 
absent exaggerated protein synthesis rates are thought to contribute to excessive 
spine growth and abnormal morphology. 
 
In the young adult hippocampus it has been observed that Fmr1 KO CA1 neurons 
possess more stubby and mushroom-like spines and fewer thin dendritic spines with 
no change in the overall spine density when compared to WT controls (Grossman et 
al. 2006). In the more mature hippocampus of Fmr1 KO mice, Levanga et al. (2011) 
observed a subtle increase in the number of filopodia-like spines when compared to 
WT neurones. This phenotype appears to be region specific as no genotype 



















Figure 1.4 Increased spine density in the Fragile X brain.  Golgi staining of distal dendrites of 
layer 5 pyramidal neurones reveal typical spine morphologies observed in (A) human FXS patient 
where an overabundance of dendritic spines are observed and (B) an unaffected individual. Figure 











Unlike the neocortex where dendritic arborisations are predominantly covered in thin 
tortuous spines during early development which progress in to more stubby 
mushroom shaped spines by adulthood, there is evidence to suggest the opposite is 
observed in the hippocampus. Initially a high abundance of mushroom-like spines 
are observed in the early stages of developments, which shift towards a greater 
number of thinner spines in adulthood (Harris et al. 1992). Thus, in both the 
hippocampus and neocortex there appears to be immature dendritic spine 
morphology in Fmr1 KO mice, which in the neocortex appears to persist into 
adulthood.  
 
Recently dendritic spines were examined in Fmr1 KO mice at the nanoscale using 
stimulated emission depletion (STED) microscopy. STED microscopy has a spatial 
resolution of ~50 nm, compared to 250 and 400 nm with confocal and two-photon 
microscopy, respectively. This has enabled a more accurate assessment of dendritic 
spines, such as head width, neck length and neck width, which are too small to be 
reliably measured by diffraction-limited microscopy techniques. This study revealed 
that at P14 CAl pyramidal neurones in Fmr1 KO hippocampal slices have fewer 
dendritic spines with wider heads whilst at P37 there were a greater number of spines 
with larger heads and shorter, narrower necks compared to WT controls indicating a 





1.2.10 Synaptic plasticity in the hippocampus of Fmr1 KO mouse  
The most prominent phenotype observed in FXS patients is impaired cognitive 
function. In the mammalian brain it is believed that activity-dependent remodelling 
of synaptic connections driven by plasticity mechanisms underlies key cognitive 
processes, such as learning and memory. Many long lasting changes in synaptic 
efficacy require the rapid synthesis of new proteins, suggesting that the translation of 
pre-existing mRNA is fundamental for the expression of certain forms of synaptic 
plasticity. 
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In response to synaptic activity, mRNAs are trafficked to dendrites where they are 
locally translated (Steward & Levy 1982). Interesting, one of the proteins 
synthesized in response to synaptic activation is FMRP which is thought to influence 
synaptic plasticity by functioning as a key regulator of mRNA translation (Weiler & 
Greenough 1993). Thus in the FXS brain where FMRP is absent, there is no longer 
the ability to modulate translation in response to synaptic activity, which has 
detrimental effects on long-lasting forms of synaptic plasticity. 
 
Indeed, investigations into the cellular mechanisms underlying learning and memory 
deficits in Fmr1 KO mice have revealed dysfunction in certain forms of synaptic 
plasticity. Long-term depression (LTD) mediated by Gp1 mGlu receptors (mGluR-
dependent LTD) appears to be enhanced in the hippocampus of Fmr1 KO mice 
(Huber et al. 2002; Zhang et al. 2009; Hou et al. 2006). Whilst investigations in to 
long-term plasticity (LTP) have revealed that certain forms of NMDA receptor 
dependent forms of LTP (NMDAR-dependent LTP) are impaired (Hu et al. 2008; 
Lauterborn et al. 2007; Shang et al. 2009). In contrast, there were no differences 
observed in NMDA receptor dependent forms of LTD (NMDAR-dependent LTD; 
Huber et al. 2002). NMDAR- and mGluR- dependent forms of LTD are 
mechanistically distinct from one another suggesting that FMRP may be specifically 
regulating the translation of proteins for the expression mGluR-dependent forms of 
synaptic plasticity.  
mGluR-dependent LTD is enhanced in Hippocampus of Fmr1 KO mice  
In Fmr1 KO mice, induction of mGluR-dependent LTD leads to an exaggerated level 
of synaptic depression at CA1 synapses. This finding was initially reported by Huber 
et al. (2002) who found that upon acute application of the Gp1 agonist (R, S)-3,5-
Dihydroxyphenlglycine (DHPG) there was a modest enhancement of mGluR-
dependent LTD by ~10-15% in the hippocampus of Fmr1 KO mice. This form of 
synaptic plasticity is mediated by a rapid endocytosis and persistent decrease in the 
surface expression of postsynaptic α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors (Snyder et al. 2001; Moult et al. 2006; 
Zhang et al. 2008). In Fmr1 KO mice, enhanced mGluR-dependent LTD results from 
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excessive AMPA receptor internalisation in response to Gp1 mGlu1/5 receptor 
activation (Nakamoto et al. 2007).  
Certain forms of LTP are impaired in the hippocampus the Fmr1 KO mouse   
In the hippocampus investigations in to LTP mechanisms have yielded conflicting 
findings. Initially, examination of late phase LTP (L-LTP) by high frequency 
stimulation (HFS) revealed no differences in the magnitude of L-LTP between Fmr1 
KO and WT mice (Godfraind et al. 1996; Larson et al. 2005; Li et al. 2002; 
Auerbach & Bear 2010; Zhang et al. 2009). However, others find NMDAR-
dependent LTP to be reduced in CA1 (Hu et al. 2008; Lauterborn et al. 2007; Shang 
et al. 2009). These discrepancies may be due to differences in stimulation protocols, 
which can induce distinct forms of LTP (Abraham & Williams 2003). For example, 
although both tetanic stimulation (Godfraind et al. 1996; Li et al. 2002) and 
conventional theta burst (Larson et al. 2005) produce normal LTP in Fmr1 KO mice, 
changing the threshold levels of theta burst afferent stimulation (from 15 bursts of 4 
pulses at 100 Hz to 5 Hz at 30 s intervals) revealed altered LTP in the Fmr1 KO mice 
(Lauterborn et al. 2007).  
 
L-LTP induced by either tetanic or conventional theta burst protocols requires both 
somatic transcription and translation to be sustained. In contrast, L-LTP induced by 
the nonconventional theta burst protocol (5 Hz, 30 s) is solely dependent on local 
dendritic mRNA translation (Huang & Kandel 2005). This indicates that FMRP may 
not regulating protein synthesis in the cell soma. Instead FMRP may only regulate 
local mRNA translation at synaptic sites. In addition, further examination of this 
nonconventional form of L-LTP revealed that the lack of LTP in Fmr1 KO mice was 
accompanied by a failure in trafficking of GluA1-containing AMPA receptors and 
Ras-dependent activation of phosphoinositide 3-kinase (PI3K), a pathway implicated 
in GluA1 insertion and LTP (Zhu et al. 2002; Qin et al. 2005b). This could indicate 
an uncoupling of the PI3K signalling from glutamatergic synaptic activation, which 
prevents GluA1 receptor insertion and an increase in synaptic strength. 
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Stimulus-induced local protein synthesis is lost in the Fmr1 KO mouse  
At individual synapses, glutamate release from the presynaptic terminus is believed 
to stimulate local protein synthesis. This process occurs independently of 
transcription and involves the translation of pre-existing dendritically localized 
mRNA, which is crucial for the transition from the early to late phases of certain 
forms of LTP and LTD (Huber et al. 2000; Huang & Kandel 2005). Evidence in 
support of local protein synthesis, rather than somatic protein synthesis, comes from 
the observation that mGluR-dependent LTD can be induced in the dendritic layer 
even when the somatic layer has been severed (Huber et al. 2000). 
 
The stable expression of mGluR-dependent LTD at CA1 synapses is reliant on newly 
synthesized proteins to maintain the persistent removal of AMPA receptors from the 
cell surface (Huber et al. 2000; Snyder et al. 2001). It is hypothesized that the 
activation of Gp1 mGlu receptors stimulates the synthesis of new proteins that 
participate in the regulation of AMPA receptor endocytosis and trafficking, thus are 
known as “LTD proteins”. If protein synthesis is blocked during mGluR-dependent 
LTD then AMPA receptor endocytosis will proceed as normal, but AMPA receptors 
will eventually recycle back to the cell surface (Snyder et al. 2001; Waung et al. 
2008). In the Fmr1 KO mouse where FMRP is absent, mGluR-dependent LTD is 
independent of new protein synthesis (Nosyreva & Huber 2006; Figure 1.5). This 
suggests that the proteins required for the maintenance of this form of LTD may 


















Figure 1.5 mGluR-dependent LTD is enhanced and independent of new protein synthesis in 
Fmr1 KO mice. Chemical induction of metabotropic glutamate receptor-dependent long-term 
depression (mGluR-dependent LTD) in the presence of the protein synthesis inhibitor anisomycin in 
CA1 of hippocampal slices from Fmr1 knockout (KO) and wild type (WT) controls. (A) In WT mice, 
anisomycin inhibits mGluR-dependent LTD induced by the Group 1 mGluR agonist R, S-
dihydroxyphenylglycine (DHPG; 100 µM; 5 min). (B) In Fmr1 KO mice mGluR-dependent LTD is 
insensitive to anisomycin. (C) Comparison of mGluR-dependent LTD in the presence of anisomycin 




1.2.11 Basal protein synthesis is elevated in the Fmr1 KO mouse 
In the Fmr1 KO brain direct measurements of basal protein synthesis both in vitro 
(Dölen et al. 2007; Osterweil et al. 2010) and in vivo (Qin et al. 2005a) reveal an 
increase in translational rates in the hippocampus and several other brain regions. 
Furthermore the activation of Gp1 mGlu receptors, under similar conditions that lead 
to elevated mGluR-dependent LTD in Fmr1 KO mice, increased basal protein 
synthesis rates in WT mice but failed to further increase elevated protein synthesis 
rates in the Fmr1 KO mice (Osterweil et al. 2010). This suggests that in the Fmr1 
KO hippocampus, mRNA translation is already saturated downstream of constitutive 
mGlu1/5 receptor activation due to loss of FMRP translational repression.  
 
The translation efficiency of several FMRP target mRNAs have been examined in 
polysomal fractions and hippocampal slice homogenates. Here PSD-95, GluA1 and 
GluA2 (AMPA receptor subunits) and CAMKII were found to be excessively 
translated in Fmr1 KO preparations (Muddashetty et al. 2007; Osterweil et al. 2010). 
This indicates that FMRPs target mRNAs are abnormally translated under steady 
state conditions in the Fmr1 KO brain, providing further evidence in support of 
FMRPs role in repressing mRNA translation. Thus it appears in the absence of 
FMRP there is exaggerated protein synthesis that consequently triggers excessive 
AMPA receptor internalisation upon activation of Gp1 mGlu receptors leading to the 
weakening of synaptic connections within the hippocampus. 
 
1.2.12 The mGluR Theory of FXS 
These findings that (1) Gp1 mGluR activation increases synthesis of FMRP, (2) 
mGluR-dependent LTD requires translation of pre-existing mRNA to be sustained, 
and (3) mGluR-dependent LTD is enhanced and independent of new protein 
synthesis led to the mGluR theory of FXS (Bear et al. 2004; Figure 1.6). This theory 
outlines how FMRP acts downstream of Gp1 mGlu receptors to halt the local mRNA 
translation of proteins required for mGluR-dependent LTD, and in the absence of 
FMRP, there is exaggerated protein synthesis that leads to excessive AMPA receptor 
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internalization and augmented LTD in response to mGluR-activation (Figure 1.6). 
Furthermore the model predicts that many of phenotypic features of FXS can be 
corrected by down regulation of Gp1 mGlu receptors. This was the first report to 
propose a targeted treatment to correct the core deficits that underlie the cognitive 
and behavioural abnormalities observed in the FXS. 
 
In support of the mGluR theory of FXS, many of the prominent phenotypes 
associated with Fmr1 KO mice can be rescued either genetically with the reduction 
of mGlu5 receptor expression or pharmacologically by reducing mGlu5 receptor 
signalling. The genetic reduction of mGlu5 receptor expression in the Fmr1 KO 
mouse corrected: increased spine morphology in L3 of the binocular visual cortex, 
elevated basal protein synthesis, exaggerated inhibitory avoidance extinction and an 
increased susceptibility AGS (Dölen et al. 2007). Whilst pharmacologically, the use 
of the negative allosteric modulators (NAMs) of Gp1 mGlu receptors such as 2-
Methyl-6-(phenylethynyl)pyridine (MPEP), or 2-chloro-4-((2,5-dimethyl-1-(4-
(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP) have been 
shown to rescue: increased prepulse inhibition, deficits in inhibitory avoidance and 
extinction, susceptibility to low-intensity auditory stimuli and AGS, hyperactivity in 
the open field, increased number of filopodia-like protrusions in hippocampal 
cultures and increased spine density in the binocular region of the visual cortex, 
enhanced hippocampal LTD, increased basal protein synthesis rates, and excessive 
internalization of  AMPA receptors at basal state (Yan et al. 2005; Michalon et al. 
2012; Michalon et al. 2014; de Vrij et al. 2008; Osterweil et al. 2010; Nakamoto et 
al. 2007). Importantly, many of these phenotypes were rescued in young adult mice 
indicating that therapeutics may still be beneficial to FXS patients when started in 
adolescence or adulthood. These studies have provided further evidence in support of 
the FMRP regulating mGluR-dependent protein synthesis and show that the 
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Figure 1.6 The mGluR theory of Fragile X Syndrome. (A) Model to explain exaggerated 
metabotropic glutamate receptor (mGluR) dependent long term depression (LTD) in CA1 of the 
hippocampus of Fmr1 KO mice based on evidence that the fragile x mental retardation protein FMRP 
is rapidly synthesized in response to mGluR-activation and functions as a repressor of mRNA at local 
dendritic sites. (B) In the Fmr1 KO mice where FMRP is absent, mRNA translational rates are 
increased leading to the excessive removal of AMPA receptors from the cell surface in response to an 














1.2.13 mGlu5 receptors couple to mRNA translational machinery 
There are two key intracellular signalling pathways thought to couple mGlu1/5 
receptor activation to mRNA translation: firstly, the mammalian target of rapamycin 
(mTOR) pathway; and secondly, the extracellular signal-regulated kinase 1/2 
(ERK1/2) pathway (Figure 1.7). Both ERK1/2 and mTOR can stimulate cap-
dependent protein translation (translation of mRNA targets with 5’ cap) by targeting 
the regulatory components of the initiation complex, primarily the eukaryotic 
translation initiation factor (EIF) 4E and the EIF4E binding protein (4E-BP) (Banko 
2006; Ronesi & Huber 2008). The initiation step of mRNA translation begins once 
EIF4E recognises the 5’ mRNA cap. This leads to the formation of the EIF4F 
complex, consisting of EIF4E, EIF4F and EIF4A, which once bound triggers the 
recruitment of the small ribosomal subunit (Richter & Sonenberg 2005). Furthermore 
both mTOR and ERK1/2 can stimulate 5’TOP mRNA translation (mRNAs 
containing a 5’ oligopyrimidine tract) through phosphorylation of S6K1/2 and RSK, 
respectively, that increases the translational capacity of cell by synthesizing 





Figure 1.7 mGlu1/5 receptor activation leads to local mRNA translation. Activation of mGlu1/5 
receptors stimulates protein synthesis via (A) the extracellular signal-regulated kinase (ERK) 
pathway, which in turn target multiple effectors to initiate mRNA translation and (B) the mammalian 




Mammalian target of rapamycin pathway 
The mGlu5 receptors couple to the mTOR signalling cascade through their 
association with Homer, a postsynaptic density scaffolding protein (Ronesi & Huber 
2008). Homer links mGlu5 receptors to PIKE, which binds and stimulates PI3K 
activity (Rong et al. 2003). PI3K phosphorylates PIP2 converting it to PIP3, which 
recruits Akt to the plasma membrane. PDK1 phosphorylates and activates Akt, 
which in turn phosphorylates and inhibits the TSC2 subunit of the tuberous sclerosis 
complex (TSC). TSC2 is a GAP protein, which hydrolyses active Rheb (GTP-bound) 
to its inactive form (GDP-bound). However in its active form, Rheb will proceed in 
activating mTOR, which can go on two form two complexes: mTORC1 or 
mTORC2.  
The mTORC1 consists of mTOR in a complex with Raptor and LST8/GβL and is a 
target of rapamycin. The mTORC1 complex will bind and phosphorylate its target 
substrates, which include 4E-BPs, and p70S6 kinases (S6K1/2). Furthermore 
mTORC1 specifically regulates the translation of 5’TOP mRNAs by removing the 
TOP sequence of these mRNAs de-repressing translation of these transcripts (Antion 
et al. 2008a). The other mTOR complex, mTORC2 contains LST8/GβL and Rictor, 
which phosphorylates Akt, PKB and PKC (Costa-Mattioli et al. 2009; Figure 1.6). 
The PI3K-Akt-mTOR stimulates cap-dependent protein synthesis through the 
activation of S6K1/2, which phosphorylate ribosomal protein S6 leading to the 
activation of EIF4B. EIF4B potentiates EIF4A activity facilitating the formation of 
EIF4F (Shahbazian et al. 2006). Furthermore, in response to mGlu1/5 activation 
mTOR signalling can facilitate protein synthesis by targeting 4E-BPs, increasing 
EIF4E availability allowing the formation the EIF4F assembly (Raught & Gingras 







The role of mammalian target of rapamycin pathway in Fmr1 KO mice 
In Fmr1 KO mice the interaction between Homer and mGlu1/5 is disrupted and 
stimulation of mGlu1/5 receptors fail to activate mTOR signalling or initiate the 
translation of 5’TOP containing mRNAs (Ronesi & Huber 2008). In contrast, 
Sharma et al. (2010) find increased phosphorylation levels of mTOR and Akt under 
basal conditions in hippocampal lysates and PSD fractions from young and more 
mature adult Fmr1 KO mice suggesting that PI3K-Akt-mTOR pathway is 
hyperactive in the absence of FMRP. Both Sharma et al. (2010) and Gross et al. 
(2010) also see increases in the activation state of Akt in cortical tissue from young 
adult mice and in cortical cultures, respectively. These discrepancies may result from 
differences in tissue preparation as Sharma et al. (2010) measured the protein 
phosphorylation levels in hippocampi that had been rapidly dissected whilst Ronesi 
et al. (2008) quantified protein expression levels in hippocampal slices that were left 
to recover for several hours in ACSF.  
 
In the hippocampus the activation of PI3K-Akt-mTOR signalling in response to 
mGlu1/5 activation is crucial for the stable expression of mGluR-dependent LTD 
(Hou & Klann 2004). Furthermore inhibition of mTOR signalling with rapamycin 
reduces basal protein synthesis in cortical synaptoneurosome preparations suggesting 
mTOR regulates basal levels mRNA translation (Muddashetty et al. 2007). Yet in 
Fmr1 KO mice, mGluR-dependent LTD and elevated protein synthesis rates are 
insensitive to the mTOR inhibitor, rapamycin (Sharma et al. 2010; Osterweil et al. 
2010). These findings could suggest that in the absence of FMRP this pathway is 
uncoupled from mGlu1/5 receptor activation and so can no longer regulate synaptic 
strength (Sharma et al. 2010). Yet in WT hippocampal slices, Osterweil et al. (2010) 
did not observe any differences in the activation state of Akt or p70S6K (two 
readouts of mTOR activity), in response to mGlu1/5 activation. This suggests that the 
PI3K-Akt-mTOR signalling cascade is not activated upon mGlu1/5 receptor 
stimulation. These discrepancies could be due to differences in the brain region 
examined (cortical synaptoneurosomes versus hippocampal slices) and also 




ERK1/2-MAPK signalling pathway 
In addition to the mTOR pathway, the ERK-MAPK signalling cascade is known to 
regulate cap-dependent protein synthesis (Banko et al. 2006). At the head of the 
ERK-MAPK signalling cascade is Ras, whose activity is regulated by GTPase 
activating proteins (GAPs), such as SynGAP and NF1. This leads to the sequential 
activation of proto-oncogene serine/threonine protein kinase Raf, 
mitogen/extracellular signal-regulated kinase (MEK1/2) and ERK1/2. Active 
ERK1/2 can stimulate cap-dependent translation via phosphorylation of RSK, which 
in turn activates S6 (Antion et al. 2008a). S6 phosphorylates EIF4b, which 
potentiates the activity of EIF4A increasing EIF4F complex formation. ERK1/2 can 
also initiate translation by activating the MAPK-interacting kinase (Mnk1), which 
also leads to the phosphorylation of eIF4E (Banko et al. 2006).  
The role of the ERK1/2-MAPK signalling cascade in Fmr1 KO mice 
In CA1 of the hippocampus, mGluR-dependent LTD is reliant on ERK-MAPK 
signalling (Gallagher et al. 2004). In the presence of 1,4-diamino-2, 3-dicyano-1, 4-
bis (2-aminophenylthio) butadiene (U0126), an inhibitor of MEK1/2, mGluR-
dependent LTD cannot be sustained (Gallagher et al. 2004). Furthermore elevated 
basal protein synthesis rates in the hippocampus of Fmr1 KO mouse are selectively 
reduced to control levels by U0126 (Osterweil et al. 2010). In the same study it was 
found that ERK1/2 signalling was unaltered in Fmr1 KO hippocampal slices and 
increased by a similar magnitude upon mGlu1/5 receptor activation to WT controls. 
These findings suggest that the elevation in protein synthesis rates in the Fmr1 KO 
hippocampus are not the result of hyperactivation of the ERK1/2 signalling but rather 
a hypersensitive response of the translational machinery to mGlu1/5 receptor 
activation due to the loss of mRNA translation repression by FMRP (Osterweil et al. 
2010). This could indicate that altered signalling in the Fmr1 KO mouse is not the 
cause of augmented protein synthesis in the hippocampus but rather a consequence 
of the loss of FMRP.  However several other studies have found steady-state levels 
of ERK1/2 signalling to be increased in the Fmr1 KO brain and found mGluR-
dependent LTD to be insensitive to inhibitors of this pathway (Hou et al. 2006; Kim 
et al. 2008). 
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1.2.14 Basal synaptic transmission in Fmr1 KO mice  
Examination of basal synaptic properties in Fmr1 KO hippocampal neurones 
revealed smaller excitatory postsynaptic currents (EPSCs) with no significant 
difference in mEPSC frequency (Braun & Segal 2000; Pfeiffer & Huber 2006). 
Furthermore there is a reduction in AMPA/NMDA receptor ratio at P14, which 
disappears by 6-7 weeks of age in Fmr1 KO mice (Pilpel et al. 2009). However, a 
separate study found no difference in AMPA/NMDA receptor ratios at the same time 
point (Hu et al. 2008). Together these findings suggest that during early development 
there may be delayed synapse maturation in Fmr1 KO mice that is mediated by 
postsynaptic disruptions that lead to reduced excitatory drive. 
 
1.2.15 Hyperexcitability in the hippocampus of Fmr1 KO mice 
Intracellular recordings of CA3 pyramidal neurons in Fmr1 KO hippocampal slices 
have revealed epileptiform bursting in response to spontaneous synaptic activity 
(Osterweil et al. 2013; Zhao et al. 2004). These ictal-like responses progresses to 
prolonged synchronized discharges and are comparable to those observed during 
epileptic seizures. Typically prolonged discharges are only observed in response the 
activation of Gp1 mGlu receptors and are dependent on ERK1/2 activation and 
mRNA translation (Chuang et al. 2005; Zhao et al. 2004). Likewise inhibition of 
either protein synthesis or ERK1/2 activity prevents the expression of synchronized 
bursting in CA3 pyramidal neurones (Osterweil et al. 2013; Chuang et al. 2005; Zhao 
et al. 2004). Thus epileptiform bursting in CA3 pyramidal neurons of Fmr1 KO slice 
resembles that observed when DHPG is applied to WT slices, indicating that in Fmr1 
KO slices there is an exaggerated response downstream of mGlu1/5-ERK1/2 
signalling leading to epileptogenesis in the FXS brain.  
 
In agreement, inhibitors of Gp1 mGlu receptors (e.g. MPEP) or Ras-ERK1/2 
signalling (e.g. lovastatin, UO126) abolish the persistence of epileptiform bursting in 
Fmr1 KO slices (Osterweil et al. 2013; Zhao et al. 2004). This indicates that mGlu1/5 
receptor responses are exaggerated in the absence of FMRP due to the loss of 
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repression of mRNA translation. This is consistent with the finding that MPEP and 
lovastatin lower seizure susceptibility in Fmr1 KO mice (Osterweil et al. 2010; 
Osterweil et al. 2013). Thus together these findings suggest that FMRP plays a role 
in regulating neuronal excitability at the synapse.  
 
1.2.16 Passive and active membrane properties in  Fmr1 KO mice 
Intrinsic properties, such as resting membrane potential (Vm), series resistance and 
rheobase, have also been examined in hippocampal slices and there appears to be no 
change in intrinsic postsynaptic excitability in Fmr1 KO mice (Pilpel et al. 2009). 
Similarly Brager et al. (2012) found no differences in Vm, input resistance (RN), and 
membrane time constant (τm) in somatic recordings from CA1 of the hippocampus. 
However dendritic recordings found Vm to be significantly more depolarised, RN was 
lower and τm was faster.  
 
These findings were consistent with an increase in Ih (the current of h-channels), 
which was due to elevated proteins levels of h-channel subunits HCN1, but not 
HCN2, in the distal dendritic segments of CA1 field of Fmr1 KO mice (Brager et al. 
2012). Between the soma and dendrites of CA1 pyramidal neurones HCN channels 
are expressed in a gradient like manner with HCN expression increasing as you 
move away from the soma. This HCN gradient is important for regulating the 
propagation of signals between the soma and the dendrites. This increase in Ih in 
Fmr1 KO dendrites could reduce dendritic excitation, which could be a 
compensatory effect due to excessive synaptic excitation within this region caused 
by the loss of FMRP. It will also cause an increase in membrane excitability by 
depolarising RN and increasing the rebound potential that follows a 
hyperpolarisation, which will increase the probability of spike initiation. 
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1.2.17 Treatment Strategies for FXS 
Collectively, these findings demonstrate how the Fmr1 KO mouse has been a 
tremendously valuable tool in identifying the role of FMRP at the synapse and the 
mechanisms in the FXS brain that underlie the learning and behavioural 
abnormalities in the absence of FMRP. This has led to the identification of potential 
therapeutic targets and the development of pharmacotherapies that seek to correct (1) 
altered mGlu5 receptor signalling, (2) enhanced protein synthesis rates, (3) 
overabundant LTD proteins, or (4) increased hyperexcitability in brain networks.  
 
As previously discussed NAMs of the mGlu5 receptor, which correct excessive 
protein synthesis rates, also rescue an extensive number of FXS phenotypes 
including abnormalities in behavioural, synaptic plasticity and spine morphology 
(Dölen et al. 2007; Michalon et al. 2012; Michalon et al. 2014; Osterweil et al. 
2010). Two compounds which downregulate mGlu5 receptor signalling, fenobam 
(Berry-Kravis 2014) and AFQ056 (Chelly & Mandel 2001), have now progressed 
into clinical trials. Similarly compounds that target downstream components of 
mGlu1/5 receptor signalling have also shown therapeutic potential. In the Fmr1 KO 
mouse, chronic treatment with lithium restored: exaggerated mGluR-dependent LTD 
(Chelly et al. 2006), increased protein synthesis rates (Leonard & Wen 2002), 
increased susceptibility to AGS (Min et al. 2009), and behavioural deficits including 
social behaviours (Mines et al. 2010).  
 
Minocycline is an antibiotic that targets the matrix metalloproteinase 9 (MMP-9), a 
protein overexpressed in Fmr1 KOs that acts downstream of mGlu1/5 receptor and is 
involved in the elongation of dendritic spines (Michaluk et al. 2011). Minocycline 
has been shown to correct hippocampal spine abnormalities and improve behavioural 
outcomes of Fmr1 KO mice in the elevated plus maze and Y-maze task (Bilousova et 
al. 2009) with several reports of its use in human patients (Leigh et al. 2013; 
Paribello et al. 2010; Utari et al. 2010). Another approach to counteract the 
hyperexcitability of excitatory strength in these mutants has been to enhance 
inhibitory function with GABA receptor agonists, such as STX209. In the Fmr1 KO 
mouse, STX209 reduces the increased susceptibility to AGS (Pacey et al. 2009) and 
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also corrects elevated protein synthesis rates and increased spine density in the cortex 
(Henderson et al. 2012).  
 
1.3 Insights Other Monogenic Causes of ID 
In addition to the mouse model of FXS, investigations in several other models of ID 
have contributed significantly to our understanding of the underlying brain 
pathophysiology associated with ID/ASD. From these studies it appears that many of 
these ID gene mutations disrupt dendritic synapse function, which contribute 
significantly to the impaired cognition and behaviour associated with ID. 
Interestingly, there are reports that specific cell types in the mammalian brain are 
responsible for distinct cognitive and behavioural deficits in models of ID. 
Furthermore biochemical analysis of these mutants has discovered novel therapeutic 
interventions, which have been validated in preclinical models and in some cases 
found to be beneficial in human patients. Moreover, several compounds have proved 
successful in improving cognitive function in other monogenic causes of ID 
indicating that there may a common pathophysiological axis that underlies ID.  
Finally studies that have utilised gene reactivation or pharmacological interventions 
have shown considerable improvements in core symptoms even when treatment 
begins in adulthood raising the intriguing possibility that these neurodevelopmental 
disorders may not lead to a permanent and irreversibly mental disability (Zoghbi & 
Bear 2012). 
 
1.3.1 The mouse model of Neurofibromatosis 1 
Studies in the mouse model of Neurofibromatosis 1 (NF1) have revealed that 
reduced levels of neurofibromin (a Ras GAP) result in a hyperactivity of Ras-
ERK1/2 signalling. NF1 heterozygous mice exhibit memory impairments in the 
Morris water (Silva et al. 1997) and hippocampal LTP (Costa et al. 2002), consistent 
with NF1 patients who display deficits in executive functions.  Interestingly, both 
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impairments in LTP and cognition in the NF1 heterozygous mutant are rescued by 
reducing Ras activity, either genetically or pharmacologically (Costa et al. 2002). 
NF1 heterozygous mice treated with lovastatin, an inhibitor of the HMG-CoA 
reductase enzyme that reduces Ras-ERK1/2 activity, no longer display deficits in 
LTP or spatial learning (Li et al. 2005). Furthermore, lovastatin has been shown to 
the effective in human NF1 patients (Mainberger et al. 2013).  
 
Recently this therapeutic strategy was examined in Fmr1 KO mice to determine 
whether lovastatin could correct increased translation rates downstream of mGlu5-
ERK1/2 signalling. Lovastatin modestly reduces ERK-MAPK activation by 
preventing the posttranslational farnesylation of Ras, preventing Ras translocating to 
the plasma membrane where it is functional. In Fmr1 KO mice, the acute application 
of lovastatin to hippocampal slices rescued elevated protein synthesis rates, enhanced 
mGluR-dependent LTD and epileptiform bursting in CA3 pyramidal neurones 
(Osterweil et al. 2013). Furthermore lovastatin administered orally or by injection 
reduced seizure susceptibility in vivo (Osterweil et al. 2013). 
  
The possibility of using lovastatin as a treatment in FXS patients and other disorders 
that arise from altered Ras-ERK1/2 signalling has a lot of therapeutic potential 
because it is already approved for treatment of hypercholesterolemia in both children 
and adults and has a well-known safety profile due to its widespread use (Costa et al. 
2002; Osterweil et al. 2013). It would now be advantageous to see whether lovastatin 
can rescue additional neurocognitive phenotypes that are reported in Fmr1 KO 
mouse to see whether it can be effective in the treatment of a broader spectrum of 
phenotypes. 
1.3.2 The mouse model of Tuberous Sclerosis 
Recent studies in the mouse model of tuberous sclerosis complex (TSC) have 
proposed a role by which mTOR signalling may also disrupt protein synthesis levels 
and impact synaptic strength. Like FXS and NF1, TSC is a monogenic cause of ID 
caused by the loss of either the TSC1 or TSC2 gene, which together form the TSC 
complex. As mentioned above, TSC represses mTOR signalling and so in its 
 48 
absence, mTOR activity is excessive (Ehninger et al. 2008). Although TSC mutants 
share similar cognitive and behavioural abnormalities to Fmr1 KO mice, 
surprisingly, examination of basal protein synthesis rates and mGluR-dependent 
LTD in TSC mutants revealed they were impaired (Auerbach et al. 2011; Chévere-
Torres et al. 2012), whilst late-phase LTP was enhanced (Ehninger et al. 2008). 
Thus, TSC mutants appear to have opposing phenotypes to those observed in the 
Fmr1 KO mice.  
 
Furthermore the cognitive deficits reported in the TSC mutants could be corrected by 
positive allosteric modulators (PAM)s of mGlu5 receptors, inhibitors of mTOR or by 
crossing TSC mutants with an Fmr1 heterozygous mouse (Ehninger et al. 2008; 
Auerbach et al. 2011). Together this data has led to the proposal of a model by which 
ERK1/2 and mTOR regulate the translation of distinct pools of mRNAs that can 
repress one another by competing for access to the same translational machinery 
(Bhakar et al. 2012). Furthermore it highlights the need to for a reliable biomarker 
for disorder in order to identify the most effective pharmacological strategy. 
 
1.3.3 The mouse model of Rett Syndrome 
In addition to pharmacologically interventions correcting dysfunctional signalling in 
mouse models of ID, other groups have taken a genetic approach to see whether the 
reintroduction of the mutant gene can reverse cognitive deficits associated with ID 
and ASD. Phenotypic rescue was successively shown in a mouse model of Rett 
syndrome (Guy et al. 2007), a disorder predominantly caused by de novo mutations 
in the MECP2 gene (Amir et al. 1999). The MECP2 gene encodes the MECP2 is one 
of a small group of methylated DNA-binding proteins that can act as transcriptional 
repressors (Klose & Bird 2006). Within the brain MECP2 is ubiquitously expressed 
and most in abundance in mature neurones.  
 
Like FXS, Rett syndrome is X-linked so boys with an MECP2 mutation are far more 
severely affected than girls, presenting with infantile encephalopathy and dying 
shortly after birth. Females who have two X chromosomes and therefore one 
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functional copy of MECP2 express this protein in a mosaic fashion due to random X-
chromosome inactivation. This means that only a proportion of cells will express the 
MeCP2 protein. Girls with Rett syndrome will develop symptoms between 6-18 
months of age after a period of normal development but then quickly regress and 
show a slowed brain and head growth, ataxia, seizures, cognitive deficits and severe 
NSID (Ropers & Hamel 2005). In girls, Rett syndrome is the leading cause of severe 
mental retardation (Cobb et al. 2010). Furthermore approximately 70% of Rett 
syndrome patients exhibit seizures and nearly all exhibit abnormal EEG patterns 
(Glaze et al. 1998). 
 
The Mecp2 null mutants develop motor impairments, tremor, breathing abnormalities 
and limb stereotypies dying at 10-20 weeks of age whilst heterozygous females have 
a normal lifespan, displaying a delayed set of symptoms that progressively worsen in 
severity but eventually stabilise after several months (Guy et al. 2001). Guy et al. 
(2007) generated a conditional KO where endogenous Mecp2 was silenced by the 
insertion of a lox stop cassette that could subsequently be deleted upon tamoxifen 
injections leading to the reactivation of Mecp2. The reintroduction of MeCP2 in 
Mecp2 null male mutants had an astonishing effect on reversal of phenotypes, 
reducing postnatal lethality and correcting neurological symptoms. Similarly in 
Mecp2 heterozygous females, activation of MeCP2 expression in adulthood reversed 
neurological symptoms and synaptic plasticity deficits in L-LTP. These findings 




The deletion of Mecp2 in specific cells or regions can reproduce some of the 
phenotypes observed in Rett syndrome. For example loss of Mecp2 postnatally in 
excitatory neurones of the forebrain led to motor impairments, increased anxiety and 
impaired fear conditioning and social behaviour (Gemelli et al. 2006). Rett syndrome 
phenotypes have also been observed when Mecp2 is deleted specifically in 
dopaminergic neurones or when lost in the amygdala (Fyffe et al. 2008; Samaco et 
al. 2009). In a separate study the specific restoration of gene function in only glia 
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cells in global Mecp2 deficient mice rescued locomotion and anxiety levels, restored 
breathing abnormalities and prolonged lifespan (Lioy et al. 2011). These findings 
highlight the role of specific cell types/regions play in certain behaviours and 
phenotypes and may mean subtle manipulations of specific circuits could be 
promising for therapeutic intervention. 
 
1.3.4 Mutations in ID-related genes define a pathological axis 
Based on these findings it is now clear that mutations in ID genes define an axis of 
synaptic pathophysiology. These studies have highlighted that protein synthesis rates 
must be tightly regulated to maintain at an optimum level of mRNA translation 
otherwise the repercussions are extensive. Altered protein synthesis rates in the ID 
brain can impact intrinsic properties of individual neurones, destabilise excitatory 
and inhibitory networks and causes aberrant synaptic plasticity mechanisms (Banko 
et al. 2006; Ronesi & Huber 2008; Auerbach et al. 2011; Osterweil et al. 2010). 
Deviations in protein synthesis rates, in either direction, disrupt synaptic function 
leading to similar cognitive impairments (Figure 1.8). Depending on which end of 
the spectrum the mutation lies will determine its phenotypic outcome (i.e. 
enhanced/impaired LTD) and treatment strategy (NAM/PAM of mGlu5 receptor; 


























Figure 1.8 The pathophysiological axis of intellectual disability. Monogenic causes of intellectual 
disability (ID) appear to require an optimum level of protein synthesis for proper synaptic function. 
Mutations in ID-related genes that lead to increased protein synthesis rates, enhanced mGluR-
dependent long-term depression (LTD) and impaired long-term potentiation (LTP), include fragile x 
syndrome (FXS), Neurofibromatosis 1 (NF1) and SYNGAP1 haploinsufficiency may be amenable to 
negative allosteric modulators (NAM) of mGlu5 receptors or inhibitors of the Ras-ERK1/2.  On the 
opposite end of the spectrum is Tuberous Sclerosis complex (TSC) caused by a mutation in either 
TSC1 or 2, which leads to opposing phenotypes including reduced protein synthesis rates, impaired 
mGluR-dependent LTD and enhanced LTP that can be corrected to wild type (WT) levels with 







1.3.5 Convergence of proteins encoded by ID-related genes 
The pathophysiological axis of ID helps explain why genetically distinct causes of 
ID share significant phenotypic overlap. For example there are now an accumulating 
number of reports that link genetic mutations in signalling molecules, which cause 
dysregulated Ras signalling known as ‘Rasopathies’ to a group of 
neurodevelopmental disorders with cognitive impairments, that resemble ID 
(Cesarini et al. 2009). These mutations are found in proteins upstream (i.e. PTPN1, 
SOS1, NF1, SYNGAP) and downstream of Ras signalling (i.e. Ras, BRAF, MEK1/2, 
FMRP). The role this pathway plays in the pathology of various genetic causes of ID 
have been confirmed in the mouse models of FXS and NF1, with a subset of 
phenotypes rescued by downregulation of the Ras-ERK1/2-MAPK signalling 
pathway (Osterweil et al. 2010; Li et al. 2005; Osterweil et al. 2013). In fact, the 
mRNA of many of the Ras related genes listed are targets of FMRP suggesting there 
be an indirect as well as direct interaction between these ID-related proteins (Darnell 
et al. 2011). Based on these findings, we have begun investigating another upstream 












1.4 Haploinsufficiency of SYNGAP1 
Like NF1, SynGAP is a Ras GAP protein, binding members of the Ras family of G- 
proteins and downregulating their activity at the synapse. Here SynGAP relays 
glutamatergic receptor activation to intracellular signalling events that are important 
for cognitive processes, such as synaptic plasticity and spine morphogenesis. In 
recent years a number of rare de novo mutations in SYNGAP1 have been identified in 
patients with NSID that are predicted to lead to the loss of one functional copy of 
SYNGAP1. With the availability of the mouse of model of Syngap1 
haploinsufficiency - the Syngap heterozygous mouse - we are now able to validate 
this mutant as an animal model of ID and see how closely it mimics the human 
condition.  
 
Furthermore we can test whether there is phenotypic overlap with other known 
genetic causes of ID that result from aberrant Ras signalling. There are already 
encouraging findings reported in literature from investigations in the Syngap 
heterozygous mice, such as elevated ERK1/2 activity in the hippocampus and 
behavioural abnormalities that are consistent with ID. This evidence already hints at 
the suggestion there may convergence between SYNGAP1, FMR1 and NF1. Here it 
will be discussed in detail the involvement of SynGAP in the physiology and 
pathology of learning and memory. 
 
 
1.4.1 Haploinsufficiency of SYNGAP1 is linked to intellectual disability 
Mutations in the SYNGAP1 gene have only recently been linked to a non-syndromic 
form of ID where the only clinical manifestation in these patients is cognitive 
impairment and behavioural abnormalities. Although, there are a minority of 
reported cases of SYNGAP1 haploinsufficiency, small screens of NSID patients 
(<100 patients) have revealed that the prevalence of SYNGAP1 mutations could be as 
high as 4%, which when extrapolated to the ID population could make it one of the 
most common causes of NSID (Hamdan et al. 2011).  Furthermore, affected 
individuals also commonly display childhood seizures and ASD. This has fuelled 
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further interest in the function of this protein at the synapse, and the consequence 
reduced SYNGAP expression has on cellular and behaviourally processes that 
underlie ID. 
 
1.4.2 Autosomal dominant de novo mutations in SYNGAP1 are deleterious  
Hamdan et al. (2009) was the first to identify rare de novo mutations in SYNGAP1 in 
patients with NSID and proposed that they were likely to be pathogenic because the 
truncated versions of SYNGAP lacked key functional domains known to regulate 
synaptic plasticity mechanisms and spinogenesis. This initial study involved 94 
patients with NSID (mixed ethnicity and gender) who underwent SYNGAP1 
sequence analysis, for which three point mutations (K138X, R579X and 
L813RFSX22) were identified. Two patients were heterozygous for nonsense 
mutation, K138X and R579X. The third patient was heterozygous for mutation 
L813RFSX22, predicted to result in a frame shift mutation that introduced a 
premutation stop codon. Interestingly, all mutations were absent from parental DNA 
samples indicating they were de novo mutations. All three patients presented with a 
similar clinical profile; a delay was observed early on in development, moderate to 
severe ID and language impairment.  In 1 of the 3 patients a strabismus was found 
whilst 2 out of 3 were mildly epileptic. In both patients with a co-diagnosis of 
epilepsy, seizures were well controlled by valproate (reduces expression of GluA1 
containing AMPA receptors at the synapse) or topiramate (inhibits AMPA receptor 
activity). Only one of the three mutations was found in the RasGAP domain 
(R579X), whilst K138X and L813RFSX22 were located in the N-terminal and SH3 
domains, respectively (Figure 1.8).  
Since this initial study further mutations in the SYNGAP1 gene have been identified 
in patients with moderate to severe ID (Figure 1.9). These include: deletion 
mutations at 6p21.3 encompassing SYNGAP1 (Writzl & Knegt 2013; Krepischi et al. 
2010; Zollino et al. 2011; Berryer et al. 2012); a balanced translocation between 
chromosome 6 and 22, that led to the truncation of the gene (Klitten et al. 2011); 
frameshift mutations (Vissers et al. 2010; Hamdan et al. 2011), a single base 
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duplication that introduced a premature stop codon (Berryer et al. 2012); and 
missense mutations (Berryer et al. 2012). These mutations are predicted to result in 
the full truncation of the protein, leaving only one functional copy of the SYNGAP1 
gene. Where paternal and maternal testing took place, no mutations were found in 
SYNGAP1 in parental DNA indicating that the majority of cases arise from 
heterozygous de novo mutations in SYNGAP1. The only exception was in one patient 
with a base duplication in SYNGAP1, whose father was also found to carry this 
mutation but in a mosaic state (Berryer et al. 2012).  
Mutations in the SYNGAP1 gene can vary in the type, location, and functional 
outcome: missense mutations affect stability and function; truncating mutations at 
the start of the protein abolish production; whilst truncating mutations in the 
RasGAP domain affect its activity (Berryer et al. 2012). All truncating mutations 
abolish the C-terminal domains that are required for SYNGAP to interact with 
components of the PSD complex. This indicates that pathogenic mutations of 
SYNGAP1 result in a loss of function. 
 
 
1.4.3 Symptoms of SYNGAP1 haploinsufficiency  
Clinical examination of these patients has unearthed a spectrum of symptoms that 
vary in severity. Behaviourally, it is widely reported that all patients appear to 
present with a psychomotor delay early on in development and language is 
moderately to severely impaired. One patient with a novel deletion in 6p21.3 
presented with connective tissue abnormalities, similar to what is observed in FXS 
patients, and was classified as hyperactive with attention deficit (Krepischi et al. 
2010). Zollino et al. (2011) reported a patient with severe mental retardation, poor 
social interaction, speech was nearly absent and seizures began which were 
continually difficult to manage. Autism has also been reported in several patients 
(Berryer et al. 2012), and autistic-like behaviours was reported in a patient with a 
balanced translocation mutation (Klitten et al. 2011), and another with reductions in 






























Figure 1.9 Mutations in SYNGAP1 are linked to non-syndromic intellectual disability. The 
SYNGAP1 gene encodes the synaptic GTPase activating protein (SYNGAP). SYNGAP contains 
several functional domains including: pleckstin homology domain, C2 domain, RASGAP domain and 
a coiled-coil motif.  Above depicts localisation of de novo SYNGAP1 mutations identified in patients 













1.4.4 SYNGAP1 Haploinsufficiency and Epilepsy 
The recent identification of ID patients with mutations in the SYNGAP1 gene has 
also revealed that epilepsy is a frequent comorbidity (Hamdan et al. 2009; Pinto et al. 
2010; Writzl & Knegt 2013; Zollino et al. 2011; Berryer et al. 2012; Klitten et al. 
2011). Furthermore SYNGAP1 mutations have also been linked to a form of epileptic 
encephalopathy, an extremely debilitating group of epilepsies characterized by 
refractory seizures and cognitive arrest that carry a poor prognosis (Carvill et al. 
2013).  
Epileptic seizures in SYNGAP1 haploinsufficiency occur early on during childhood 
with the age of onset varying from 3 months to 4 years of age, affecting both males 
and females. All SYNGAP1 haploinsufficiency patients present with generalized 
seizures either clonic-tonic, absence or myoclonic seizure, with one report of febrile 
seizures (Hamdan et al. 2011). The frequency of seizures can be high, with one 
patient reported to have up to 100 seizures per day prior to treatment (Writzl & 
Knegt 2013). To assess the incidence of epilepsy in patients with SYNGAP1 
haploinsufficiency patients, greater cohorts of SYNGAP1 haploinsufficiency patients 
are required. However, together these findings suggest that SYNGAP1 may play a 
role in the pathogenesis of generalized epilepsy. 
Abnormal EEG patterns are observed in all patients with SYNGAP1 
haploinsufficiency, which are predominantly characterized by generalized spike 
waves or bioccipital spikes. It would also be interesting to see if abnormal EEG 
patterns extend to SYNGAP1 haploinsufficiency patients that do not present with 
seizures to see whether it may be a biomarker for the disorder. Following treatment 
with anticonvulsants, such as topiramate and valproic acid, the majority of patients 
become seizure free or are well managed (Hamdan et al. 2009; Vissers et al. 2010; 
Hamdan et al. 2011; Writzl & Knegt 2013; Berryer et al. 2012; Zollino et al. 2011). 
There were three cases where seizures were not well controlled, with a relapse of 
seizures (Klitten et al. 2011; Berryer et al. 2012) indicating that the degree of 
severity varies considerably amongst patients. Thus it appears that both the FMR1 
and SYNGAP1 gene can influence seizure susceptibility, with the greatest risk 
presenting during childhood.  
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1.4.5 The SYNGAP1 gene 
Prior to any disease association, SynGAP was originally discovered in 1998 by two 
independent laboratories through the screening and sequencing PSD-95 binding 
proteins (Kim et al. 1998; Chen et al. 1998). Both groups cloned Syngap cDNA, later 
identified as Syngap α1 and began characterising its properties.  The human gene that 
encodes SYNGAP, SYNGAP1, is located on chromosome 6 (6p21.3) and encodes a 
protein consisting of 1343 amino acids with a molecular weight of ~140kDa. 
Western blot analysis, using an antibody against the C-terminal tail, revealed a 
doublet/triplet band, which indicates that multiple SynGAP isoforms may arise from 
alternative splicing of the 5’ end (Kim et al. 1998). In fact, both the N- and C- 
terminal domains can both differ amongst SynGAP isoforms. Four distinct N-
terminal isoforms of SynGAP have been identified, denoted as A, B, C and E, which 
arise from alternative transcription start sites (Li et al. 2001). The C-terminus of 
SynGAP can also vary as a result of alternative splicing of Syngap mRNA, giving 
rise to SynGAP isoforms α1, α2, β1, β2, β3, β4, and γ. 
1.4.6 SynGAP protein structure 
Analysis of the amino acid structure revealed that SynGAP contains several 
functional domains (Figure 1.1). Each isoform contains a highly conserved central 
GAP domain that activates the intrinsic GTPase activity of Ras (Chen et al. 1998), 
and is crucial for regulation of synaptic transmission (Rumbaugh et al. 2006). 
Similarly, a calcium/lipid binding (C2) domain are common to all isoforms and 
serves as Ca2+ dependent membrane binding domain (Chen et al. 1998). SynGAP A, 
B and E (but not SynGAP C) contain unique peptide sequences with a complete 
pleckstin homology (PH) domain for phospholipid binding, which may be important 
for membrane trafficking and protein-protein interactions (Li et al. 2001). 
Furthermore the presence of the C2 and PH domains suggests that SynGAP may 
respond to changes in intracellular Ca2+ and phospholipid second messengers, such 




Alternative splicing of Syngap mRNA leads to multiple the C-terminal isoforms for 
which there are at least seven variants (α1, α2, β1, β2, β3, β4, and γ) encoding five 
different protein isoforms all of which have unique C-terminal tails (Li et al. 2001). 
The C-terminus contains several phosphorylation sites, which are targets of CAMKII 
and protein tyrosine kinases (H. Chen et al. 1998). There appears to be 10 sequential 
histidine residues that may serve as binding sites for divalent metal ions, such as 
Zn2+ and Cu2+. Furthermore there is a proline-rich region between positions 770 and 
800 that is highlighted in the Uniprot database as being a potential SH3 binding 
domain, which would likely serve as a protein-protein interaction domain.  
 
 
SynGAP α1 contains a PDZ binding domain (QTRV) in its C-terminal tail enabling 
it to bind to scaffolding proteins, such as PSD-95, SAP102 (synapse associated 
protein 102) and MUPP1 (Chen et al. 1998; Kim et al. 1998; Li et al. 2001; 
Krapivinsky et al. 2004). Deletion of the C-terminus of SynGAP, specifically the 
QTRV motif, prevents binding of SynGAP to the PDZ domains of PSD-95 and 
SAP102 (Kim et al. 1998). In contrast, SynGAP α2 lacks a PDZ binding domain and 































Figure 1.10 The protein domains of SynGAP isoforms.  The central domain consists of pleckstin 
homology (PH), a calcium/lipid binding (C2) domain and a conserved GTPase activating protein 
(GAP) domain. N-terminal isoforms include A, B, C and E, which arise from different transcription 







1.4.7 SynGAP localisation 
All SynGAP isoforms are specifically expressed in the brain (Li et al. 2001), 
predominantly in the cortex, hippocampus and olfactory bulb with lower expression 
detected in the cerebellum, brainstem, thalamus and brain stem (Kim et al. 1998). 
SynGAP expression shows dynamic changes throughout development with mRNA 
levels continually increasing in the first postnatal weeks, peaking at P14 before 
declining into adulthood (McMahon et al. 2012; Clement et al. 2012). Immunoblots 
of rat cortical homogenates and cytosolic and membrane fractions revealed that 
SynGAP α1 is membrane associated and found solely in excitatory neurones where it 
displays a punctate-like expression (Kim et al. 1998). In contrast, SynGAP β is 
detected in both excitatory and inhibitory neurones (Moon et al. 2008). In the 
hippocampus, the highest level of immunoreactivity for both SynGAP α1 and β is 
detected in the dendritic fields of CA1-3 and in the molecular layer of the dentate 
gyrus (Moon et al. 2008). Western blot analysis of subcellular fractions from rat 
forebrains revealed that SynGAP is highly enriched in the PSD, where it co-localises 
with GluN2B subunit of the NMDA receptor and scaffolding proteins PSD-95 and 
SAP102 supporting the notion that SynGAP is located within the NMDA receptor 
complex (Chen et al. 1998).  
 
 
The expression of γ variant is markedly reduced compared to the α and β forms. 
SynGAP β expression is restricted to the PSD, whilst SynGAP α1 is detected in both 
the PSD and other subcellular locations (Li et al. 2001). This is surprising 
considering only SynGAP α1 possesses the QTRV motif required for binding to 
PSD-95, which is thought to anchor SynGAP α1 within the PSD. Yet SynGAP β, 
which lacks a PDZ binding domain, is isolated to the PSD fraction suggesting it may 
have a binding partner that localises it to the PSD. Interestingly, Vazquez et al. 
(2004) demonstrated that mutation of the QTRV motif (ΔSXV) in the C-terminus of 
SynGAP did not alter the targeting of recombinant SynGAP to the synapse 
suggesting PSD-95 binding is not crucial for targeting SynGAP to spines.  
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There is evidence to suggest that SynGAP localisation at the PSD is regulated in an 
activity-dependent manner. In hippocampal neuronal cultures, depolarisation of cells 
with either high extracellular K+ or NMDA, led to the redistribution of SynGAP 
away from the postsynaptic membrane to the cytosolic side of the PSD, coincidently 
in the same general location where CAMKII is concentrated (Yang et al. 2011). 
Yang et al. (2011) proposes that upon depolarisation, the movement of SynGAP 
away from the PSD may free up the PDZ domain of PSD-95 to other proteins, for 
example AMPA receptors that bind to PSD-95 indirectly via transmembrane AMPA 
receptor regulatory protein (TARP)s. 
 
 
1.4.8 SynGAP interactions 
SynGAP α1 interacts with scaffolding proteins at the PSD 
SynGAP α1 co-immunoprecipitates with PSD-95 and SAP102, two PSD scaffolding 
proteins that are highly abundant at the synapse (Kim et al. 1998). Furthermore, the 
carboxyl terminus containing the QTRV motif strongly interacts with PSD-95 in a 
yeast two-hybrid assay (Chen et al. 1998). Deletion analysis of the C-terminus of 
SynGAP α1 revealed that the QTRV sequence is crucial for SynGAP binding to the 
PDZ domain of PSD-95 and SAP102 (Kim et al. 1998). At the PSD it is likely that 
SynGAP α1 is in a complex with PSD-95 and SAP102 so is ideally positioned to 
regulate Ras dependent signalling upon synaptic stimulation.  
 
SynGAP interacts with MUPP1 
SynGAP has been shown to interact with MUPP1 a large scaffolding protein, which 
has multiple PDZ domains. MUPP1 forms part of the NMDA receptor signalling 
complex at excitatory synapses and allows CAMKII to indirectly interact with 
SynGAP α1 (Krapivinsky et al. 2004). The interaction between MUPP1 and 
SynGAP can be partially disrupted by truncation of the PDZ recognition motif. 
However, disruption of MUPP1 interaction with SynGAP leads to the 
dephosphorylation of SynGAP, inactivation of p38 MAP kinase and an increase the 
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frequency and amplitude of AMPA receptor mediated mEPSCs (Krapivinsky et al. 
2004; Rama et al. 2008). 
 
SynGAP β interacts with CAMKII 
SynGAP β, which lacks the PDZ binding domain directly binds to the α subunit of 
CAMKII, which is thought to localise SynGAP β to the PSD fraction (Li et al. 2001). 
The interaction between SynGAP β and CAMKII is lost upon autophosphorylation 
of the α subunit of CAMKII. This could indicate that the interaction between these 
two proteins is regulated in an activity-dependent manner. 
 
SynGAP interacts with the GluN2B subunit of NMDA receptors  
SynGAP associates with the GluN2B subunit of NMDA receptors through its 
association with PSD-95 (Kim et al. 1998). In turn PSD-95 interacts with the PDZ-
binding motif (ESDV) located on the C-terminal tail of the GluN2B subunit. 
Stimulation of cultured neurones with NMDA results in an increase in SynGAP 
phosphorylation at specific serine residues indicating that SynGAP function is 
regulated in an activity-dependent manner. Similar to Syngap KD neurones, GluN2B 
mutants show enhanced AMPA receptor-mediated synaptic transmission caused by 
an increase in AMPA receptor insertion that is dependent on protein synthesis (Wang 
et al. 2013). This indicates that both GluN2B and SynGAP negatively regulate 
excitatory synapse strength. Furthermore, genetic knockout of GluN2B leads to 
increased protein synthesis rates, which can be corrected, along with increased 
mEPSC amplitude, with the MEK1/2/ERK1/2 inhibitor U0126 (Wang et al. 2013). If 
Syngap was knocked down in GluN2B neurones, this did not further increase 
mEPSC amplitude, whilst overexpression of SynGAP corrected enhanced mEPSC 
amplitude. Thus SynGAP acts downstream of GluN2B and they both regulate the 
same intracellular pathways. This evidence suggests that positive modulation of the 
GluN2B-containing NMDA receptors could be a potential therapeutic target for 
downregulating hyperactive pathways that are present in Syngap heterozygous mice. 
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SynGAP interacts with Unc51.1 and 51.2 
SynGAP has been shown to play a role in the early stages of cerebellar granule cell 
axon formation. Unc51.1 and Unc51.2 are serine/threonine kinases that are localized 
to axonal shafts and growth cones where they play a role in axon elongation. A yeast 
two-hybrid screen, prepared from P6 mouse cerebellum revealed that the C terminal 
tail of Unc51.1 and 51.2 interact with both SynGAP α1 and α2, showing higher 
affinity for α2 isoform (Tomoda et al. 2004).  SynGAP protein levels were detected 
from as early as E16 and levels continued to increase in the cerebellum peaking at 
P20. In granule cell cultures, SynGAP α2 was localized to extending axons whilst α1 
was found only at the cell soma. Overexpression of SynGAP in granule cell cultures 
led to axon truncation, which could be either fully or partially restored with co-
expression of Ras or Unc51.1 respectively.  
Unc51.1 suppresses the GAP activity of SynGAP, upregulating both Ras and Rab5 
activity, through which it exerts control of axon formation (Tomoda et al. 2004). 
Rab5 is a member of the Ras-like small GTPases, localized to synaptic vesicles, 
which is essential for endocytic membrane fission and trafficking necessary for axon 
formation. Overexpression of SynGAP leads to abnormal vesicular structures within 
extending axons of granule cells. Thus SynGAP may be regulating axon formation 
through two pathways: Rab5 for organisation of membrane vesicles and Ras for 
long-term maintenance of gene expression. 
 
1.4.9 SynGAP regulates Ras family of G-proteins 
SynGAP is highly enriched at the PSD, forming part of the NMDA receptor 
complex, where it couples NMDA receptor activation to downstream Ras mediated 
signalling cascades (Chen et al. 1998). SynGAP contains 29 consensus sites 
(RXXS/T) for phosphorylation by CAMKII and it has been demonstrated in vitro 
that CAMKII regulates the activity of SynGAP (Oh et al. 2004). Initially, it was 
observed that when endogenous CAMKII activity is increased by pre-
phosphorylation in isolated PSDs, GAP activity was inhibited by 80-93%. This 
turned out to be an artefact from residual adenosine triphosphate (ATP) and the 
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presence of pyrophosphatase in the Ras GAP assay (Chen et al. 1998). In fact, Oh et 
al. (2004) went on to show that when CAMKII phosphorylates SynGAP, its GAP 
activity increases by 70-95%. Phosphorylation of SynGAP by CAMKII is reversible 
and occurs at multiple sites.  
 
In WT cortical neurones, transfection of constitutively active CAMKII (T286D) 
leads to a reduction in AMPA receptor-mediated mEPSC amplitude. In the absence 
of SynGAP, mEPSC amplitude is elevated and cannot be corrected by transfection of 
constitutively active CAMKII (T286D) indicating that CAMKII lies upstream of 
SynGAP and can only regulate AMPA receptor mediated synaptic transmission 
when SynGAP is present (Wang et al. 2013).  CAMKII in turn is activated by either 
Ca2+ entry in to the synapse predominantly via NMDA receptor activation or through 
a Ca2+-independent mechanism that results from the autophosphorylation of 
CAMKII at T286 (Coultrap & Bayer 2012). 
 
 
SynGAP in its activated form specifically binds and inactivates members of the Ras 
family of small G-proteins, which include Ras, Rap1, Rap2 and Rab5 (Ye & Carew 
2010; Tomoda et al. 2004; Figure 1.11). Although, SynGAP specifically activates 
both Ras and Rap, an in vitro study found that SynGAP preferentially activates Rap 
GTPases, stimulating Rap GTPase activity more potently than Ras GTPase activity 
(Krapivinsky et al. 2004). Ras G-proteins converge on to the multiple downstream 
signalling cascades including the ERK1/2-MAPK, PI3K and p38-MAPK pathways, 
which mediate the phosphorylation of synaptic plasticity proteins as well as their 
local transcription, translation and trafficking at dendritic spines (Stornetta & Zhu 
2011). Ras mediated pathways play a crucial role in the expression of certain forms 
of synaptic plasticity by mediating the trafficking of AMPA receptors that lead to 
changes in synaptic strength (Stornetta & Zhu 2011). Overexpression of SynGAP in 
neuronal cultures decreases the number of AMPA receptors at the synapse 
(Rumbaugh et al. 2006), whilst Syngap heterozygote and KO cortical cultures show 
an increase in the number of AMPA receptor clusters at the synapse and fewer 

















Figure 1.11 SynGAP binding Ras family of G proteins. The synaptic GTPase activating protein 
(SynGAP) bind GTP-bound Ras (active) family members (Ras, Rap1 and Rap2) and convert these 













1.4.10 SynGAP isoforms: Expression and function  
SynGAP isoform expression is regulated in activity-dependent, which in turn has 
differential effects on synaptic strength depending on which combinations of N- and 
C-terminal isoforms are expressed (Figure 1.12). Stimulation of cortical mouse 
cultures changes the relative abundance of N- terminal SynGAP isoforms without 
changing total mRNA levels (McMahon et al. 2012). Both Syngap B and C mRNA 
are upregulated, whilst Syngap A is down regulated. These activity-dependent 
changes in Syngap N-terminal isoform mRNA levels are abolished by inhibition of 
network activity with TTX. In contrast, increased network activity has no effect on 
protein levels of C-terminal isoforms α1 and α2 (McMahon et al. 2012). However it 
is still unknown what combinations of SynGAP isoforms exist in the mammalian 
brain and how activity-dependent changes in SynGAP N- terminal isoforms arise. 
 
The functional consequences of the differential expression of SynGAP isoforms were 
examined in forebrain neurones transfected with plasmids containing combinations 
of N- and C- terminal isoforms. Examination of mEPSCs in transfected forebrain 
cultures revealed that expression of N-terminal isoforms SynGAP A, B or C with the 
α1 C-terminal tail led an increase in the number of silent synapses, whilst expression 
of SynGAP A or B isoforms with α2 had no effect on the proportion of silent 
synapses (McMahon et al. 2012). The functional properties of mEPSCs were 
assessed in terms of mean mEPSC amplitude and frequency. In SynGAPAα1 the 
mean mEPSC amplitude, indicative of postsynaptic receptor density, is decreased 
whilst being elevated in Bα2 and Cα2 neurones, with no change detected in 
SynGAPAα2 expressing neurones. The mEPSC event frequency, that reflects 
presynaptic release probability, is also influenced by SynGAP isoform expression. In 
neurones transfected with SynGAPAα1, event frequency was drastically reduced 
compared to WT neurones, whilst SynGAPBα2 expression cells displayed an 
increase in mEPSC frequency. Neurones expressing SynGAPAα2 had comparable 
mEPSC values to control cells. Thus, it appears that the distinct combinations of N- 
and C- terminal domains determine the functional effects of SynGAP at excitatory 
synapses. Whether these different isoform combinations preferentially bind to 
different Ras family members requires further investigation but could provide further 
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1.4.11 Mouse model of Syngap1 haploinsufficiency 
The Syngap heterozygous mouse was first generated by Kim et al. (2003) by 
insertion of a neomycin cassette into the site of exon 7 and 8 of the Syngap1 gene 
that resulted in the deletion of the region encoding the C2 domain of SynGAP 
protein. This insertion led to the generation of transcripts with premature stop 
codons. Since then, several groups have generated their own versions via the 
insertion of a neomycin cassette in to the Syngap1 allele. Vazquez et al. (2004) 
generated a Syngap heterozygous mouse by inserting a neomycin cassette flanked by 
two lox P sites into intron 3 of the Syngap1 gene with an additional lox P site at 
intron 9. This meant that upon exposure to cre recombinase exons 4-9 were deleted, 
which encoded the PH and C2 domain of the SynGAP protein. Komiyama et al. 
(2002) used a similar approach except the neomycin cassette was inserted in to a 
region that resulted in the deletion of the region encoding C2 and GAP domain. All 
transgenic lines generated mutants that had only one functional Syngap1 allele.  Thus 
Syngap heterozygous neurons displayed approximately half as much SynGAP 
protein expression, whilst full knockouts produce no detectable levels of SynGAP 
protein (Vazquez et al. 2004). Clement et al. (2012) developed a conditional KO 
SynGAP transgenic mouse where SynGAP expression could be lost in temporal 
manner. In addition this mouse line was engineered so that SynGAP could be 
conditionally rescued at a later developmental time point, correcting reduced 



















Figure 1.12 SynGAP N- and C-termini isoforms determine synaptic strength. Schematic 
illustrating the functional consequences of SynGAP isoform expression on synaptic strength based on 
recorded miniature excitatory postsynaptic currents (mEPSC) in forebrain cultures. Overexpression of 
N-terminal isoform Syngap A and C-terminal isoform α1 reduce synaptic strength, with Syngap A 
having greater influence on synaptic strength than any other isoform. In contrast expression of N-
terminal isoform B and C and C-terminal isoform α2 increase synaptic strength. Figure from 







1.4.12 Behavioural phenotypes in Syngap mutant mice 
Initial observations of Syngap KO mice reported no gross anatomical abnormalities 
and pups appeared to feed and breathe normally. However, the majority of pups died 
between P2-7, indicating that SynGAP expression is crucial for postnatal viability 
(Komiyama et al. 2002). Although it remains unclear why Syngap KO mice die, 
there is evidence that suggests Syngap null mice have enhanced cortical apoptosis 
(Knuesel et al. 2005). In stark contrast Syngap heterozygote mice, which have a 50% 
reduction in SynGAP protein expression levels, appear to develop normally and are 
viable and fertile. They display no sign of seizures, tremor, ataxia or other 
neurological abnormalities (Komiyama et al. 2002). There also appears to be normal 
development of tissues and organs, similar to WT mice. This might not be surprising 
considering SynGAP expression is isolated to the brain, however no gross 
anatomical abnormalities were detected in the brain either at P5 (Kim et al. 2003). 
 
Behavioural studies of Syngap heterozygous mice have reported a multitude of 
deficits indicating that SynGAP expression is crucial for the normal development of 
human cognition. One of the most robust behavioural phenotypes to be observed in 
Syngap heterozygous mice is increased locomotive activity in the open field at both 
juvenile and adult ages (Guo et al. 2009; Clement et al. 2012; Muhia et al. 2010). 
This is accompanied by increased exploratory behaviour of the central zone 
compared to WT counterparts that remain close to the periphery during exploration. 
This suggests Syngap heterozygous mice are more hyperactive than WT counterparts 
and may have abnormal anxiety levels. In the elevated plus maze, spontaneous 
anxiety-like behaviour was assessed by the amount of time spent in the open arm 
relative to the closed arm. Syngap heterozygote mice spend more time in the open 
arm, indicating a reduced anxiety level compared to WT mice (Muhia et al. 2010). 
Although contextual fear conditioning appeared normal in Syngap heterozygote 
mice, cued fear conditioning was impaired with Syngap heterozygotes displaying 
significantly less freezing upon receiving an audio cue, which had been previously 
paired a with a foot shock (Muhia et al. 2010). 
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In the Morris water maze Syngap heterozygous mice display a slower rate of 
learning, initially swimming much longer path lengths to reach a submerged platform 
relative to their WT counterparts (Muhia et al. 2010; Komiyama et al. 2002). They 
also display mild deficits in spatial memory when the platform is moved from its pre-
learnt location. Working and reference memory were also examined in the radial arm 
maze and found to be significantly impaired in Syngap heterozygote mice (Muhia et 
al. 2010). 
 
With the exception of thermal nociception, Syngap heterozygous mice appear to have 
enhanced responses to sensory stimuli in vivo. Syngap heterozygote mice display a 
reduced seizure threshold upon exposure to audiogenic and fluorothyl-induced 
seizures, enhanced acoustic startle and reduced prepulse inhibition (Clement et al. 
2012). Electroencephalography (EEG) recordings in Syngap mutants revealed 
frequent and widespread cortical epileptiform discharges that were absent in WT 
littermates (Ozkan et al. 2014). Furthermore it is observed in vitro, using laser 
photolysis of caged glutamate paired with fast-voltage-sensitive dye imaging, that 
signal propagation through the hippocampus and cortex is dramatically amplified in 
brain slices prepared from neonatal and adult Syngap heterozygous mice, 
respectively (Clement et al. 2012) (Ozkan et al. 2014). Muhia et al. (2010) found a 
significant reduction in calbindin-positive inhibitory interneurons in the 
hippocampus that may contribute to network instability in a brain region that is most 
vulnerable to epileptic activity. This data suggests that there is disrupted processing 
of auditory information leading to hypersensitive responses to auditory stimuli as 
well as alterations in sensory-motor gating in the Syngap heterozygote brain and 
could explain the increased incidence of epilepsy in patients with only one functional 
copy of SYNGAP1. 
 
In terms of sociability, when Syngap heterozygote mice were presented with an 
unfamiliar mouse there sociality scored normally. Yet if Syngap heterozygotes had to 
discriminate between a familiar or novel mouse they did not show a preference, 
unlike WT mice. This indicates that Syngap heterozygote mice are unable to 
discriminate a conspecific in a social setting that is required for an organized social 
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hierarchy amongst a group of animals. Furthermore, if they were given the choice 
between socialising with another mouse or isolation, Syngap heterozygotes showed a 
preference for isolation compared to WT siblings suggesting reduced social 
interaction (Guo et al. 2009). 
 
Thus, it appears that Syngap heterozygote mice have deficits in working and 
reference memory, along with increased hyperactivity, abnormal anxiety levels and 
impairments in social recognition. This validates the Syngap heterozygous mouse as 
a robust model of SYNGAP1 haploinsufficiency recapitulating the 
neuropathophysiology associated with the human condition. Many of the behavioural 
phenotypes described above overlap with those reported in the mouse model of FXS. 
This suggests that the consequence of either loss of FMRP or reduced SynGAP 
expression levels result in disruptions of similar neural circuits, most notably in the 
amygdala and hippocampus.  Furthermore, many of these abnormal behaviours, 
including increased susceptibility to AGS, spatial learning, response inhibition and 
temporal discrimination, are linked to altered glutamatergic transmission, which may 
make them amenable to therapeutic interventions.  
 
A recent study investigated which distinct cellular populations may contribute to 
behavioural abnormalities observed in the Syngap heterozygous mice (Ozkan et al. 
2014). Here they crossed a conditional Syngap KO line with a mouse driver line that 
would specifically induce cre-mediated recombination of Syngap1 gene in forebrain 
glutamatergic neurones and glia within regions that included the frontal cortex and 
hippocampus. Disruption of Syngap1 in forebrain pyramidal cells was sufficient to 
induce similar behavioural deficits to those reported in the conventional Syngap 
heterozygous mice, which included increased time spent in the open arm of the 
elevated plus maze, hyperactivity in the open field, impairments in spontaneous 
alternation test, reduced freezing during contextual fear conditioning and an 
increased susceptibility to flurothyl-induced seizures (Ozkan et al. 2014). These 
findings suggest that Syngap1 haploinsufficiency in forebrain glutamatergic neurons 
and glia are specifically responsible for certain cognitive deficits observed in the 
Syngap heterozygous mouse. 
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Efforts have been taken to see whether behavioural and cognitive impairments in 
Syngap heterozygous mice can be rescued by the conditional reversal of Syngap1 
haploinsufficiency. Initially a similar approach was taken to that reported by Guy et 
al. (2010) who successively reversed the deficits reported in Rett Syndrome.  Here a 
mouse line was engineered with a lox P sites on exon 5/6 and 7/8 of the Syngap1 
gene, which was crossed with a hemizygous inducible and ubiquitously-expression 
Cre-ERt2 driver line that was effective in rescuing gene expression in adult mice 
(Guy et al., 2007). Prior to genetic reversal animals were put through a battery of 
behavioural tasks at 8 weeks, administered tamoxifen for 5 consecutive days and 
then retested 1 month later in the behavioural battery following genetic reversal. 
However, both Syngap heterozygous mice with and without genetic reversal 
displayed increased time in the open arm of the elevated plus maze, increased 
activity in the open field, and a lack of spontaneous alternation in the T-maze 
(Clement et al., 2012). Thus reintroduction of Syngap expression in adulthood did 
not rescue basic working memory in Syngap heterozygous mice, like it did in the 
mouse model of Rett syndrome, suggesting that Syngap1 haploinsufficiency is 
disorder of development.  
 
This suggests that loss of SynGAP is particularly damaging to the developmental 
brain and may mean there is a more limited time window for therapeutic 
intervention. Unlike Mecp2 whose expression is preferentially abundant in mature 
neurones (Shahbazian et al. 2002), Syngap mRNA and protein expression peaks 
early on in postnatal development (P14) (Clement et al. 2012). Thus perhaps the 
reversal of Syngap1 haploinsufficiency at over 8 weeks of age was too late when the 
majority of behavioural and synaptic plasticity deficits have manifested and led to 
secondary consequences. 
 
The region-specific deletion of Syngap1 using a conditional KO crossed with an 
EMX1-ire-Cre driver mice, which induces Cre-mediated recombination in forebrain 
glutamatergic neurones, lead to a reduction of SynGAP expression in the prefrontal 
cortex and hippocampus, without a detectable difference in SynGAP expression in 
the striatum. These mice displayed similar behavioural deficits to those reported in 
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the conventional Syngap heterozygous mice, which included increased time spent in 
the open arm of the elevated plus maze, hyperactivity in the open field, impairments 
in spontaneous alternation test, reduced percentage freezing during contextual fear 
conditioning and an increased susceptibility to audiogenic seizures (Ozkan et al. 
2014). Interestingly, when the mutation was specifically reversed in the 
glutamatergic neurones and glia in the forebrain all behavioural deficits were 
prevented with the exception of hyperactive in the open field and increased 
susceptibility to flurothyl-induced seizures indicating that brain regions outwith of 
the forebrain may be contributing to these abnormalities (Ozkan et al. 2014).  
 
1.4.13 Spine phenotypes in Syngap heterozygous mice 
SynGAP expression levels increase during the first two weeks of postnatal life 
peaking at P14, which coincides with synaptogenesis (Clement et al. 2012). 
Examination of spine development in hippocampal cultures at DIV 10 revealed that 
Syngap KO pyramidal neurones had a subtle increase in the number of protrusions, 
which was absent in more mature cultures (DIV 21) (Vazquez et al. 2004). Unlike 
WT neurones that displayed thinner elongated spines, in Syngap KO neurones the 
head width and area of protrusions were markedly increased. This increase in spine 
head size was also observed when more mature Syngap KO neurones were examined 
(DIV 21), indicating that abnormalities in spine morphology persist in to adulthood. 
Similarly, Carlisle et al. (2008) found that adult hippocampal neurones from Syngap 
heterozygous mice had more mushroom-shaped spines with a larger head volume 
and length relative to WT neurones. The abnormal spine morphology Vazquez et al. 
(2004) reported in Syngap KO neurones at DIV 10 could be reversed towards that of 






In Syngap KO neurones, the increased dendritic spine size was accompanied with 
larger clusters of synaptic proteins including PSD-95, GluA1 and an GluN1 
(Vazquez et al. 2004). Although the number of clusters was similar between 
genotypes, the proximity of these clusters to the head of the spine was abnormal in 
Syngap KO neurones. In WT neurones, protein clusters were smaller and localised to 
the dendritic shafts whilst in Syngap KO neurones they were localised in the tips of 
spines. The composition of these clusters was also altered, with more Syngap KO 
protrusions containing AMPA receptors and NMDA receptors, as opposed to just 
NMDA receptors, indicating that the proportion of silent synapses in Syngap KO 
neurones are far fewer at DIV 10 than in WT neurones. 
 
Clement et al. (2012) investigated dendritic spine size, density and dynamics in 
granule cells of the dentate gyrus. At P9, Syngap heterozygote granule cells had 
similar spine head widths, however by P14 head diameter was significantly larger 
and this phenotype persisted in to adulthood. This, in turn, shifted the morphological 
classification towards more mushroom-like spines with fewer stubby spines by P14. 
However, overall spine density was unaltered in Syngap mutants versus WT mice. 
Examination of dendritic branches revealed that dendritic arborisations were 
unaltered in Syngap heterozygote mice but overall spatial volume occupied by these 
arborisations was decreased relative to WT counterparts (Clement et al. 2012). At 
P14, spine motility was reduced to an adult-like rate in Syngap mutants relative to 
WT mice.  The replication of spine phenotype in slice provides further support for 
the SynGAP playing a key role in the maturation rate of dendritic spines in multiple 









Since spine structure is regulated by actin dynamics that is in turn is regulated by 
cofilin signalling (Gu et al. 2010). Basal levels of phosphorylated cofilin were 
examined in both hippocampal and forebrain homogenates from young and adult 
Syngap heterozygous mice, respectively (Carlisle et al. 2008; Clement et al. 2012). 
Both groups reported increased phosphorylation of cofilin at steady-state levels. This 
is thought to be mediated by aberrant Ras signalling, which consequently effects Rac 
downstream signalling (Carlisle et al. 2008). Rac phosphorylates and inactivates 
cofilin leading to an increase in actin polymerization thought to underlie exaggerated 
spine growth. 
 
In the hippocampus, the loss of FMRP or reduced expression of SynGAP appears to 
impact spine development. In both mutants, spine morphology was abnormal in CA1 
pyramidal neurones at both young and adult ages. Data from the Syngap 
heterozygous mutants at P14 Clement et al. (2012) agrees with those findings 
reported by Grossman et al. (2010) in Fmr1 KOs at a similar time point. However, 
Levanga et al. (2011) reported that the increase in spine head width in Fmr1 KO 
mice did not persist in to adulthood. They observed a shift towards a greater number 
of elongated protrusions in the hippocampus of adult Fmr1 KO mice. However, these 














1.4.14 Syngap heterozygous mice display incomplete cellular segregation in the 
somatosensory cortex 
The role of SynGAP in the development and lamination of the cortex was assessed 
by Barnett et al. (2006). Here it was found that there is complete loss of cellular 
segregation into barrels in layer 4 of the primary somatosensory cortex in Syngap 
KO mice. Examination of these afferents in Syngap KO brains revealed that they 
terminate and segregate in to rows in layer 4 correctly but do not segregate into a 
barrel-like pattern. This incomplete segregation of TCAs was also observed in the 
barreloids of thalamus but not in the barrelettes of the brainstem. In Syngap 
heterozygotes, normal segregation of TCAs into whisker-related patches is observed, 
yet there was significant reduction in barrel segregation, with a reduction in the ratio 
of cells in the barrel wall relative to barrel hollow.  
 
1.4.15 Synaptic transmission in the hippocampus of Syngap heterozygous mice 
During development SynGAP plays a significant role in regulating glutamatergic 
signalling at the synapse. A recent study by Clement et al. (2012) investigated basal 
synaptic transmission in the medial perforant pathway and Schaffer collateral 
pathway of the hippocampus at various time points to elucidate whether basal 
synaptic activity of AMPA receptors in Syngap heterozygous mice is altered. Based 
on the I/O relationship they found synaptic transmission to be normal at very early 
ages (P9) but increased in Syngap heterozygous mice by P14. This increase in I/O 
function was accompanied by an increase in the ratio of AMPA/NMDA receptor 
currents in DGNs, the result of increased incorporation of AMPA receptors. By P21 
synaptic transmission in WT reached the same level observed Syngap heterozygous 
slices. This is in agreement with other reports that find basal synaptic transmission in 
the hippocampus of adult heterozygous mice is intact (Komiyama et al. 2002; Kim et 
al. 2003). Thus, SynGAP might regulate a ‘critical period’ of synapse maturation and 
the reduction of SynGAP results in a premature acceleration of synaptic strength 
during early development. 
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In contrast, the I/O relationship in layer2/3 of the medial prefrontal cortex was absent 
at young ages but increased in adult Syngap heterozygous acute slices, where 
mEPSC frequency and amplitude were also elevated (Ozkan et al. 2014). In the same 
study a reduction in miniature inhibitory postsynaptic currents (mIPSCs) and a 
reduced firing rate in parvalbumin positive inhibitory neurones at 6 weeks of age, 
was observed in medial prefrontal slices from Syngap heterozygous mice. Genetic 
reversal of Syngap haploinsufficiency failed to restore elevated synaptic strength in 
L2/3 of the medial prefrontal cortex in Syngap heterozygous mutants (Ozkan et al. 
2014). The observed imbalance in excitation to inhibition (E/I) ratio in adult Syngap 
heterozygous mice is also reported in the mouse model of NF1 (Cui et al. 2008). 
 
These findings suggest that during development, reduced SynGAP expression 
increases E/I ratio in different cell types and time points, which underlies the 
hyperexcitability phenotypes reported in the hippocampus and prefrontal cortex at 
the same developmental time points in Syngap heterozygous brain (Clement et al. 
2012; Ozkan et al. 2014). This increase in excitatory drive from granule cells and 
pyramidal neurons of CA1 and layer2/3 of the medial prefrontal cortex will likely 
disrupt local synaptic circuits, which is supported by amplified signal propagation 
that is observed in these regions (Clement et al. 2012; Ozkan et al. 2014). 
 
The relationship between loss/reduced levels of SynGAP and synaptic activity of 
AMPA receptor has also been examined in neuronal cultures. Analysis of mEPSCs 
revealed that AMPA receptor mediated synaptic transmission was potentiated in 
Syngap KO and KD (KD of Syngap α) hippocampal neurones relative to WT 
counterparts (Wang et al. 2013; Rumbaugh et al. 2006). The potentiation of mEPSCs 
resulted from an increase in the frequency of events with no change in the amplitude 
(Rumbaugh et al. 2006), the latter partially contradicting other studies which have 
shown an increase in mEPSC amplitude as well (Vazquez et al. 2004; Clement et al. 
2012). In contrast, Wang et al. (2013) observed an increase in mEPSC amplitude not 
in frequency in cortical neurones with KD levels of SynGAP. The same group went 
on to show that the increase in mEPSC amplitude was the result of enhanced 
incorporation of GluA2-containing AMPA receptors indicating that under basal 
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conditions SynGAP represses the insertion of Ca2+ permeable AMPA receptors. The 
potentiation of mEPSCs amplitudes could be corrected by either the expression of 
WT SynGAP in KO/KD neurones, or by the inhibition of protein synthesis, mTOR 
or ERK1/2 (Wang et al. 2013).  
 
 
1.4.16 LTP is impaired in the hippocampus of Syngap heterozygous mice 
Electrophysiological recordings in hippocampal CA1 have revealed that LTP, 
induced by a variety of stimulation paradigms, is consistently impaired in Syngap 
heterozygous mice (Komiyama et al. 2002; Kim et al. 2003; Ozkan et al. 2014). 
There was significantly less potentiation observed in Syngap mutants relative to WT 
slices, upon application of HFS (2 × trains of 100 Hz and 6 × trains of 100 Hz) or 
theta-burst stimulation to the Schaffer collateral pathway. This LTP deficit occurred 
in the absence of any alterations in basal synaptic transmission, paired pulse ratios or 
NMDA receptor mediated synaptic currents and could be restored to WT levels by 
the genetic reversal of Syngap haploinsufficiency (Komiyama et al. 2002; Ozkan et 
al. 2014). This finding suggests that basal synaptic activity of AMPA receptors in 
Syngap mutants is normal, however their recruitment to the membrane surface upon 
LTP-inducing stimuli is defective.  
 
Examination of downstream signalling pathways involved in LTP expression 
following theta burst stimulation revealed that both Ras-GAP and ERK1/2 activity 
levels were dramatically increased in WT slices. In contrast, no significant increases 
in the activation state of Ras-GAP and ERK1/2 were observed in Syngap mutant 
hippocampal slices (Ozkan et al. 2014), however basal activity levels of Ras-GAP 
and ERK1/2 were already significantly elevated suggesting that this pathway is 
saturated in the hippocampus of Syngap heterozygous mice. Genetic reversal of 
Syngap haploinsufficiency normalised increased levels of basal Ras and ERK1/2 
activity (Ozkan et al. 2014).  
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1.4.17 NMDAR-dependent LTD in the hippocampus of Syngap heterozygous 
mice  
The role of SynGAP in NMDAR-dependent forms of LTD has been examined in 
hippocampal CA1 and appears specific to certain LTD stimulation protocols. LTD 
induced by paired pulse low frequency stimulation (PP-LFS) appears intact whilst 
LTD induced by the acute application of NMDA (5 min in presence of high Ca2+) is 
significantly impaired (Carlisle et al. 2008; Kim et al. 2003). Although PP-LFS is 
normally considered a Gp1 mGluR-dependent form of LTD, experimental conditions 
were manipulated so that only NMDA receptors would be activated (ACSF 




1.4.18 Basal protein synthesis Rates are elevated in the cortex of Syngap 
heterozygous mice 
In Syngap KD cortical cultures, basal levels of protein synthesis were assessed using 
fluorescent non-canonical amino acid tagging (FUNCAT) (Wang et al. 2013). This 
technique involves replacing endogenous methionine with azidohomoalanine (AHA), 
which is incorporated into newly translated proteins in methionine’s place. In Syngap 
KD neurones there was an increased AHA signal in dendrites suggesting that during 
basal conditions SynGAP suppresses mRNA translation at local synaptic sites. The 
introduction of WT Syngap in KD neurones, rescued enhanced protein synthesis 
rates, however overexpression of Syngap in WT neurones did not suppress protein 
synthesis rates further. Similarly, enhanced protein synthesis rates in Syngap KD 
neurones could be corrected by either mTOR or ERK1/2 inhibition suggesting that 






1.4.19 Downstream signalling cascades regulated by SynGAP 
SynGAP negatively regulates the activity of Ras family members, which include 
Ras, Rap1 and Rap2. These small G-proteins cycle between an active (GTP-bound) 
and inactive (GDP-bound) state regulated by guanine exchange factors (GEF) and 
GAP proteins. GAP proteins, such as SynGAP, convert active Ras in to its inactive 
form by enhancing the rate of GTP hydrolysis. This prevents further activation of 
downstream targets of Ras signalling, which include the ERK1/2-MAPK, PI3K-Akt-
mTOR and P38-MAPK pathways. Ras-mediated signalling plays a crucial role in 
regulating protein synthesis rates and the expression of certain forms of synaptic 
plasticity (Osterweil et al. 2010; Hou & Klann 2004; Gallagher et al. 2004; Sharma 
et al. 2010). Thus not surprisingly, in the Syngap heterozygous brain Ras activity is 
significantly elevated, which is likely to have detrimental effects on a wide array of 
cellular processes considering the number of effectors that lie downstream of Ras 
signalling (Carlisle et al. 2008). 
mTOR signalling cascade 
At present the activity of mTOR and components of this pathway have not been 
assessed when SynGAP expression is either lost or reduced. However, inhibition of 
mTOR signalling by rapamycin corrected enhanced mEPSC amplitude and elevated 
protein synthesis rates in Syngap KD cortical cultures (Wang et al. 2013). Likewise 
overexpression of mTOR increased mEPSC amplitude in WT cultures to a level that 
was observed in Syngap KD neurones. These findings suggest that in the absence of 
SynGAP the mTOR signalling pathway is hyperactive and under basal conditions 
SynGAP normally downregulates mTOR activity, inhibiting AMPA receptor 
insertion via a protein synthesis dependent mechanism.  
ERK1/2-MAPK signalling cascade 
Basal levels of MEK1/2 and ERK1/2 activity are enhanced in the hippocampus of 
Syngap heterozygote mice in the absence of any changes in total protein expression 
(Komiyama et al. 2002; Ozkan et al. 2014), which is reproduced in Syngap KO 
neuronal cultures (Rumbaugh et al. 2006) but not consistently (Krapivinsky et al. 
2004). Likewise overexpression of SynGAP reduces ERK1/2 activity in neuronal 
cultures whilst inhibition of the Ras-ERK1/2 pathway with U0126 corrects the 
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increase in mEPSC amplitude observed in Syngap KD cortical neurones (Wang et al. 
2013). Together this data suggests that ERK1/2 is a downstream target of SynGAP 
and under basal conditions SynGAP suppresses the activity of ERK1/2 signalling 
limiting the insertion of AMPA receptors at the synapse. Thus, when SynGAP 
expression levels are reduced or absent, ERK1/2-MAPK signalling cascade is 
hyperactive.  
p38 signalling cascade 
In Syngap KO cortical neurones, it was reported that p38 activity was markedly 
reduced compared to WT neurones (Rumbaugh et al. 2006). Yet Krapivinsky et al. 
(2004) finds p38 activity to be increased in Syngap KO hippocampal neurones. These 
discrepancies could be due to differences in neuronal cultures (cortical neurones vs. 
hippocampal neurone). Also, Krapivinsky et al. (2004) uses hippocampal cultures 
from mice that only lack the α isoform of SynGAP.  
 
1.4.20 Convergence of FMRP and SynGAP 
The mouse model of Syngap1 haploinsufficiency shares many of the cognitive 
disturbances reported in Fmr1 KO mice, including learning and memory deficits, 
impaired social interactions and an increased susceptibility to epileptic seizures. 
Furthermore there appears to be further phenotypic between Syngap heterozygous 
and Fmr1 KO mice at the cellular and molecular level. Two key pathways implicated 
in the pathology of FXS, ERK1/2 and mTOR, appear to be hyperactive and 
dysregulated in Syngap heterozygous brain. Furthermore, protein synthesis rates are 
elevated in Syngap KD cortical cultures and accompanied by increases in AMPA 
receptor insertion at the postsynapse (Wang et al. 2013). Likewise, NMDAR-
dependent forms of LTP are impaired in the hippocampus of Syngap heterozygous 
mice consistent with Fmr1 KO mice (Komiyama et al. 2002; Kim et al. 2003; Ozkan 
et al. 2014).  
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1.5 Aims of this thesis 
 
Based on pathophysiological axis of ID, one would predict that mutations in Fmr1 
and Syngap1 reside on the same part of the spectrum, perhaps even share the same 
pathological axis (Figure 1.7). This is founded on the evidence that: (1) Ras-ERK1/2 
activity is elevated in the hippocampus of Syngap heterozygous mice, (2) LTP is 
impaired, and (3) protein synthesis rates are increased in Syngap KD cultures. If true, 
then one would suspect that mGlu1/5 dependent synaptic plasticity and protein 
synthesis to be exaggerated in the hippocampus of Syngap heterozygous mice, the 
consequence of hyperactivation of Ras-mediated signalling. Thus, the focus of this 
thesis is to determine whether these two genetically distinct causes of ID share 




Chapter 3: Characterise mGluR-dependent synaptic plasticity and basal protein 
synthesis rates in the hippocampus of Fmr1 KO and Syngap heterozygous rodents to 
determine whether: 
 
1.) mGluR-dependent LTD is enhanced and independent of new protein in our 
mouse model of FXS. 
2.) mRNA translational rates are elevated in Fmr1 KO mice and if these 
phenotype translates to the rat model of FXS. 
3.) Syngap heterozygous mice share a similar hippocampal pathophysiology to 
Fmr1 KO mice. 








Chapter 4: Analyse the activation states of key components of the ERK1/2 and 
mTOR signalling cascade and measure expression levels of synaptic proteins to 
determine whether: 
 
1.) Syngap1 haploinsufficiency results from a hyperactivation of ERK1/2 and/or 
mTOR signalling. 
2.) protein synthesis rates are saturated downstream of mGlu1/5 receptor 
activation. 




Chapter 5: Pharmacological rescue of the hippocampal pathophysiology in Syngap 
heterozygous mice to determine whether: 
 
1.) elevated protein rates and mGluR-dependent LTD lie downstream of ERK1/2 
or mTOR signalling. 
2.) therapeutic interventions utilised in the Fmr1 KO can restore normal synaptic 
function in Syngap heterozygous mice  
3.) alterations in mGlu5 receptor signalling can be restored in adult mice 
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Chapter 2: Materials & Methods 
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2.1  Common Methods  
There are several rodent transgenic lines used in this thesis and below gives a brief 
description of each mutant line.  There are some particulars that are common to all 
and are mentioned here.  
2.1.1 Housing and Breeding 
All animals were group housed and maintained in a facility that was kept on a 12:12 
h light: dark cycle and treated in accordance with UK Home Office regulations. All 
experimental animals were male, and mutants were generated with wild-type (WT) 
littermate controls. Experiments were performed blind to genotype, unless otherwise 
stated.  
2.1.2 Generation of the Fmr1 Knockout Mouse 
Fmr1 knockout (KO) mice were originally purchased from Jackson laboratories and 
were generated by interrupting exon 5 with the positive selection marker gene, 
neomycin Figure 2.1 A. Mice were backcrossed by at least 10 generations on to the 
C57Black/6JOla background (Harlan), from the original C57Black6J (Jackson), by 
crossing an Fmr1 heterozygous females mouse WT males selected from previous 
litters.  
2.1.3 Generation of the Syngap Heterozygous Mouse 
The Syngap mutant mouse was generated by Komiyama et al. (2002) at the Sanger 
Institute. Deletion of the Syngap1 gene involved the insertion of a targeting vector 
that consisted of a coding sequence for hemagglutinin epitope tag followed by stop 
codons and an internal ribosomal entry site (IRES)-lacZpolyA_MC1neo-polyA 
cassette, which resulted in the deletion of exons encoding the C2 domain and part of 
the GAP domain of the Syngap1 gene (Figure 2.1 B). Immunoblotting of 
hippocampal extracts revealed a 50% reduction in SynGAP expression (Komiyama 











Figure 2.1 Generation of Fmr1 KO, Syngap Heterozygous & Double Mutant Lines. (A) The 
Fmr1 knockout (KO) mouse was generated by the insertion of a neomycin cassette into exon 5 of the 
Fmr1 gene. (B) Exonic structure of the Syngap1 gene with the targeting vector that contains: HA; 
hemaglutinin sequence; IRES, internal ribosome entry site, LacZ, ß-galactosidase gene; neo, 
neomycin resistant gene. The resultant vector deletes the region encoding the C2 and GAP domains of 
the Syngap1 gene. (C) Mating of an Fmr1 KO female with Syngap heterozygous male generates WT, 













Animals were initially bred on an MF1 genetic background (Sanger Institute) before 
being partially backcrossed onto a C57Black6JOla line. Syngap heterozygous 





2.1.4 Generation of a Syngap Heterozygote and Fmr1 Knockout Double Mutant 
Syngap heterozygous and Fmr1 KO double mutant mice were generated by crossing 
a Syngap heterozygote males with female Fmr1 heterozygotes, which were partially 
and fully backcrossed and bred on a C57Black6JOla background, respectively. From 
the cross there were four possible outcomes:  WT, Fmr1 KO single mutant, Fmr1 
KO and Syngap heterozygote double mutant and Syngap heterozygote single mutant 
(Figure 2.1 C). Only first generations of litters were used for experimental purposes. 
2.1.5 Generation of the Fmr1 KO Rat  
 
The rat model of FXS was purchased from Sigma SAGE laboratories and bred on a 
Sprague Dawley background. Fmr1 KO rats were generated using a zinc-nuclease 
methodology that involves these DNA-binding proteins creating a double strand 
break at the Fmr1 locus, deleting the gene and resulting in the loss of FMRP 
(Hamilton et al. 2014).  
2.1.6 Genotyping  
DNA Digest  
Tissue in the form of ear and tail clips was collected in 1.5 ml eppendorfs from mice 
at P14 or during hippocampal slice preparation. DNA was extracted using the 
Wizard® SV Genomic DNA Purification System (Promega) according to the 
manufacturer’s instructions with a minor modification to the DNA elution step.  
 
For DNA digestion, 20 mg of tissue sample was digested in 275 µl of digestion 
solution master mix consisting of 200 µl nuclei lysis solution, 50 µl EDTA (0.5 M, 
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pH 8.0), 20 µl proteinase K (20 mg/ml) and 5 µl RNase A solution (4 mg/ml). 
Samples were mixed and incubated overnight (16-18 hours) in a water bath at 55 ◦C. 
DNA Purification  
For DNA extraction and purification, 250 µl of Wizard® SV Lysis Buffer was added 
to each sample and mixed. Sample lysate was transferred to a separate Wizard® SV 
mini-column assembly and spun at 13000 × g for 3 minutes. The mini-column was 
removed and the liquid was discarded. Next, 650 µl of Wizard® SV wash solution 
(with 95% ethanol) was added to each assembly and centrifuged at 13,000 × g for 1 
minute. This step was repeated for a total of 4 washes discarding liquid waste 
between washes. After the final wash the mini-column was spun at 13000 × g for 2 
minutes to dry the binding matrix.  The mini-column was transferred to fresh 1.5 ml 
eppendorf tubes and 250 µl of nuclease-free water was added and left to incubate at 
room temperature for 4 minutes. The mini-column plus elution tube was then 
centrifuged at 13000 × g for 3 minutes. The mini-column was removed and the DNA 
stored in the elution tube at -20 ◦C. 
Fmr1 PCR reaction 
For each DNA sample, one reaction was performed with two sets of primer pairs: 
2009/2010 (Sigma-Aldrich: 2009, 5’ – GTG GTT AGC TAA AGT GAG GAT GAT 
-3’; 2010 5’- CAG GTT TGT TGG GAT TAA CAG ATC –3’), amplifies the 500 bp 
product of the WT allele; and 162/163 (Sigma-Aldrich: 162, 5’ –CCG GTT CTT 
TTT GTC AAG ACC G -3’; 163, 5’- CGG CAG GAG CAA GGT GAG AT -3’), 
detects the neomycin cassette of the KO allele. The PCR reaction mix for each 
reaction, consisted of 4.25 µl of double distilled water (ddH2O), 6.25 µl of Promega 
GoTaq Green Master Mix and 0.5µl of 2009 (20 µM), 0.5 µl of 2010 (20 µM), or 0.5 
µl of 162 (20 µM) and 0.5 µl of 163 (20 µM). From the PCR reaction mix 11.5 µl 
was transferred to PCR tubes (Scientific Laboratory Supplies Ltd) and 1 µl of the 
DNA sample was added. The thermocycling conditions of the PCR reaction for 
primer pairs 2009/2010 and 162/163 are summarised in Table 2.1. The PCR products 
consisted of a 197 bp band, which represents the neomycin cassette of the Fmr1 KO 
allele, and a 500bp band, which indicates the presence of the Fmr1 gene. These PCR 
 90 
products were run on a 0.75 % agarose (Sigma-Aldrich) gel at 50 mV for 35 minutes 
with a 100 bp DNA ladder (New England BioLabs). 
Syngap PCR reaction 
To detect the presence of the transgenic cassette in the Syngap allele two sets of 
primers were used: Syn12R (Sigma-Aldrich; 5’ – CAT ACA AGA ATT GCT GCA 
TAG AAC -3’), a common reverse primer; in conjunction with either Fcass1A 
(Sigma-Aldrich; 5’ – CTT CCT CGT GCT TTA CGG TAT C -3’), a forward primer 
complementary to the transgenic cassette or Syn11R (Sigma-Aldrich; 5’ – TTC ATG 
GAG CGG GAA CAC CTC ATA T -3’), a forward primer complementary to the 
WT sequence. The PCR reaction mix consisted of 4.25 µl of ddH2O, 6.25 µl of 
Promega GoTaq Green Master Mix, 0.50 µl of Syn12R (20 µM) and 0.50 µl of 
Fcass1A (20 µM) or 0.50 µl of Syn11R (20 µM). 1 µl of purified DNA was added to 
the reaction mix and spun. Thermocycling conditions are summarised in Table 2.1. 
The PCR product of the reaction is approximately 1 kb for the KO allele and 2.5 kb 
for the WT reaction. These are detected by running the PCR products on a 0.6% 






















Table 2.1 Thermocycling conditions for Syngap and Fmr1 genotyping.  
 
  
 Genotyping Thermocycling Conditions 
Syngap1  Fmr1  
Step Temperature (ºC) Duration Temperature (ºC) Duration 
1 95 15 min 94 15 min 
2 95 30 sec 94 30 sec 
3 94 10 sec 63 10 sec 
4 55 30 sec Go to Step 3 34X 30 sec 
5 68 3 min  72 1 min  
6 Go to Step 3 10X   72 2 min 
7 94 10 sec 4 1 hr 
8 55 30 sec 
  
9 68 3 mins 
10 Add 20 secs/cycle    
11 Go to Step 7 28X   
12 68 7 min 















2.2  Methods for Electrophysiology  
2.2.1 Preparation of Horizontal Hippocampal Slices for Extracellular & 
Intracellular Recordings 
Horizontal hippocampal slices from male mice were prepared from postnatal day 20-
32 (P20-32). For experiments involving a comparison between WT and mutant mice, 
animals were chosen at random, and all experiments and data analyses were 
performed blind to the genotype of the animal. After slice preparation on each 
experimental day, the ear and tail were preserved for use in genotyping. All 
chemicals for ACSF were purchased from Sigma-Aldrich. 
 
Briefly, animals were deeply anaesthetized by inhalation of isofluorane released as 
fumes from liquid stock, and killed by decapitation.  The skin covering the skull was 
cut along the midline and peeled back. Using forceps the skull was then cut along the 
midline and towards both ear bones. Brains were removed using a spatula and 400 
µm thick slices were cut using a Leica VT1200S in pre-oxygenated ice-cold 
dissection buffer containing (in mM): NaCl, 86; NaH2PO4, 1.2; KCl, 25; NaHCO3, 
25; glucose, 20; sucrose, 75; CaCl2, 0.5; MgCl2, 7; saturated with 95% O2, 5% CO2.  
 
Slices were hemisected and recovered for 30 minutes at 35 oC in artificial 
cerebrospinal fluid (ACSF) containing (in mM): NaCl, 124; NaH2PO4, 1.2; KCl, 25; 
NaHCO3, 25; glucose, 20; CaCl2, 2; MgCl2; 1, saturated with 95% O2, 5% CO2. The 
hippocampus was sectioned from the rest of the slice and an incision made through 
CA1/CA3 boundary. Slices were left to recover for a further 30 minutes at room 
temperature prior to any experimentation. 
2.2.2 Extracellular Recordings in CA1 of the Hippocampus 
For electrophysiological recordings, slices were placed in a submersion chamber 
heated to either room temperature or 30 ◦C (Fine Science Tools) and perfused with 
pre-oxygenated ACSF containing picrotoxin (50 µM; Abcam), at a rate of 4 ml/min, 
kept constant using a peristaltic pump (Watson Marlow). For field recordings at 30 
°C, ACSF was heated and oxygenated on a Stuart Scientific hotplate. 
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Field excitatory postsynaptic potentials (fEPSPs) were recorded with extracellular 
recording glass microelectrodes (1-4 MΩ; Harvard Apparatus) filled with ACSF and 
placed in the stratum radiatum of CA1 (Figure 2.2). Synaptic responses were evoked 
by applying a current pulse (Stimulator; Digitimer Ltd) every 30 seconds to the 
Schaffer collateral axons with a concentric bipolar nickel/ chromium (80%/20%;) 
stimulating electrode. 
 
2.2.3 Stimulation Paradigms 
Stable baseline responses were recorded every 30 seconds for 30 minutes before the 
induction of any stimulation paradigm. For chemical inductions the following 
compounds were used. (R, S)-3, 5-Dihydroxyphenylglycine (DHPG), D-(-)-2-
Amino-5-phosphonopentanoic acid (D-AP5), anisomycin, picrotoxin and rapamycin 
were purchased from Abcam. CTEP (RO4956371) and U0126-EtOH (U0126) were 
purchased from SelleckChem and lovastatin was purchased from Merck. DHPG and 
D-AP5 were dissolved in ddH2O, whilst anisomycin, rapamycin, CTEP and U0126 
were dissolved in Dimethylsulphoxide (DMSO). To maintain the DMSO 
concentration constant (0.0005%) between experiments, picrotoxin was dissolved in 
either DMSO or ddH2O depending on whether additional inhibitors (e.g. CTEP, 
U0126, rapamycin) were to be added to the ACSF. 
Input-Output Response  
Basal synaptic transmission (input-output relationship) was examined in the CA1 by 
increasing the duration of the current pulse (input) in increments of 20 µs from 20-
200 µs and recording their respective output values by measuring the slope of the 
fEPSP waveform relative to the amplitude of the presynaptic volley. 
 
From the input-output curve the stimulation intensity that yielded 40% of the 
maximum response (prior to contamination by a population- or P- spike) was 
estimated and used to determine paired-pulse ratios and establish a new baseline 
prior the induction of a long-term depression (LTD) paradigm. 
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Paired-Pulse Facilitation 
Paired-pulse facilitation, a form of presynaptic facilitation induced by two stimuli 
presented in rapid succession, was measured by examining the ratio of the fEPSP 
slope of the second pulse relative to the first. Each pulse lasted 0.1 ms delivered at an 
inter-pulse interval ranging from 20-100 ms. 
Induction of Metabotropic Glutamate Receptor Dependent LTD 
mGluR-dependent LTD was induced in CA1 by applying either: 900 paired pulses at 
1 Hz to the Schaffer collateral pathway (PP-LFS), lasting 15 minutes; or the Gp1 
mGlu receptor agonist DHPG (30 µM, 50 µM or 100 µM) in the presence of the 
NMDA receptor antagonist (D-AP5; 50 µM), perfusing the slice for 5 minutes before 
the slice was re-perfused in ACSF containing picrotoxin (50 µM;).  
 
 
For mGluR-dependent LTD experiments in the presence of anisomycin (20 µM), 
rapamycin (20 nM) or U0126 (5 µM or 20 µM), hippocampal slices were 
preincubated in inhibitors or combinations of inhibitors for at 20-30 minutes prior to 
LTD induction and remained in the bathing solution throughout the remainder of the 
recording.   
 
2.2.4 Field Analysis 
Waveform data was collected using WinLTP 1999-2009 (WinLTP Ltd., University 
of Bristol), amplified 1000 times (npi electronics), filtered at 1.3 kHz and digitized 
(National Instruments) at 20 kHz. The data was exported to Microsoft Excel and 
statistical analysis performed in Origin. After genotyping, normalised data were 
averaged across experiments and expressed as a mean ± SEM. Statistics were 
performed using each animal as an ‘n’. Significant differences between two groups) 
were determined using a Student’s t-test (p < 0.05). For experiments involving more 
than two genotypes a one-way analysis of variance (ANOVA) with a Bonferroni 
post-hoc test was used to determine significance (p < 0.05). 
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2.3 Methods for Biochemistry 
2.3.1 Preparation of Transverse Hippocampal Slices  
Protein levels were measured following the protocol outlined in Osterweil et al. 
(2010). On each day 4 animals from both mutant and WT groups were prepared from 
young adult rodent males (P25-32) in an interleaved manner. Animals were given an 
overdose of isoflurane released as fumes from liquid stock, and killed by 
decapitation. The brains were collected using a spatula and the hippocampus was 
dissected in pre-oxygenated ice-cold artificial cerebrospinal fluid (ACSF) containing 
(in mM): NaCl, 124; NaH2PO4, 1.25; KCl, 3; NaHCO3, 26; glucose, 10; CaCl2, 2; 
MgCl2, 1, saturated in 95% O2 and 5% CO2.  Slices were cut (500 µm) using a 
Stoelting tissue slicer. Four dorsal hippocampal slices were taken and left to recover 
in netwells (Corning, Sigma-Aldrich) for at least 4 hours at 30 oC in preoxygenated 
ACSF to allow protein synthesis rates to recover.  
 
2.3.2 Metabolic Labelling  
Slices were transferred to a second recovery chamber containing preoxygenated 
ACSF containing actinomycin D (ActD, 25µM; Tocris), heated to 30 oC and left to 
incubate for 30 minutes to inhibit transcription. For DHPG (100 µM) experiments, 
slices were incubated in ~0.37 MBq/ml of 35S-Met/Cys express protein labelling mix 
(Perkin Elmer) -/+ drug for 5 mins and then transferred to fresh ACSF with 
approximately ~0.37 Mbq/ml 35S–Met/Cys for 40 minutes to measure protein 
synthesis. For metabolic labelling experiments in the presence of CTEP (10 µM & 
20 µM), U0126 (5 µM), lovastatin (50 µM & 100 µM) or rapamycin (20 nM), slices 
were incubated +/- drug during ActD exposure (30 min) and transferred to fresh 
ACSF containing ~0.37 Mbq/ml of 35S-Met/Cys -/+ drug for 45 minutes. Slices were 






















Figure 2.2 Measuring basal protein synthesis in dorsal hippocampal slices. Hippocampi were 
rapidly dissected from rodents between P25-32 and four dorsal transverse hippocampal slices were 
prepared. Slices were left to recover in artificial cerebrospinal fluid (ACSF) for 4 hrs. before 
transcription was blocked with Actinomycin D (ActD; 25 µM) ± vehicle or inhibitor for 30 mins. 
Newly synthesized proteins were metabolically labelled with 35S Methionine-Cysteine (Met/Cys) 
protein labelling mix ± vehicle or inhibitor for 45 minutes. Samples were homogenized and proteins 
precipitated using trichloroacetic acid (TCA) and resolubilised. Counts were measured and normalised 








2.3.3 Processing  
To measure protein levels, slices were homogenized in 150 µl of homogenising 
buffer containing 10 mM HEPES pH 7.4, 2 mM EDTA, 2 mM EGTA, 1% triton X-
100 (Sigma-Aldrich), protease and phosphatase inhibitors. From the homogenate, 75 
µl was removed and taken for western blotting (see section 2.4.3) by adding 50 µl of 
x4 Laemmli samples buffer containing 10% β-mercaptoethanol (Sigma-Aldrich) and 
frozen at -20 oC.  To the remaining homogenate, proteins were precipitated using 
trichloroacetic acid (TCA, 12.5%; Sigma-Aldrich), vortexed and incubated on ice for 
10 minutes before being spun at 13000 × g in a microfuge for 10 minutes at 4 oC. 
The supernatant was removed and 500 µl of ice-cold ddH2O was added to the 
homogenate, inverted and spun at 13000 × g for 5 minutes at 4 oC. Once again the 
supernatant was removed and replaced with 150 µl of NaOH (1 M) and left to 
incubate at 37 oC to dissolve the pellet. The pH was readjusted by adding 50 µl of 
HCl (0.33 M) and 50 µl of sample was added to scintillation vials (Perkin Elmer) 
containing 10 ml of scintillation cocktail (Promega) in triplicates. Sample vials were 
loaded into a scintillation counter, set to read 35S at 2 minutes per sample, which 
gave the number of counts per minute (CPM; Figure 2.3). 
 
2.3.4 BSA Protein Assay for Metabolically Labelled Hippocampal Slices 
The protein concentration of each sample was determined using a Bio-Rad DC kit. 
Initially BSA standards were made using a 10mg/ml BSA stock (New England Bio 
Lab), which was diluted with ddH2O to make a 2mg/ml solution. This 2mg/ml stock 
was then used to make serial dilutions in ddH2O, which ranged from 2mg/ml to 
0.0625 mg/ml. For the protein assay, 5 µl of either BSA standard or protein sample 
were added to a 96-well Nunc plates (Scientific Laboratory Supplies Ltd) in 
triplicate. Next, 25 µl of reagent A containing reagent S’ (20 µl of reagent S for 
every ml of reagent A) was added, followed by 200 µl of reagent B. Plated samples 
were t left to incubate at room temperature for 15 minutes before being read on a 
FluoStar Optima plate reader (BMG Labtech) at an absorbance of 740 nm. Proteins 
concentrations for each sample were calculated based on the BSA standard curve. 
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2.3.5 Analysis of Protein Samples 
The scintillation counts for each sample were divided by the protein concentration, 
as calculated from the BSA standard curve to find cpm/µg.  This value was 
normalised to all other samples by dividing cpm/µg by the cpm for the ACSF control 
sample. To find the number of cpm/µg/µl the previous value was divided by volume 
of sample added to the scintillation (50 µl). 
 
CPM/µμg/µμl     =   
100    (cpm/µμg)/  (CPM  for  ACSF)
Volume  of  sample  added  to  scintillant  
                                                
 
Once the average CPM/µg/µl was calculated for each triplicate. The mean and S.E. 
were calculated for each hippocampal slice. The average % change in protein 
synthesis for each set of hippocampal slices were calculated and expressed as a 
percentage of the WT control. 
  
%  Change  in  basal  protein  synthesis   =       
100  (CPM/µμg/µμl  for  Mutant
CPM/µμg/µμl  for  WT  pair   
 
Statistics were performed using each animal as an ‘n’. Significant differences 
between genotypes (WT versus mutant) were determined by a paired Student’s t-test 
(p < 0.05). However for comparisons of more than two experimental factors 
(genotype & treatment) significance was determined using a two-way ANOVA with 





2.3.6 Western Blotting of Metabolically Labelled Hippocampal Slices 
Loading, Running & Transfer of a Polyacrylamide Gel 
SDS-polyacrylamide gel electrophoresis was performed on metabolically labelled 
protein samples by boiling samples containing 4X Laemmli buffer and 10% β-
mercaptoethanol. For every sample, 10 µl was loaded per lane in to Bio-Rad Mini-
protean precast gels (percentage of polyacrylamide gel varied from 7.5% to 12% 
depending on the protein of interest). Gels were run at constant current in buffer 
containing (in mM): Tris, 25; glycine, 190; SDS, 0.1%; ddH2O. Protein gels were 
electroblotted on to nitrocellulose membrane (Bio-Rad) in buffer containing (in 
mM): Tris, 25; glycine, 190; methanol, 20%; ddH2O. 
 
2.3.7 Western blotting of Hippocampal Homogenates and Synaptoneurosome 
Preparations 
Animals were given an overdose of isoflurane released as fumes from liquid stock, 
and killed by decapitation. The brains were collected using a spatula in pre-
oxygenated ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM): NaCl, 
124; NaH2PO4, 1.25; KCl, 3; NaHCO3, 26; glucose, 10; CaCl2, 2; MgCl2, 1, 
saturated in 95% O2 and 5% CO2. Hippocampi were dissected and frozen on dry and 
stored at -80 oC. Samples were shipped on dry ice to M.I.T (Boston, USA) for 
homogenization and western blotting.  
Homogenization of Hippocampi  
Hippocampi were homogenized in 2 ml glass homogenizers in ice cold 
homogenizing buffer containing (in mM): HEPES, 10; NaCl, 150; EDTA, 2; EGTA, 
2; protease inhibitor cocktail III. From the homogenate 108 µl was removed and 
added to 12 µl of Triton X-100. From this sample 20 µl was removed for a protein 
assay. To the remaining volume, 100 µl of 4X Laemmeli buffer and 10% β-
mercaptoethanol was added and boiled. 
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Preparation of Synaptoneurosomes from Hippocampal Homogenates 
Hippocampal homogenate was filtrated through a 105 µm filter holder using a 3 ml 
syringe (18G needle). The filter was removed and liquid re-filtrated through a 5 µm 
filter holder. Filtrate was spun for 10 minutes at 1000 × g at 4 oC to collect the 
synaptoneurosome pellet, which was then resuspended in 150 µl homogenization 
buffer and Triton X-100.  From the synaptoneurosome homogenate 100 µl was 
added to 100 µl 4X Laemmeli buffer and 10% β-mercaptoethanol and boiled. 
 
BSA Protein Assay for Hippocampal Homogenate and Synaptoneurosome 
Preparations 
The protein concentration of hippocampal and synaptoneurosome homogenates were 
measured using a Bio-Rad DC kit as outlined in section 2.4.4. However, once 
proteins concentrations were calculated using the BSA standard curve, all protein 
concentrations were adjusted to 1 mg/ml. 
 
Making Gels for Western blotting  
Polyacrylamide gels  (10%) were made from two gels: a separating and stacking gel. 
The separating gel contained in ml: ddH2O, 61.5; 30% acrylamide, 49.5; separating 
buffer, 37.5; 10% SDS, 1.5; 10% ammonium persulfate (APS), 1.5; Temed, 75 µl. 
The stacking gel was composed of (in ml): ddH2O, 45.75; 30% acrylamide, 9.75; 
stacking buffer, 18.75; 10% SDS, 0.75; 10% APS, 0.75; Temed, 75 µl; few crystals 
of bromophenol blue. The separation gel was poured into a gel multicaster and a 0.5-
1ml of butanol was poured on to the top of each gel and left for 20-30 minutes to 
polymerise. Once gels were set the butanol was poured off and the tops of the gels 





Loading, Running & Transfer of a Polyacrylamide Gel 
For loading, hippocampal and synaptoneurosomes samples were boiled and 10 µl/ 
per lane was loaded in to gels. Gels were run in a dodeca cell at constant voltage 150 
V in x1 Tris/Glycine/SDS buffer (TGS) diluted in ddH2O from 10X stock (Bio-Rad), 
which contained (in mM): Tris 25mM, glycine 192, 0.1% SDS and ddH2O. Protein 
gels were electroblotted on to nitrocellulose membrane (Bio-Rad) in transfer buffer 
containing 1x TG buffer (Bio-Rad), methanol 20% and ddH2O. 
 
MemCode stain of Membrane 
To visualise all proteins on membranes for quantification purposes a Thermo 
Scientific MemCode Reversible Protein Stain was used according to manufacturer’s 
instructions. Briefly, membranes were incubated in MemCode stain at room 
temperature for 1 minute and replaced with destain shaking vigorously. Destain was 
left to incubate for 5 minutes with membranes being continually shaken. Membranes 
were washed repeatedly with ddH2O and scanned on greyscale.  
 
For LICOR Imaging of Proteins of Interest 
Western blot membranes were cut at specific molecular weights (50, 75 or/and 100 
kDA) so that multiple proteins could be examined on the same gel. They were 
blocked with Odyssey blocking buffer (Li-COR Bioscience) made up in 1 x 
phosphate buffered saline (PBS; Sigma-Aldrich) in a 1:1 ratio for 30 minutes. Block 
was poured off and antibodies made up in a 1:1 ratio of Odyssey blocking buffer and 
PBS with 0.1% tween (Boston Bio Products) and membranes were then probed with 
primary antibody (Table 2.2) and incubated at room temperature for a minimum of 4 
hrs. or overnight at 4 oC. Membranes were repeatedly washed with PBS and 0.1% 
Tween. The respective fluorescent conjugated secondary, either anti-rabbit or anti-
mouse (Li-COR Biosciences), were diluted 1 in 10000 in blocking buffer in a 1:1 
ratio with 1 x PBS and Tween 0.1% and left to incubate for 45 minutes on a rocker. 
The secondary antibody was then discarded and blots washed with 1x PBS 
repeatedly. Membranes were imaged on an Odyssey infrared imaging system (Li-
COR Bioscience). Blots were stripped with 1 x stripping buffer (Millipore) for 30 
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minutes and then repeatedly washed with 1 X PBS before being reprobed in primary 
antibody. 
For ECL Imaging of Proteins of Interest 
For enhanced chemiluminesence (ECL), membranes were cut at specific molecular 
weights (50, 75, 100 or/and 150 kDA) so that multiple proteins could be examined 
on the same gel. They were then blocked with 5% BSA in Tris buffered saline with 
Tween (TBS-T, Bio-Rad) containing (in mM): Tris pH 7.5, 20; NaCl, 150; Tween-20 
0.1%.  The block was poured off and membranes were probed with primary 
antibodies made up in 5% BSA and TBS-T and left overnight at 4 oC (Table 2.2). 
Primary antibodies were poured off and membranes were washed in TBS-T. Blots 
were incubated in secondary antibodies, either anti-rabbit HRP or anti-mouse HRP 
secondary antibodies (GE Healthcare), diluted 1 in 5000 in 3% BSA in TBS-T for 30 
minutes at room temperature then membranes were washed repeatedly with TBS-T. 
Using the ECL Plus Kit, reagent A and B were mixed in a 40:1 ratio and poured over 
the blots and imaged. An exposure series was performed, which ranged from 1 
second to 5 minutes and films were scanned on gray scale. If blots were to be 
reprobed they were washed in TBS-T on a shaker. TBS-T was poured off and 
replaced with 100 ml stripping buffer and 700 µl of beta-mercaptoethanol (Sigma) 
and blots left to incubate to 55 oC for 45 minutes. Blots were washed with several 
times with ddH2O, which was replaced with TBS-T and left to incubate at room 
temperature for 1 hr. Membrane were then left to incubate in 5% BSA block 
(described above) and left to incubate for 1 hr. at room temperature before incubated 
once again being incubated in their appropriate primary antibody overnight at 4 oC. 
 
Protein Quantification 
Imaged gels were uploaded in to Image J and densitometry was performed using the 
analyser software (for full blots of each anti-protein antibody see appendix). Protein 
bands were analysed and included in figures if the band was sufficiently quantifiable 
without the interference of contaminants, such as air bubbles. The expression levels 
of proteins examined via licor methodology were normalised to the loading control 
β-actin (Abcam) whilst those obtained via ECL were normalised to total protein stain 
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obtained by MemCode stain. Protein expression levels were also expressed as a ratio 
between the phosphorylated and unphosphorylated form of the protein. To identify 
and quantify mGlu5 receptor expression in hippocampal homogenates and 
synaptoneurosome preparations, an mGlu5 KO sample was run with all other 
samples. This is because there is no distinctive band produced, rather a smear, which 
can be determined from the known molecular weight of mGlu5 and using the mGlu5 
KO sample as a comparison to determine the boundaries for quantification. For 
GluA2 and PTEN, several bands were observed on the blot, so the one selected was 
based on the predicted molecular weight of each protein. In hindsight, to be 
confident that the right band was selected for GluA2 or PTEN, homogenates of 
GluA2 or PTEN KOs would need to be run alongside samples. For anti phospho/total 
ERK1/2 a double band was produced that was analysed individua 
  
When comparing WT and mutant values, the WT protein levels were considered to 
be 100% and mutant values were expressed as a percentage ± S.E.M. of the WT 
value. When both genotypes and drugs treatments were being compared, all were 
normalised to the WT vehicle value and expressed as a percentage ± S.E.M.  
Significant differences between two groups (e.g. WT versus mutants) paired 
Student’s t-test (p < 0.05). However for more than two groups (genotype x treatment) 
significance was determined using a two-way ANOVA and Bonferroni post-hoc test 
(p < 0.05). It should be noted that western blots performed via ECL methodology 
were only technically replicated once, whilst western blottings performed via licor 
















Table 2.2 Primary antibodies for western blotting 
 
Antigen Host Company Dilution Apparent 
MW (KDa) 
Actin Rabbit Abcam 1:20,000 42 
Akt Rabbit CST 1:1000 60 
CAMKII alpha Mouse Zymed 1:10000 50 
ERK1/2 (p44/42 MAP Kinase)  Rabbit CST 1:1000 44+42 
GluA1 Rabbit Upstate 06-306 1:4000 100 
GluA2 Mouse Chemicon 1:1000 102 
mGlu5 Rabbit Neuromics 1:500 132 
mTOR Rabbit CST 1:1000 289 
GluN1 Goat Sc-1467 1:4000 120 
GluN2A Rabbit MoPro A6473 1:500 180 
GluN2B Goat Sc-1469 1:500 178 
p38-MAPK Rabbit CST 1:200 38 
p70 S6 Kinase  Rabbit CST 1:1000 70 
Phospho-Akt (Ser473) Rabbit CST 1:1000 60 
Phospho-Akt (Thr308) Rabbit CST 1:1000 60 
Phospho-ERK1/2  (p44/42 MAP 
Kinase [Thr202/Tyr204]) 
Rabbit CST 1:1000 44+42 
Phospho-mTOR (Ser2448) Rabbit CST 1:1000 289 
Phospho-p38 (Thr180/Tyr182) Rabbit CST 1:200 38 
Phospho-p70 S6 Kinase (Thr389)  Rabbit CST 1:1000 70+85 
Phospho-PTEN 
(Ser380/Thr382/383)  
Rabbit CST 1:1000 54 
Phospho-S6 Ribosomal Protein 
(Ser235/236) 
Rabbit CST 1:500 32 
Phospho-S6 Ribosomal Protein 
(Ser240/241) 
Rabbit CST 1:500 32 
PTEN Rabbit CST 1:500 54 
S6 Ribosomal Protein  Rabbit CST 1:500 32 
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Chapter 3  
Characterisation of Hippocampal 
Pathophysiology in Fmr1-/y & Syngap+/- 






Chapter 3: Characterisation of Hippocampal Pathophysiology in Fmr1-/y 
Chapter 3.1 Key Findings  
 
 
1. In CA1, chemically induced mGluR-dependent LTD induces a 
robust and long-lasting form of synaptic depression that involves both 
presynaptic and postsynaptic mechanisms in young adult hippocampal 
slices. 
 
2. Consistent with previous reports, mGluR-dependent LTD and is 
enhanced and independent of new protein synthesis and is accompanied 
by increased basal protein synthesis rates in the hippocampus of Fmr1 
KO mice 
 
3. Importantly, the electrophysiological and biochemical phenotypes 
we observe in the hippocampus of Fmr1 KO mice translate to the rat 
model of FXS. 
 
4. Similarly to Fmr1 KO mice, mGluR-dependent LTD is increased 
and independent of new protein synthesis in the hippocampus of Syngap 
heterozygous mice, which also show exaggerated levels of basal protein 
synthesis. 
 
5.  In the Fmr1 KO x Syngap heterozygous double mutants, Syngap1 
haploinsufficiency occludes the increase in mGluR-dependent LTD 





FXS and SYNGAP1 haploinsufficiency are two highly pathogenic causes of ID and 
ASD that have dramatic consequences on the developing brain. FXS is caused by a 
CGG expansion mutation in the FMR1 gene triggering partial or complete loss of the 
RNA-binding protein FMRP whilst SYNGAP1 haploinsufficiency arises from 
autosomal-dominant de novo mutations in the SYNGAP1 gene leading to the 
truncation of the full-length protein. Extensive investigations in the Fmr1 KO mouse 
have revealed abnormalities in long-lasting forms of synaptic plasticity and protein 
synthesis rates downstream of the mGlu5-ERK1/2 signalling (Huber et al. 2002; 
Osterweil et al. 2010). This has implicated mGlu5-ERK1/2 signalling in the 
pathogenesis of ID and ASD and led to the development of novel therapeutics that 
specifically downregulate this signalling cascade.  
 
Currently, FXS is the most common inherited form of ID and the leading genetic 
cause of ASD (Wang et al. 2010). However recently, the genetic screening of small 
cohorts of ID patients has revealed that mutations in SYNGAP1 are also highly 
prevalent in the ID population with a high comorbidity of epilepsy and ASD 
(Hamdan et al. 2009; Hamdan et al. 2011). Already, investigations in the mouse 
model of this disorder have begun to elucidate the pathophysiological deficits 
associated with the reduction of SynGAP expression in the mammalian brain. 
Intriguingly, Syngap heterozygous mice share similar behavioural deficits to the 
Fmr1 KO mouse, including subtle learning and memory deficits in the Morris water 
maze, hyperactivity in the open field, abnormal anxiety levels, an increased 
susceptibility to sensory stimuli and impairments in social interaction. Furthermore 
Syngap heterozygous mice exhibit dendritic spine abnormalities that suggest 






Indeed investigations into synaptic plasticity mechanisms in Syngap heterozygous 
mice have revealed that LTP and NMDA receptor mediated forms of LTD are 
impaired in the hippocampus (Carlisle et al. 2008; Komiyama et al. 2002; Kim et al. 
2003) and are accompanied by alterations in Ras-ERK1/2 activity. At the synapse, 
SynGAP is an upstream regulator of the Ras family of G-proteins. Ras family 
members converge on a diverse range of cellular processes including those that 
regulate synaptic plasticity and protein synthesis (Ye & Carew 2010; Stornetta & 
Zhu 2011). Through investigations in the mouse model of NF1, which expresses 
reduced levels of the Ras GAP neurofibromin, the role of Ras signalling in the 
neuropathology of ID has been firmly established. Similarly to Syngap heterozygous 
mice, in the NF1 heterozygous mouse the activity levels of Ras and ERK1/2 are 
elevated, and this is accompanied by impairments in LTP and deficits in spatial 
memory (Silva et al. 1997; Costa et al. 2002; Li et al. 2005). Importantly, these 
hippocampal-dependent phenotypes can both be rescued by disrupting Ras signalling 
either genetically or pharmacologically (Guilding et al. 2007; Li et al. 2005). 
 
Furthermore it has recently been reported that the pharmacological reduction of Ras-
ERK1/2 signalling corrects elevated protein synthesis rates, r enhanced mGluR-
dependent and epileptogenesis in the mouse model of FXS (Osterweil et al. 2013). 
However in the Fmr1 KO brain, Ras-mediated signalling appears intact even though 
translational rates are saturated downstream of mGlu5 receptor activation (Osterweil 
et al. 2010). This suggests that the translational apparatus may be hypersensitive to 
constitutive mGlu5 signalling due to the loss of functional repression by FMRP.  
 
In contrast, Ras-ERK1/2 activity is increased in the hippocampus of Syngap 
heterozygous mice (Rumbaugh et al. 2006; Komiyama et al. 2002; Ozkan et al. 
2014), suggesting that the pathophysiology associated with this disorder may too 
result from a hyperactivity, as opposed to a hypersensitivity, of the Ras-ERK1/2 
signalling pathway. Thus it was hypothesized that this could consequently lead to 
similar alterations in mGlu5 dependent synaptic plasticity and basal protein synthesis 
to those reported in Fmr1 KO mice. In support of this hypothesis, Syngap KD 
cortical cultures show increased protein synthesis rates (Wang et al. 2013). This 
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suggests that SynGAP may lie within a signalling pathway that couples cell surface 
receptors to the mRNA translational machinery.  
 
Thus in this chapter, Gp1 mGluR-dependent LTD and basal protein synthesis rates 
are examined in the hippocampus of Syngap heterozygous mice, alongside Fmr1 KO 
mice. Firstly, we want to establish whether the key electrophysiological and 
biochemical findings reported in the Fmr1 KO can be reproduced in our mouse 
model of FXS. Secondly, whether Syngap heterozygous mice share similar 
abnormalities in mGluR-dependent synaptic plasticity and protein synthesis, and 
thirdly, whether the Fmr1 KO and Syngap heterozygous share a common 
pathophysiological axis.  
 
3.3 mGluR-dependent LTD at CA1 synapses 
Extracellular recordings were performed in the CA1 field of horizontal hippocampal 
slices prepared from WT males between P20-30 by placing a stimulating electrode in 
the Schaffer collateral pathway and recording from the apical dendrites of CA1 
pyramidal neurones, which project in to stratum radiatum (Figure 3.1 A). In CA1, 
the application of a single current pulse every 30 seconds to the Schaffer Collateral 
pathway, generated a fEPSP that is the summation postsynaptic potentials from a 
population of CA1 apical dendrites. The evoked fEPSP consisted of a short negative 
potential from which the slope and amplitude are used as a measure of synaptic 
strength (Figure 3.1 B). By plotting the slope of fEPSP (mV/ms) against time (mins), 
changes in synaptic strength can be observed by an increase or decrease in the slope 
of the fEPSP. Once synaptic responses stabilise and produce a baseline of 20 minutes 
or more the mean of baseline response is calculated and all responses from that point 
are normalised to this value and expressed as a percentage of the baseline response. 
The magnitude of LTD is based on the last 20 minutes of a recording and is 
expressed as a percentage of the predrug baseline. In the absence of an LTD or LTP 
inducing stimulus, fEPSPs recordings will remain stable for at least 80 minutes 





Figure 3.1 mGluR-dependent LTD in CA1 of the hippocampus. (A) Schematic of extracellular 
recordings in the hippocampus showing placement of stimulating (S) electrode in the Schaffer 
collateral pathway and recording (R) electrode in stratum radiatum of CA1. Image adapted from Biel 
et al. (2009). (B) Application of single current pulse generates a fEPSP from which the slope (mV/ms) 
expressed as a % of the mean baseline fEPSP and plotted against time. (C) Stable baseline fEPSPs 
were recorded for 80 minutes in CA1 region of hippocampal slices. Example recordings of mGluR-
dependent LTD induced by either: (D) applying 900-paired pulses at 1 Hz to the Schaffer collateral 
pathway or (E) the acute application of the Gp1 mGlu receptor agonist (DHPG, 50 µM). (F) PP-LFS 
leads to high LTD failure rate compared to (G) DHPG (50 µM) induced mGluR-dependent LTD in 
hippocampal slices from WT mice.  
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3.3.1 Chemically-induced mGluR-dependent LTD evokes a robust form of 
synaptic depression in CA1 
At Schaffer collateral/CA1 synapses mGluR-dependent LTD can be induced either: 
pharmacologically, by the application of orthosteric agonists of mGlu1/5 receptors 
such as DHPG (Palmer et al. 1997); or synaptically, by repeatedly applying paired-
pulses at 1 Hz for 15 minutes to the Schaffer collateral pathway (Huber et al. 2000; 
Kemp & Bashir 1999; Figure 3.1 C and D). Preliminary investigations of mGluR-
dependent LTD in hippocampal slices from WT mice revealed that on average the 
chemical induction of mGluR-dependent LTD was far more reliable at inducing a 
depression of synaptic responses compared to PP-LFS (Figure 3.1 E & F). It was 
calculated that PP-LFS led to a depression of synaptic responses (of > 10%) in 4 out 
of 10 slices, and of those that depressed the mean LTD was 21 ± 4%. In contrast, 
only 4 out of 18 slices failed to depress, more than 10%, following chemical 
induction of LTD (50 µM DHPG), which had a mean LTD of 28 ± 3% (n = 14).  
 
To improve the consistency of PP-LFS induced LTD it was recommended that the 
stimulation intensity be increased to at least 70% of the maximum response prior to 
LTD induction. Alternatively the number of paired-pulses could be increased to 1200 
pulses, however we were advised that the former was more reliable (Personal 
communication, B. Auerbach, M.I.T.). Thus, the stimulus intensity was increased to 
70% of the maximal response, but LTD was still only observed in 4 out of 8 slices 
with a mean LTD of 18 ± 3% (n = 4). Furthermore, it was a concern that high 
stimulation intensities for long periods of time could jeopardise slice health. Recently 
we were advised to increase the frequency at which pulses were delivered to the 
Schaffer collateral pathway by applying 900 paired pulses at 3 Hz rather than at 1 Hz 
(Personal communication, Professor A. Randall, University of Exeter). However, in 





3.3.2 Chemical mGluR-dependent LTD induces a long-lasting form of synaptic 
depression 
Further investigations in to chemically induced mGluR-dependent LTD revealed that 
upon application of DHPG (50-100 µM) there was a transient loss of synaptic 
responses within minutes, which only partially recovered over the 60-minute 
recording. Depressed fEPSPs stabilised and remained depressed for several hours 
(Mean LTD: 80 mins 53 ± 2%; 140 mins 53 ± 4%; n = 3; Figure 3.2 A). Furthermore 
a single application of DHPG (100 µM) did not induce a saturating level of LTD in 
hippocampal slices from young adult mice as further depression of synaptic 
responses was observed following a second application of DHPG (1st 81 ± 3%; 2nd 76 
± 6%; n = 8, t-test *p = 0.03; Figure 3.2 B).   
 
3.3.3 mGluR-dependent LTD reduces presynaptic function 
Previous studies in young rats (P4-18) revealed that the expression of mGluR-
dependent LTD involves a reduction in presynaptic function (Fitzjohn et al. 2001; 
Bolshakov & Siegelbaum 1994). Here the paired pulse ratio (%) of fEPSPs was 
examined during baseline recordings and 60 minutes after DHPG application at 
Schaffer Collateral/CA1 synapses in hippocampal slices from young adult mice 
(P25-30). The application of DHPG (100 µM) led to a significant increase in the PPR 
(PPR: before DHPG 1.39 ± 0.08%; after DHPG 1.67 ± 0.08%; n = 10; t-test *p = 
0.03; Figure 3.2 C), suggesting that mGluR-dependent LTD leads to a reduction in 






Figure 3.2 DHPG-induced mGluR-dependent LTD in CA1 of the hippocampus. Acute 
application of Gp1 mGlu receptor agonist DHPG (100 µM, 5 mins) induces a rapid depression of 
fEPSPs that only partially recovered in WT hippocampal slices. (A) DHPG-induced a long lasting 
depression of fEPSPs (80 mins 53 ± 2%; 140 mins 53 ± 4%; n = 3). (B) A second application of 
DHPG leads to further depression of synaptic responses (1st 81 ± 3; 2nd 72 ± 5; n = 8, *p = 0.03). (C) 
Paired pulse ratios (PPR)s were measured during baseline and 60 minutes after DHPG stimulation and 
reveal an increase in the PPR following DHPG application (PPR: baseline 1.39 ± 0.08%; DHPG 1.67 
± 0.08%; n = 10;  t-test *p = 0.03). 
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3.3.4 GluR-dependent LTD is dependent on new protein synthesis 
In CA1 of the hippocampus mGluR-dependent LTD is dependent on new protein 
synthesis (Huber et al. 2000). To investigate the protein synthesis dependency of 
mGluR-dependent LTD in CA1, hippocampal slices were incubated in the 
translational inhibitor anisomycin (20 µM) at various time points.  Anisomycin had 
no effect on basal synaptic transmission and stable fEPSPs were obtained for at least 
80 minutes in the presence of the drug alone (Figure 3.3A). Preincubation of 
hippocampal slices in anisomycin (20 µM) for at least 20 minutes prior to the 
induction of LTD and throughout the remainder of the recording strongly abolishes 
mGluR-dependent LTD in CA1. The acute application of anisomycin (5 mins) 
during DHPG wash-on failed to inhibit mGluR-dependent LTD (Figure 3.3B). 
Preincubation of hippocampal slices for 20 mins only, prior to mGluR-dependent 
LTD, caused a gradual return of fEPSP back towards baseline values (Figure 3.3C). 
However, if anisomycin was applied during LTD induction, but not before, then 


































Figure 3.3 The expression of mGluR-dependent LTD requires new protein synthesis. (A) In the 
presence of anisomycin basal synaptic responses remain stable during an 80 minute recording in WT 
hippocampal slices (n = 2). (B) The acute application of anisomycin (5 mins, 20 µM) failed to inhibit 
DHPG-induced mGluR-dependent (5 mins, 100 µM) in the WT hippocampus (WT 76 ± 19%, n = 3). 
(C) Preincubation of WT hippocampal slices in anisomycin (20 min, 20µM) prevented the full 
expression of DHPG-induced mGluR-dependent LTD in CA1 of WT mice (88 ± 7%, n = 3). (D) 
mGluR-dependent LTD was fully inhibited when anisomycin was added (60 mins, 20 µM) to the 






3.4 Results in the Fmr1 KO Mouse 
3.4.1 mGluR-dependent LTD is enhanced in Fmr1 KO mice 
 
One of the key findings reported in the Fmr1 KO mouse, between P21-30, is that 
mGluR-dependent LTD is enhanced in CA1 of the hippocampus (Huber et al. 2002). 
In contrast NMDAR-dependent LTD, whose expression and maintenance does not 
require new protein synthesis, is intact (Huber et al. 2002). Here, mGluR-dependent 
LTD was examined in hippocampal slices from young adult Fmr1 KO and WT mice 
(P20-30) with the acute application DHPG. Consistent with previous findings the 
acute application of 30 µM (Figure 3.4 A) and 100 µM DHPG (Figure 3.4 B) 
induced a depression of synaptic responses that was significantly greater in Fmr1 KO 
slices compared to WT controls (30 µM: WT: 99 ± 9%, n = 9; Fmr1 KO: 79 ± 9%, n 
= 11, 100 µM: WT: 77 ± 5%, n = 17; Fmr1 KO: 63 ± 4%, n = 19), showing a 
modest effect size of ~ 20% and ~14% between genotypes respectively (Figure 3.4 
C). The difference in the magnitude of LTD between Fmr1 KO and WT mice is in 





Figure 3.4 mGluR-dependent LTD is enhanced in CA1 of the hippocampus in Fmr1 KO Mice. 
Extracellular recordings were performed in CA1 region of hippocampal slices from Fmr1 KO and WT 
littermates. (A) The application the Gp1 mGluR agonist DHPG (5 mins, 30 µM) induced a 
significantly greater depression in the slope of fEPSP in Fmr1 KO slices compared to WT littermates 
(WT 91 ± 4%, n = 6; KO 72 ± 5%, n = 7; t-test *p = 0.02). (B) Similarly, application of DHPG (5 
mins, 100 µM) induced a significantly greater LTD in Fmr1 KO and WT littermates (WT 77 ± 5%, n 
= 17; KO 63 ± 4%, n = 17; t-test *p = 0.04). (C) Summary of LTD magnitudes in Fmr1 KO and WT 
littermates induced by the application 30 µM and 100 µM DHPG. Bar chart represents the mean (± 
S.E.) depression of fEPSP relative to pre-drug baseline. Scale bar 200 µV, 10 ms. 
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3.4.2 mGluR-dependent LTD is independent of new protein synthesis in Fmr1 
KO mice 
 
In the hippocampus of Fmr1 KO mice it is reported that mGluR-dependent LTD is 
insensitive to translational inhibitors, such as anisomycin and cycloheximide 
(Nosyreva & Huber 2006). This indicates that elevated mGluR-dependent LTD is no 
longer dependent on new protein synthesis, which supports the role of FMRP as an 
RNA-binding protein that suppresses translation of its RNA targets at the synapse. 
Here the dependency of mGluR-dependent LTD was examined in hippocampal slices 
from Fmr1 KO and WT littermates (Figure 3.5A). Hippocampal slices were 
incubated in the translational inhibitor anisomycin (20 µM) for at least 20 minutes 
prior to the induction of mGluR-dependent LTD, which was present throughout the 
remainder of the experiment. Anisomycin had no effect on basal synaptic 
transmission; however immediately following DHPG washout depressed fEPSPs 
were strongly inhibited in WT slices (WT Anisomycin: 91 ± 5%, n = 8). In contrast, 
anisomycin had no effect on the establishment of LTD in Fmr1 KO slices (KO 
anisomycin: 65 ± 7%, n = 10) making the differences in LTD magnitude between 
Fmr1 KO and WT mice far more evident (*p = 0.01; Figure 3.5B). Thus in 
agreement with existing findings, DHPG-induced mGluR-dependent LTD is 
enhanced and independent of new protein synthesis in our mouse model of FXS 








Figure 3.5 mGluR-dependent LTD is Independent of protein synthesis in the hippocampus of 
Fmr1 KO mice. (A) In WT slices the protein synthesis inhibitor anisomycin (20 µM) prevented 
DHPG-induced mGluR-dependent LTD (5 min, 100 µM), whilst the magnitude of LTD in Fmr1-/y 
mutants remained intact (WT 91 ± 6%, n = 8; KO 65 ± 7%, n = 9, t-test *p = 0.01). (B) Summary of 
LTD magnitude with and without anisomycin in Fmr1 KO and WT mice. Bar chart represents the 










3.4.3 Basal synaptic transmission is intact Fmr1 KO mice 
Basal synaptic properties, such as input-output function and PPRs, have been 
previously examined in Fmr1 KO mice and reported to be intact (Huber et al. 2002; 
Pilpel et al. 2009). Here we assessed I/O function in Fmr1 KO mice and WT 
littermates by increasing the duration of the current pulse applied to the Schaffer 
collateral pathway from 20-200 µs in 20 µs intervals, plotting the slope of fEPSPs 
against the amplitude of the presynaptic volley (Figure 3.6A). In agreement with 
previous reports, basal synaptic transmission is intact in CA1 of young adult Fmr1 
KO mice (Huber et al. 2002). This indicates that the elevation in mGluR-dependent 
LTD in Fmr1 KO mouse is not the consequence of general synaptic dysfunction.  
 
PPRs were also examined in Fmr1 KO and WT littermates by applying two 
concurrent pulses to the Schaffer collateral pathway at three different pulse intervals, 
ranging from 20-100 ms (Figure 3.6 B). No significant differences were observed in 
PPRs between Fmr1 KO and WT mice at any inter-pulse interval (20 ms: WT 1.65 ± 
0.05%, n = 4; KO 1.28 ± 0.14%, n = 5; 50 ms: WT 1.81 ± 0.07%, n = 4; KO 1.57 ± 
0.11%, n = 5; 100: WT 1.42 ± 0.06%, n = 4; KO 1.42 ± 0.07%, n = 5; ANOVA, p > 







Figure 3.6 Basal Synaptic Transmission is intact in the hippocampus of Fmr1 KO Mice. 
Extracellular recordings were performed in CA1 of hippocampal slices from WT and Fmr1 knockout 
(KO) mice. (A) Input-output (IO) function was assessed in Fmr1 KO mice and WT littermates by 
increasing the duration of the current pulse from 20 to 200 µs with increments of 20 µs. I/O function 
was intact in the hippocampus of Fmr1 KO mice compared to WT litters (t-test of slopes following 
linear regression, p > 0.05). (B) Application of two concurrent pulses, delivered at 3 different pulse 
intervals (20, 50 and 100 ms) to the Schaffer collateral pathway leads to facilitation of the second 
fEPSP slope. Paired-pulse ratios, calculated from the slope of the second pulse to the first, are similar 
between WT and Fmr1 KO mice at all three inter-pulse intervals (ANOVA p > 0.05). 
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3.4.4 Basal Protein Synthesis Rates are elevated in Fmr1 KO Mice 
 
FMRP binds and regulates the translation of several hundred mRNAs (Darnell et al. 
2011). Thus in FXS where FMRP is absent, it is hypothesized that mRNA translation 
is derepressed leading to excessive translation of FMRPs mRNA transcripts (Bear et 
al. 2004). Basal protein synthesis rates can be measured directly using a radioactive 
amino acid substitute that can either be administered in vivo by injection (Qin et al. 
2005a), or in vitro by incubating brains slices in ACSF containing a protein synthesis 
labeling mix, such as 35S-Met/Cys (Dölen et al. 2007; Osterweil et al. 2010). As 
mRNA is translated the radioactive isotope is incorporated into newly synthesized 
proteins and can then be quantitatively measured. Using this techniques, both in vitro 
and in vivo studies have revealed that protein synthesis rates are elevated in the 
hippocampus and several other brain structures in the Fmr1 KO mouse, which may 
explain why mGluR-dependent LTD is no longer dependent on new protein 
synthesis in this mutant (Qin et al. 2005a; Dölen et al. 2007; Osterweil et al. 2010). 
 
As we were able to reproduce the electrophysiological phenotypes in our mouse 
model of FXS, we decided to examine protein synthesis rates following the same 
experimental strategy implored by Osterweil et al. (2010). Basal protein synthesis 
rates were assessed in dorsal hippocampal slices prepared from Fmr1 KO and WT 
littermates at P25-30 by measuring the incorporation of 35S-Met/Cys in to newly 
synthesized proteins. Figure 3.7A outlines the experiment timeline in which 
hippocampal slices were prepared from Fmr1 KO and WT mice. Hippocampal slices 
were left to recover for 4 hours in ACSF, before transcription was blocked with 
actinomycin D (25 µM) and protein synthesis measured by incubating slices in 35S 
Met/Cys protein labelling mix for 45 minutes. In Fmr1 KO mice 35S incorporation 
was significantly enhanced in comparison to WT littermates (Fmr1 KO 121 ± 7%; 
WT 100 ± 2%; n = 6; t-test *p = 0.03; Figure 3.7 B). The magnitude of this elevated 
protein synthesis rate in Fmr1 KOs is in agreement with other in vitro measurements 
in the same region (Osterweil et al. 2010) and those reported in the ventral 
hippocampus (Dölen et al. 2007), both of which were obtained from Fmr1 KO on a 










Figure 3.7 Basal protein synthesis rates are elevated in the hippocampus of Fmr1 KO mice and 
rats. (A) Schematic of experimental timeline for 35[S]-Met/Cys metabolic labeling: slices were 
recovered in ACSF for 4 hours, incubated in actinomycin D (Act-D), then protein synthesis was 
measured with 35[S]-Met/Cys for 45 mins. (B) Basal protein synthesis levels were significantly 
elevated in dorsal hippocampal slices from Fmr1 KO versus WT mice (Fmr1-/y: 121 ± 7%; WT: 100 ± 
2%; n = 6; t-test *p = 0.03). (C) Increased protein synthesis rates were also observed in hippocampal 
slices prepared from Fmr1 KO versus WT rats (KO: 119 ± 5%; WT: 100 ± 2%; t-test *p = 0.022; n = 







3.5. Results from the Fmr1 KO Rat  
3.5.1 Fmr1 KO Rat recapitulates core deficits reported in the mouse model of 
FXS 
Recently SAGE laboratories generated the rat model of FXS using a zinc-finger 
nuclease methodology (Cui et al. 2011; Hamilton et al. 2014). Here we investigated 
whether the core physiological and biochemical phenotypes reported in the Fmr1 KO 
mouse translate to the rat model of FXS. mGluR-dependent LTD and its dependence 
on new protein synthesis were assessed in the hippocampus of Fmr1 KO rats.  
Consistent with the Fmr1 KO mouse, mGluR-dependent LTD (50 µM) in Fmr1 KO 
rats was enhanced and insensitive to the translational inhibitor cycloheximide (100 
µM) at CA1 synapses (Personal communication, A. Jackson). Furthermore basal 
protein synthesis levels in dorsal hippocampal slices from young adult Fmr1 KO rats 
(P25-32) were exaggerated compared to WT littermates (Fmr1 KO 119 ± 5%; WT 
100 ± 2%; n = 11; t-test *p = 0.002; Figure 3.7 C). This indicates that the core 
hippocampal phenotypes reported in in the mouse model of FXS translate to other 
mammalian species. Thus, it would be interesting to see whether pharmacological 
strategies employed in correcting deficits in the Fmr1 KO mouse are efficacious in 










3.6. Results in Syngap Heterozygote Mouse  
3.6.1 mGluR-dependent LTD is enhanced in Syngap heterozygote mice 
Electrophysiological recordings in the hippocampus of Syngap heterozygous mice 
have revealed impairments in NMDAR-dependent forms of LTP and LTD 
(Komiyama et al. 2002; Kim et al. 2003; Carlisle et al. 2008). At present, mGluR-
dependent forms of synaptic plasticity have not been investigated in Syngap 
heterozygous mice even though signaling downstream of mGlu5 receptors is 
hyperactivity in the hippocampus of Syngap heterozygous mice.  
 
To examine mGluR-dependent LTD at Schaffer collateral synapses in CA1, 
extracellular recordings were performed in horizontal hippocampal slices from 
Syngap heterozygotes and WT littermates. Here it was observed that the application 
of DHPG (30 µM) induced a depression of synaptic responses that was significantly 
increased in Syngap heterozygous mice compared to WT littermates (30 µM: WT 
90.9 ± 2.88%, n = 10 vs. Het 75 ± 6%, n = 12, t-test *p = 0.02). Similarly, induction 
of mGluR-dependent LTD with 100 µM DHPG elicited a significantly greater LTD 
in Syngap heterozygous mice compared to WT littermates (100 µM: 74 ± 6%, n = 12 
vs. Het 56 ± 5%, n = 14, t-test *p = 0.03). Thus consistent with Fmr1 KO mice 
reduced SynGAP expression results in enhanced depression of synaptic responses 
upon activation of the Gp1 mGlu receptors. Furthermore the magnitude of LTD 














Figure 3.8 DHPG-induced mGluR-dependent LTD is enhanced in the hippocampus of Syngap 
heterozygous mice. Extracellular recordings were performed in CA1 region of hippocampal slices 
from Syngap heterozygous (SG+/-, Het) and WT littermates. (A) The application of DHPG (5 mins, 30 
µM) induced LTD that was significantly increased in Syngap het mice versus WT littermates (WT 91 
± 3%, n = 10; SG +/- 75 ± 6%, n = 12; t-test *p = 0.02) (B) Similarly, the application of DHPG (5 mins, 
100 µM) induced a significantly greater LTD in Syngap het hippocampal slices compared to WT 
littermates (WT 74 ± 6%, n = 12; SG +/- 56 ± 5%, n = 14; t-test *p = 0.03). (C) Summary of LTD 
magnitude induced by the application of 30 µM and 100 µM DHPG in Syngap heterozygous and WT 
mice. Bar chart represents the mean (± S.E.) depression of fEPSP relative to pre-drug baseline. Scale 
bar 200 µV, 10 ms. 
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3.6.2 mGluR-dependent LTD is independent of new Protein synthesis in Syngap 
heterozygous mice 
 
At the synapse, SynGAP down regulates Ras activated ERK1/2 and mTOR 
signalling, both of which initiate cap-dependent mRNA translation that is required to 
maintain long-lasting forms of synaptic plasticity. In Syngap heterozygotes where 
SynGAP expression is reduced, the activity of Ras and ERK1/2 are increased 
(Komiyama et al. 2002; Carlisle et al. 2008), which could lead to the over-activation 
of the translational machinery governing basal protein synthesis rates. Together with 
the finding that mGluR-dependent LTD is enhanced in CA1 of the hippocampus, one 
would predict that activity-dependent protein synthesis at local dendritic sites may be 
lost in the Syngap heterozygous mice. 
 
To examine the consequence of Syngap1 haploinsufficiency on the protein synthesis-
dependent component of mGluR-dependent LTD, slices were preincubated in the 
translational inhibitor anisomycin (20 µM) for at least 20 minutes prior to LTD 
induction. In WT mice anisomycin inhibited mGluR-dependent LTD induced by the 
acute application of DHPG (50 µM), whilst vehicle treated slices showed a typical 
level of depression (WT veh 77.0 ± 3.3%, n = 18 vs. WT aniso 90 ± 4%, n = 12, t-
test *p = 0.01; Figure 3.9 A). In contrast, inhibition of translation in hippocampal 
slices from Syngap mutants had no significant effect on the magnitude of LTD and 
synaptic responses remained depressed to a similar level as vehicle treated slices 
(Het veh 62 ± 5 %, n = 15 vs. Het aniso 64 ± 4 %, n = 14, t-test p = 0.728, Figure 3.9 
B). Thus in the presence of anisomycin the differences in LTD magnitude between 
genotypes was far more pronounced (*p = 0.000096; Figure 3.9 C). This indicates 
that mGluR-dependent LTD is independent of new protein synthesis in the 
hippocampus of Syngap heterozygous mice. This situation could arise, if the proteins 
required for the maintenance of LTD are already present and overabundant at CA1 










Figure 3.9 mGluR-dependent LTD is independent of protein synthesis in the hippocampus of 
Syngap heterozygous mice. (A) In WT slices the protein synthesis inhibitor anisomycin (aniso, 20 
µM) prevented the expression of DHPG-induced mGluR-dependent LTD (5mins, 50 µM) in CA1 of 
the hippocampus (WT veh 77.0 ± 3 %, n = 18 vs. WT aniso 90 ± 4 %, n = 12, t-test *p = 0.01). In 
contrast, DHPG-induced mGluR-dependent LTD was intact in the presence of anisomycin in CA1 of 
Syngap heterozygous (SG+/-, Het) slices (SG +/- veh 62 ± 5 %, n = 15 vs. SG +/- aniso 64 ± 4 %, n = 14, 
t-test p = 0.728). (C) Comparison of DHPG induced mGluR-dependent LTD in the presence of 
anisomycin in WT and het hippocampal slices (t-test  *p = 0.000096). Scale bar 200 µV, 10 ms. 
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3.6.3 Basal synaptic transmission is intact in Syngap heterozygous mice 
In Syngap heterozygous mice there is dramatic increase in AMPA receptor mediated 
synaptic transmission during the early stages of development (Clement et al. 2012).  
This abnormal increase in synaptic strength is observed at multiple synapses in the 
hippocampus and arose from an increase in AMPA receptor expression at excitatory 
synapses. This was initially detected as a difference in I/O function in hippocampal 
slices from Syngap heterozygous and WT mice. However by P21, basal synaptic 
transmission in Syngap heterozygous mice is indistinguishable from WT mice, as 
AMPA receptor expression increases at WT synapses. This indicates that Syngap1 
haploinsufficiency results in an early maturation of synapses.  
 
Here I/O function was examined at Schaffer collateral synapses in CA1 of 
hippocampal slices from young adult Syngap heterozygous and WT mice (P25-32). 
Consistent with previous reports there was no detectable difference in basal synaptic 
transmission between Syngap heterozygous and WT mice at adult ages (t-test of 
slopes following linear regression, p > 0.05) (Clement et al. 2012; Komiyama et al. 
2002).  
 
Presynaptic function was also examined in CA1 of young adult Syngap heterozygous 
and WT slices. No detectable differences (ANOVA, p > 0.05) were observed in the 
PPR at any inter-pulse interval: 20 ms (WT 1.80 ± 0.16%, n = 13; Het 1.91 ± 0.21%, 
n = 11), 50 ms (WT 1.53 ± 0.06%, n = 13; Het 1.67 ± 0.15%, n = 11) and 100 ms 


















Figure 3.10 Basal synaptic transmission is unaltered in the hippocampus of Syngap 
heterozygous mice. (A) Input-output (IO) curves were generated by plotting the fibre volley 
amplitude and slope of fEPSPs against the slope of the fEPSPs elicited by increasing the pulse 
duration from 20-200 µs. I/O function was intact in the hippocampus of Syngap heterozygous (SG +/-, 
Het) mice compared to WT litters (t-test of slopes following linear regression, p > 0.05).  (B) The 
application of two concurrent pulses with an inter-pulse interval of 20, 50 and 100 ms to the Schaffer 
collateral pathway generated similar paired pulse facilitation in WT and Syngap het mice at all three 
inter-pulse intervals (ANOVA p > 0.05). 
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3.6.4 Basal protein synthesis levels are elevated in Syngap heterozygous mice 
So far the electrophysiological findings in Syngap heterozygous mice are comparable 
to those observed in Fmr1 KO mice; mGluR-dependent LTD is enhanced and 
independent of new protein synthesis in area CA1 of the hippocampus. The increased 
LTD in Fmr1 KO mice correlates with elevated protein synthesis rates that are 
regulated by mGlu1/5 receptor activation via the Ras-ERK1/2-MAPK signalling 
cascade. Thus, basal protein rates were examined in hippocampal slices from young 
adult Syngap heterozygous mice to determine whether the independency of mGluR-
dependent LTD to new protein synthesis resulted from increased translational rates 
under steady state conditions. An identical approach was used to that reported in 
3.5.4. Consistent with the Fmr1 KO mice, the incorporation of 35S Met/Cys was 
significantly increased in dorsal hippocampal slices from Syngap heterozygous mice 
compared to wild-type littermates (WT 100 ± 4%; Het 140 ± 12%; n = 12; t-test *p = 
0.02). Furthermore, the increase in 35S incorporation was substantially higher in 
Syngap heterozygous mice compared to Fmr1 KO mice, 40% in Syngap 





























Figure 3.11 Basal protein synthesis rates are elevated in the hippocampus of Syngap 
heterozygous mice. (A) Schematic of experimental timeline for 35[S]-Met/Cys metabolic labeling: 
slices were recovered in ACSF for 4 hours, incubated in actinomycin D (Act-D), then protein 
synthesis measured with 35[S]-Met/Cys for 45 mins. (B) Basal protein synthesis levels were 
significantly elevated in dorsal hippocampal slices from Syngap heterozygous (het, SG +/-) mice 






3.7 Results in the Fmr1-/y Syngap +/-Double Mutant  
3.7.1 Syngap1 haploinsufficiency occludes mGluR-mediated LTD in Fmr1 KO 
mice 
Our findings that two distinct ID/ASD-related mutations causing FXS and Syngap 
haploinsufficiency mice share similar alterations in mGluR-dependent LTD raised 
the intriguing possibility that they may converge on the same pathophysiological 
axis. To directly test this hypothesis, we generated double mutant mice by 
introducing the deletion of Fmr1 in to the Syngap heterozygous mouse. To determine 
whether Syngap1 haploinsufficiency exacerbates or occludes the enhanced LTD 
phenotype observed in Fmr1 KO mouse, mGluR-dependent LTD was re-examined at 
CA1 synapses of all four genotypes produced from this cross (Figure 3.12A). 
Consistent with our previous findings, mGluR-dependent LTD was increased in 
Fmr1 KO (Fmr1 KO 62 ± 5, n = 10, p = 0.08) and Syngap heterozygous (Syngap Het 
60 ± 4%, n = 10, ANOVA *p = 0.049) single mutants compared to WT litters (WT 
78 ± 3%, n = 9). Similarly mGluR-dependent LTD was found to be significantly 
enhanced in the Syngap heterozygous Fmr1 KO double mutants relative to WT 
littermates (Double 59 ± 4; n = 12, ANOVA *p = 0.02), however not significantly 
different from Fmr1 KO and Syngap heterozygous single mutants (p > 0.05; Figure 
3.12B). As the magnitude of LTD was similar between the double mutant and Fmr1 
KO and Syngap heterozygous single mutants it suggests that Syngap1 
haploinsufficiency occludes the increase in DHPG-induced mGluR-dependent LTD 
caused by the loss of FMRP. This indicates that mutations in Syngap1 and Fmr1 

















Figure 3.12 Syngap haploinsufficiency occludes the increase in mGluR-dependent LTD in the 
hippocampus in Fmr1 KO mice. (A) The application of the Gp1 agonist DHPG (5 mins, 100 µM) 
induced a depression of fEPSPs in SG+/- Fmr1-/y double mutants (59 ± 4%, n = 12) that was 
significantly greater than the depression observed in WT littermates (WT 78 ± 3%; n = 9, ANOVA *p 
= 0.02). Yet, the magnitude of LTD observed in the SG+/- Fmr1-/y double mutants was not significantly 
different from SG+/- (60 ± 4%, n = 10, ANOVA *p = 0.049) and Fmr1-/y  (62 ± 5%, n = 10, ANOVA p 
= 0.08) single mutant mice. (B) Summary of LTD magnitude for all four genotypes. Bar chart 







3.7.2 DHPG induces a non-saturating level of mGluR-dependent LTD 
The introduction of the Fmr1 mutation into Syngap heterozygous mice occluded 
further depression of synaptic responses induced by the acute application of DHPG 
(100 µM). However this could arise if the concentration of DHPG used was inducing 
a saturating level of LTD. To determine whether the finding reported in 3.7.1 
resulted from a “floor effect”, a subsequent induction of chemical LTD was 
performed 60 minutes after the first to establish whether DHPG was causing a 
saturating level of LTD following the first induction (Figure 3.13). In all genotypes, 
the magnitude of depression was greater following the second application of DHPG: 
WT (1st 81 ± 3%; 76 ± 6%; n = 8, t-test *p = 0.03); Fmr1 KOs (1st 73 ± 4%; 2nd 61 
± 5%; n = 3, *p = 0.002); Syngap heterozygous  (1st 68 ± 7%; 2nd 51 ± 9%; n = 5, 
*p = 0.02) and double mutants (1st 68 ± 11%; 2nd 55 ± 8%; n = 4, p = 0.0996). These 
findings indicate that following DHPG-induced mGluR-dependent LTD synapses 
can still be further depressed by second induction of chemical LTD suggesting that 
the same intracellular mechanism is utilized in Fmr1 KO and Syngap heterozygous 




















Figure 3.13 DHPG induces a non-saturating level of mGluR-dependent LTD. Extracellular 
recordings in CA1 region of hippocampal slices from WT, Syngap heterozygous (Het, SG+/-), Fmr1 
knockout (KO, Fmr1-/y) and Fmr1 KO and Syngap heterozygous cross (Double, Fmr1-/y x SG+/-). (A) 
The application of the Gp1 agonist DHPG (5 mins, 100 µM) induced a depression of fEPSPs, that 
were further reduced following a second application of DHPG (5 mins, 100 µM) 1 hr. after the initial 
LTD induction. (B) Summary of LTD magnitude for all four genotypes. Bar chart represents the mean 
(± S.E.) depression of fEPSP relative to pre-drug baseline for all four genotypes after the 1st and 2nd 
application of DHPG. Significance differences between LTD magnitude induced by the 1st and 2nd 
application of DHPG were observed in WT (1st 81 ± 3%; 2nd 81 ± 3%; n = 8, *p = 0.03), Fmr1-/y (1st 
73 ± 4%; 2nd 61 ± 5%; n = 3, *p = 0.002) and SG+/- (1st 68 ± 7%; 2nd 51 ± 9%; n = 5, *p = 0.02) mice, 
determined using a paired t-test  (p < 0.05). Although the magnitude of LTD increased between the 1st 
and 2nd LTD stimulus in the double mutant slices this was not significant (1st 68 ± 11%; 2nd 55 ± 8%; n 




In this chapter, the physiological properties of Gp1 mGluR-dependent LTD and 
protein synthesis have been investigated in CA1 of the hippocampus. Furthermore, 
these mGlu1/5 mediated cellular processes have been examined in the context of two 
highly penetrant forms ID and ASD, FXS and Syngap1 haploinsufficiency. It is 
already suspected that distinct genetic causes of ID may share a common 
pathophysiological axis. However this hypothesis is based on gene ontology 
databases of known protein function and on the observation that human ID patients 
and mouse models of ID can share similar phenotypic manifestations. Here, it was 
directly tested to determine whether two pathogenic mutations of ID, in Fmr1 and 
Syngap1, share similar abnormalities in synaptic plasticity and protein synthesis by 
converging on a shared biochemical pathway.  
 
3.8.1 Physiological properties of mGluR-dependent LTD  
In CA1 of the hippocampus mGluR-dependent LTD is typically induced either: 
pharmacologically, by the application of orthosteric agonists of mGlu1/5 receptors 
such as DHPG (Palmer et al. 1997); or synaptically, by repeatedly applying  paired-
pulses at 1 Hz for 15 minutes to the Schaffer collateral pathway (Huber et al. 2000; 
Kemp & Bashir 1999). The induction and expression mechanisms of this form of 
LTD differ over development (Nosyreva et al. 2005) and include both presynaptic 
and postsynaptic mechanisms. 
 
Induction of mGluR-dependent LTD involve the activation of mGlu1 and mGlu5 
receptors, which are predominantly expressed on the postsynaptic side of both 
excitatory and inhibitory neurones (Nicoletti et al. 2011). At dendritic spines mGlu1/5 
receptors are found at both perisynaptic and extrasynaptic sites and are activated 
following prolonged synaptic transmission (Pin et al. 2005). Here they interact with 
scaffolding proteins, such as Homer, which in turn couple mGlu5 receptors to the 
GluN2B subunit of the NMDA receptor via a link of scaffolding proteins, which 
include Shank and PSD-95 (Collett & Collingridge 2004). 
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Gp1 mGlu receptors are coupled to Gq/11 heterotrimeric G-proteins whose activity 
stimulates the hydrolysis of PIP2 by phospholipase C (PLC) producing IP3 and DAG. 
In turn IP3 and DAG activate Ca2+ release from intracellular stores and protein kinase 
C (PKC) (Fitzjohn & Collingridge 2001; Hermans & Challiss 2001). However, it 
appears that mGluR-dependent LTD does not use this canonical pathway as the 
induction of this form of LTD is insensitive to PKC inhibitors (Hou & Klann 2004; 
Gallagher et al. 2004) and occurs independently of changes in postsynaptic Ca2+ 
(Fitzjohn & Collingridge 2001). Instead, mGluR-dependent LTD is dependent on 
Ca2+-independent mechanisms that include the PI3K, p38 MAPK and ERK1/2 
MAPK intracellular signalling cascades (Hou & Klann 2004; Gallagher et al. 2004; 
Moult et al. 2008). 
 
The expression of mGluR-dependent LTD at CA1 synapses involves the endocytosis 
of ionotropic AMPA receptors from the cell surface (Moult et al. 2006; Snyder et al. 
2001). In addition to postsynaptic changes, the expression of this form LTD is 
accompanied by presynaptic alterations that are likely mediated by retrograde 
signalling. Together, these expression mechanisms result in a long-lasting weakening 
of synaptic inputs to CA1 pyramidal neurones that is maintained by new protein 
synthesis at local dendritic sites (Huber et al. 2000). 
 
Electrophysiological recordings in CA1 can capture the depression of synaptic 
transmission following an LTD inducing stimulus. This is observed as a change in 
the slope and amplitude of the corresponding fEPSP or EPSC to the same applied 
stimulus depending on whether extracellular or intracellular recordings are 
performed. Intracellular recordings of mGluR-dependent LTD commonly use whole-
cell recordings, which involve voltage clamping cells to −70 mV and observing a 
decrease in EPSC amplitude following a 5-minute application of DHPG. In certain 
brain regions, such as the amygdala, where the dendrites of neurones do not form a 
uniform layer, intracellular recordings are the only way in which to measure changes 




In contrast, the hippocampus has a highly structured and orderly arrangement of cell 
and dendritic layers. Here extracellular recordings are possible and provide several 
advantages. Firstly, it measures the summation of postsynaptic potentials generated 
from a population of CA1 apical dendrites to an evoked stimulus in the presynaptic 
cell, rather than the response of single cell. Secondly, extracellular recordings leave 
the internal environment of the neuron in tact whereas and whole-cell recordings 
involve washing out the internal environment of a cell and replacing it with internal 
solution. This could disrupt intracellular signalling cascades that are crucial for the 
induction, expression and maintenance of mGluR-dependent LTD. One way to 
counteract this disadvantage is to perform perforated patch recordings, which would 
cause minimal disruption to the internal environment of the target cell. However in 
this chapter extracellular recordings were exclusively used to measure mGluR-
dependent LTD in CA1 synapses of the hippocampus. 
 
To facilitate the induction of mGluR-dependent LTD in hippocampal slices, the 
GABAA receptor antagonist picrotoxin (PTX, 50 µM) was added to the ACSF during 
electrophysiological recordings. PTX eliminated any influence from the inhibitory 
GABAergic synapses that may be disrupted in mouse models of ID (Adusei et al. 
2010; Clement et al. 2012). Furthermore, blocking inhibitory synaptic transmission 
has been previously shown to increase the overall excitability of the slice, lowering 
the threshold for induction of mGluR-dependent LTD and inducing a form of LTD 
that is independent of NMDA receptor activation (Palmer et al. 1997). This suggests 
that when chemical mGluR-dependent LTD is induced under conditions that increase 
neuronal excitability then perhaps Ca2+ entry is sufficient, without NMDA receptor 
activation, so NMDA receptor antagonists have little effect on LTD. However, to 
eliminate any potential confounding factor by NMDA receptor activation, these 







In addition, during preparation of hippocampal slices an incision was made through 
CA3:CA1 boundary. This prevented the generation of epileptiform activity in CA1 
following the stimulation of the Schaffer collateral pathway; the probability of which 
was far greater when inhibitory input to CA1 was blocked with PTX. The occurrence 
of epileptic activity in CA1 is caused by recurrent excitatory loops in CA3, as axons 
not only project to CA1 but also to other levels of CA3. 
 
 
In this chapter, mGluR-dependent LTD was initially evoked both chemically and by 
synaptic stimulation. Here we observed that the induction of mGluR-dependent LTD 
with DHPG (>50 µM) or by the application of 900 paired-pulses induced a long 
lasting form depression of excitatory transmission at Schaffer collateral synapses in 
young adult mouse. DHPG-induced mGluR-dependent LTD shares a common 
expression mechanism with PP-LFS (Huber et al. 2001). However, induction of 
mGluR-dependent LTD with PP-LFS is considered more physiologically relevant, as 
DHPG-induced mGluR-dependent LTD does not require concurrent stimulation of 
the presynaptic terminus.  
 
Initial investigations in hippocampal slices from young adult mice utilised both LTD 
stimulation paradigms. However, it was found that a depression of fEPSPs of 10% or 
more was not consistently observed using the synaptic induction protocol. It has been 
previously reported that PP-LFS induces a “reliable” depression of fEPSPs in CA1 of 
the rat hippocampus (Kemp & Bashir 1997), which may not translate to the mouse. 
Discussions with other laboratories regarding this form of mGluR-dependent LTD 
revealed that I was not isolated in observing a high LTD failure rate when using this 
stimulation paradigm. Two independent laboratories had tried various manipulations 
of the stimulation protocol to improve LTD success rate. These included: (1) 
increasing baseline responses to 60-70% of the maximum response, (2) increasing 
the number of paired pulses from 900 pulses to 1200, or (3) increasing the frequency 
at which the pulses were delivered to the Schaffer collateral pathway. To try and 
optimise experimental conditions the stimulation intensity of the current pulse was 
increased to 70% of the maximum fEPSP but no significant level of improvement 
was observed to warrant further investigation. 
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In contrast, DHPG-induced mGluR-dependent LTD consistently induced a 
depression of synaptic responses, most likely because chemical induction maximises 
the number of synapses affected and thus induces a more robust form of LTD. This 
induction protocol also provided several other advantages because: (1) on average 
DHPG (50-100 µM) induced a greater magnitude of LTD, (2) it would allow us to 
assess the affect of protein synthesis inhibitors on LTD expression, and (3) this form 
of stimulation paradigm could be translated to biochemical studies at a later stage. 
The latter point was of particular importance, as we wanted examined the 
dependence of mGluR-dependent LTD on new protein synthesis using the 
translational inhibitor anisomycin, which abolished LTD in WT hippocampal slices.  
Without a reliable form of LTD, it would have been difficult to assess whether the 
lack of LTD resulted from a failed LTD expression or the inhibition of new protein 
synthesis. Thus to progress with our investigations in to mGluR-dependent LTD 
mechanisms in rodent models of ID, pharmacological LTD induction protocols were 
solely used.  
 
During chemical induction of LTD, the activation of Gp1 mGlu receptors with 
DHPG (50 – 100 µM) leads to an initial reduction in synaptic transmission that is 
caused by a transient membrane depolarisation (TMD). This TMD results from an 
increase in the membrane input resistance that occurs independently of changes in 
fEPSPs and leads to increased neuronal firing (Brager & Johnston 2007). It is a 
associated with a decrease in Ih that could reduce inactivation of T- and N- type 
calcium channels thus increasing neuronal excitability and preventing the loss of 
neuronal output following an LTD stimulus (Zho et al. 2002; Brager & Johnston 
2007; Brager et al. 2012). This alteration in membrane excitability is short-lived and 
membrane resistance and resting membrane potential return back to baseline level 30 






In contrast, fEPSPs only partially recover producing a plateau depression, which fails 
to return to baseline an hour after DHPG application. In fact, mGluR-dependent 
LTD, induced by 100 µM DHPG, can persist for several hours indicating that 
DHPG-induced mGluR-dependent LTD causes a long lasting reduction in excitatory 
synaptic transmission at CA1 synapses. A single application of DHPG (100 µM) 
does not induce a saturating level of mGluR-dependent LTD at CA1 synapses as a 
further application of DHPG, 60 mins after the first, led to a significantly greater 
level of depression. Although not shown in this study, mGluR-dependent LTD is 
saturable, as no further depression is observed following a third application of DHPG 
(Huber et al. 2001). 
 
Furthermore the magnitude mGluR-dependent LTD induced by DHPG shows a 
dose-dependent relationship as lowering the Gp1 agonist concentration reduced the 
magnitude but not the duration of the LTD, consistent with previous studies (Palmer 
et al. 1997; Huber et al. 2001). In WT hippocampal slices, the induction of chemical 
LTD with 30 µM DHPG led to an initial TMD of synaptic responses, however 
fEPSPs failed to stabilise at a depressed level and instead returned to baseline or 
showed a depression of less than 10%. At 100 µM LTD induction was significantly 
elevated compared to baseline responses. Thus, our findings from WT mice revealed 













The expression of mGluR-dependent LTD in young adult mice involves both a 
presynaptic and postsynaptic mechanism (Fitzjohn et al. 2001; Huber et al. 2001; 
Snyder et al. 2001; Nosyreva 2005). In this study, PPRs were examined in the same 
population of synapses before and after DHPG application to examine whether 
mGluR-dependent LTD expression at CA1 synapses involves a presynaptic change. 
Stimulation of the Schaffer collateral axons with two current pulses in quick 
succession, with an inter-pulse interval of 50 ms led to an increase in the slope and 
amplitude of the second fEPSP compared to the first. The potentiation of the second 
pulse is due to an increase in the presynaptic Ca2+ concentration from the residual 
Ca2+ left over from the initial pulse, which increases the probability of vesicle release 
from the presynaptic terminal (Zucker 1989).  
 
In WT slices, it was observed that the application of DHPG significantly increased 
PPRs, which occurred in parallel with a depression of fEPSPs. Increases in the PPRs 
following an LTD-inducing stimulus have been previously reported at CA1 synapses 
(Fitzjohn et al. 2001), and is also observed in other brain regions (Choi & Lovinger 
1997). The magnitude of the PPR is inversely proportional to the presynaptic release 
probability (Manabe et al. 1993). This suggests that mGluR-dependent LTD may 
lead a decrease in the release probability of glutamate from the presynaptic terminal. 
This could be explained by postsynaptic alterations being communicated back to the 
presynaptic terminus via a retrograde signalling mechanism. Potential retrograde 
messengers include 12-lipoxygenase metabolites of arachidonic acid (Feinmark et al. 
2003). Likewise an alternative mechanism by which an LTD inducing stimulus could 
result in an increase in the PPR is via the preferential loss of AMPA receptors from 
synapses where the probability of release is greater leading to the activation of low 
probability synapses (Poncer & Malinow 2001). Thus to strengthen this finding that 
chemical LTD causes a presynaptic change, the rate of blockade of NMDA receptor 
mediated responses to MK-801 could have been examined, as well as the frequency 





Changes in synaptic strength also involve a postsynaptic mechanism, which results in 
the insertion or removal or GluA1- and GluA2/3-containing AMPA receptors from 
the postsynaptic terminal. Although measurements of AMPA receptor surface 
expression were not directly measured here, it is reported that the expression of 
DHPG-induced LTD also involves the internalisation of AMPA receptors from the 
cell surface (Snyder et al. 2001) (Nosyreva 2005), via a mechanism that is Ca2+ 
independent and most likely involves MAPK signalling pathways, which are 
examined further in Chapter 4. DHPG-induced decreases in AMPA receptor surface 
expression is developmentally regulated as it only observed in hippocampal slices 
prepared from adolescent ages (P21-28) not at immature synapses (P8-15) (Nosyreva 
2005). Furthermore, the induction of mGluR-dependent LTD at more mature 
synapses leads to a decrease in the expression of AMPA receptors at the cell surface 
that is dependent on new protein synthesis, as preincubation of hippocampal slices in 
translational inhibitors prior to LTD induction failed to show a reduced AMPA 
receptor surface expression 60 minutes after DHPG treatment (Nosyreva et al. 2005). 
 
This indicates that the persistent depression of excitatory transmission following Gp1 
mGlu1/5 receptor activation is dependent on rapid mRNA translation, highlighting the 
dependence of mGluR-dependent LTD on new protein synthesis. It has previously 
been reported that Gp1 mGlu receptor activation induces new protein synthesis of 
pre-existing mRNA at local dendritic sites (Huber et al. 2000). Consistent, with 
Nosyreva et al. (2006) it was shown that the pharmacological inhibition of mRNA 
translation with anisomycin resulted in a reduced or total loss of LTD expression an 
hour after induction in young adult hippocampal slices.  
 
The dependence of mGluR-dependent LTD on mRNA translation is developmentally 
regulated as mGluR-dependent LTD in neonatal hippocampal slices is insensitive to 
protein synthesis inhibitors (Nosyreva et al. 2005). This could mean that the 
expression of mGluR-dependent LTD at immature synapses is governed solely by 
presynaptic changes, which persists in to adulthood but is accompanied by a 
reduction in AMPA receptor surface expression and a dependence on new protein 
synthesis.  Thus in the adolescent brain there appears to be greater tractability in 
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regulating in long-term synaptic strength at Schaffer collateral/CA1 synapses. 
Interestingly, it is observed in this study that mGluR-dependent LTD is not always 
fully abolished in the presence of translational inhibitors. As changes in paired-pulse 
facilitation are not dependent on new protein synthesis, it could mean that the 
residual LTD is mediated by presynatically. 
 
It is hypothesized that the proteins rapidly synthesized in response to mGlu1/5 
activation are involved in the endocytosis of AMPA receptors from the cell surface 
or AMPA receptor trafficking following endocytosis. Thus, these newly synthesized 
proteins have been termed “LTD proteins”. Several of these proteins have been 
identified, based on their expression profiles following mGlu1/5 receptor activation. 
Their involvement in changing the functional properties of synapses is beginning to 
be unravelled and is discussed later on.  
 
3.8.2 LTD and protein synthesis downstream of mGlu1/5 receptor activation is 
disrupted in the mouse model of FXS  
In this chapter, DHPG-induced mGluR-dependent LTD was investigated in the Fmr1 
KO mouse. FXS is caused by a CGG expansion mutation in the Fmr1 gene, which 
encodes the RNA binding protein FMRP. FMRP is rapidly synthesized in response 
to Gp1 mGlu receptor activation and is hypothesized to negatively represses mRNA 
translation at dendritic sites (Weiler et al. 1997). The link between mGlu1/5 signalling 
and FXS has already been previously studied, however it was important to determine 
whether abnormalities in mGlu1/5 signalling could be reproduced in the Fmr1 KO 
mouse that was bred on a different strain background. The modest enhancements in 
mGluR-dependent LTD in the Fmr1 KO mice is not always observed (Hou et al. 
2006; Ronesi & Huber 2008). Likewise, in WT rodents the protein synthesis 
dependency of mGluR-dependent LTD it not always present (Moult et al. 2008). 
Thus, it needed to be established whether the mGlu1/5-mediated pathology associated 
with FXS could be reproduced in our mouse model of FXS.  
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Here, it was shown that DHPG-induced mGluR-dependent LTD is enhanced in the 
hippocampus of Fmr1 KO mice relative to WT littermates, reproducing the original 
findings reported by Huber et al. (2002). This excessive LTD in Fmr1 KO 
hippocampal slices occurred in the absence of any significant alterations in AMPA 
receptor mediated synaptic transmission indicating that basally synapses are 
functionally intact. In contrast, under Gp1 mGlu receptor stimulated conditions there 
is an excessive weakening of synapses in the Fmr1 KO brain. In has been shown 
previously in culture and through biotinylation studies in slices, that enhanced 
mGluR-dependent LTD arises from the excessive removal of AMPA receptors from 
the postsynaptic terminal leading to an exaggerated depression of synaptic responses 
in the Fmr1 KO brain.  
 
Also we observed that mGluR-dependent LTD in the hippocampus of Fmr1 KO 
mice remained excessively depressed in the presence of the translational inhibitor 
anisomycin, indicating that this form of synaptic plasticity occurs independently of 
new protein synthesis. This suggests that the proteins involved in the removal of 
AMPA receptors from the postsynaptic sites are already sufficiently present in the 
Fmr1 KO hippocampus to allow mGluR-dependent LTD to proceed without the need 
for new protein synthesis.  
 
In this study basal protein synthesis rates were directly measured in the hippocampus 
of Fmr1 KO mice and were found to be elevated by 20% in comparison to WT 
littermates. The magnitude of this increase is in close agreement with other in vitro 
studies in the hippocampus of Fmr1 KO mice (Osterweil et al. 2010; Dölen et al. 
2007; Michalon et al. 2012). Furthermore, in vivo studies have revealed that 
increased basal protein synthesis rates are elevated in several other brain regions 
(Qin et al. 2005a) but show a selectivity indicating that FMRP may regulate mRNA 





The major components of the protein synthesis machinery, which include ribosomes 
translation factors and mRNAs are present in dendritic shafts and spines suggesting 
that there is local protein synthesis, that is independent of transcription in the cell 
soma, which may be mediating long-lasting forms of synaptic plasticity, such as 
mGluR-dependent LTD (Sutton & Schuman 2006). At these dendritic sites FMRP is 
associated with mRNAs, RNA granules and translating polyribosomes.  FMRP 
functions as an RNA binding protein, repressing translation of a subset of mRNAs 
(~4% all known mRNAs) encoding proteins that are involved in synaptic maturation 
and plasticity (Darnell et al. 2011).  At local dendritic sites it is thought to regulate 
activity-dependent protein synthesis, functioning to repress mRNA translation 
primarily at postsynaptic sites following mGlu1/5 receptor activation. Fmr1 mRNA 
itself is rapidly translated following mGlu1/5 receptor activation (Weiler et al. 1997), 
and interacts with many of the transcripts that are translated following an mGluR-
dependent LTD stimulus (Bassell & Warren 2008).  
 
The electrophysiological phenotypes observed in the Fmr1 KO, reported here and 
elsewhere, support the hypothesis that FMRP plays a prominent role in mGluR-
dependent protein synthesis and plasticity. Our findings indicate that FMRP 
functions to suppress steady-state levels of mRNA translation. The exact mechanism 
by which FMRP represses the translation of its target mRNAs is not clear, however 
there is evidence to suggest it may be via targeting initiation through interactions 
with: non coding RNA BC1 protein, which could increase FMRP binding to target 
mRNAs (Zalfa et al. 2003); or CYFIP1, a EIF4E binding protein which competes 
with EIF4G for EIF4E (Napoli et al. 2008). There is also evidence to suggest that 
FMRP may target a post-initiation step, as FMRP associated with translating 
polyribosomes (Stefani 2004).  
 
Further investigations into protein synthesis in Fmr1 KOs revealed that mRNA 
translation is saturated downstream of constitutive mGlu1/5-ERK1/2 activity 
(Osterweil et al. 2010). In Fmr1 KO mice, the excessive basal protein synthesis rates 
are rescued by inhibiting mGlu5, Ras or ERK1/2 (Michalon et al. 2012; Osterweil et 
al. 2010; Osterweil et al. 2013). This indicates that in the Fmr1 KO brain, protein 
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synthesis rates are not decoupled from mGlu1/5 activation because if this was the 
case, inhibition of mGlu1/5 would have no effect on the elevated protein synthesis 
rates in the Fmr1 KO mouse. 
 
Efforts have been made to identify potential target mRNAs of FMRP. Through UV 
cross-linking studies, FMRP was found to interact with several hundred mRNAs 
(Darnell et al. 2011). Many of these transcripts are implicated in synaptic functions 
that are disrupted in the Fmr1 KO brain. These include mRNAs encoding: 
cytoskeletal associated protein (Arc) (Zalfa et al. 2003; Chowdhury et al. 2006), 
amyloid precursor protein (APP) (Westmark & Malter 2007), microtubule-associated 
protein 1B (MAP-1b) (Davidkova & Carroll et al. 2007) and striatal-enriched protein 
tyrosine phosphatase (STEP) (Zhang et al. 2008), components of AMPA receptor 
endocytosis machinery or involved in AMPA receptor internalization; the catalytic 
subunit of PI3K p-110  and PIKE-L (Sharma et al. 2010; Gross et al. 2010), 
components of mGlu1/5 mediated downstream signalling; PSD-95 (Todd et al. 2003),  
involved in anchoring  and stabilising glutamatergic receptors at the cell surface.  
 
The majority of these transcripts are up regulated in response to mGlu1/5 receptor 
stimulation. In contrast, the same targets appear to be overabundant and no longer up 
regulated in an activity-dependent manner in the Fmr1 KO brain. Thus it is 
hypothesized that the surplus of these LTD proteins lead to excessive AMPA 
receptor internalization in response to mGlu1/5 activation, eliminating the 
requirement for new protein synthesis and causing an exaggerated depression of 














3.8.3 Core deficits observed in Fmr1 KO mice translate to the rat model of FXS 
 
The generation of the rat model of FXS has enabled us to investigate whether the 
core pathophysiological phenotypes in the Fmr1 KO mouse translate to another 
rodent specie (Hamilton et al. 2014). Here we report that cellular processes 
associated with Gp1 mGlu receptor signalling, including DHPG-induced LTD and 
basal protein synthesis rates, are elevated in hippocampal slices prepared from young 
adult Fmr1 KO rats (P25-32). It has not been previously shown whether mGlu1/5 
receptor phenotypes associated with the loss of FMRP are shared between two 
independent mammalian species. Here it is reported that the Fmr1 KO rats exhibit 
increased basal protein synthesis rates alongside altered Gp1 mGluR-dependent 
synaptic plasticity in the hippocampus. These findings further validate the mGluR 
theory of FXS and suggest a strong evolutionary link between FMRP and mGlu1/5 
receptor signalling. Thus, it would be interesting to determine whether 
pharmacological strategies employed in correcting deficits in the Fmr1 KO mouse 
are efficacious in the Fmr1 KO rats.  
 
The rat model of FXS will also be a useful tool in studying more complex 
behavioural paradigms as rats display a richer social behavioural repertoire and level 
of communication compared to mice. This will be particular important when 
assessing the social and communication deficits in genetic models of ID and ASD, 
such as FXS and Syngap1 haploinsufficiency, where these phenotypes are prominent 
features of the disorder. Also, there are greater similarities in the physiology of rats 
and humans, so the rat model of FXS may provide a more sensitive tool in evaluating 
the potential therapeutic treatments for ID and ASD. Rats are also preferentially used 
by pharmaceutical companies for many aspects of drug development including 
investigating the potential side effects of a compound and how it will be metabolized 
in humans (Gilby & O'Brien 2013). Thus the rat model of FXS will be an important 
preclinical model of ID.  
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3.8.4. The mouse model of Syngap1 haploinsufficiency mimics the hippocampal 
pathophysiology associated with FXS.  
 
One of the key questions that need to be addressed in the ID and ASD field is 
whether genetically distinct causes of ID share similar phenotypic manifestations at 
the cellular and molecular level. Here electrophysiological and biochemical studies 
were employed to examine another genetic cause of ID that results from mutations in 
SYNGAP1. SYNGAP1 encodes the synaptic GAP protein, SynGAP that regulates 
Ras-mediated signalling. There is now a substantial body of evidence that link 
genetic mutations in Ras-associated proteins to neurodevelopmental disorders. 
Furthermore, there is evidence to suggest that elevated protein synthesis rates in the 
Fmr1 KO mouse result from a hypersensitivity of the translation machinery to 
mGlu1/5 signalling through Ras-ERK1/2-MAPK signalling pathway (Osterweil et al. 
2010; Osterweil et al. 2013). In Syngap heterozygous mice both Ras and ERK1/2 are 
hyperactive in the hippocampus (Komiyama et al. 2002; Carlisle et al. 2008; Ozkan 
et al. 2014), which we hypothesized could lead to similar phenotypic manifestations, 
in terms of mGlu1/5 receptor-mediated processes, such as mGluR-dependent LTD and 
protein synthesis at local dendritic sites. Thus the aim of this chapter was to 
determine whether mutations in Syngap1 share similar dysfunction in Gp1 mGluR-
dependent LTD and protein synthesis.  
 
In this thesis, it is shown for the first time that mGluR-dependent LTD is enhanced in 
the hippocampus of young adult Syngap heterozygous mice, which is observed at 
various concentrations of DHPG (30, 50 and 100 µM). Furthermore, inhibition of 
mRNA translation with anisomycin fails to abolish mGluR-dependent LTD in 
hippocampal slices from Syngap heterozygous mice indicating that this form of 
plasticity is no longer reliant on new protein synthesis at CA1 synapses. These 
findings suggest that SynGAP may be one of several intracellular components 
linking mGlu1/5 receptor activation to mRNA translational machinery, which governs 
the persistent removal of AMPA receptors from the cell surface upon mGlu1/5 
receptor activation. Thus, SynGAP may function as a modulator of synaptic strength 
at CA1 synapses.  
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At the PSD SynGAP is bound to PSD-95 and SAP102 and interacts with the GluN2B 
subunit of the NMDA receptor (Kim et al. 1998). Thus it is ideally positioned to 
relay synaptic activation of both ionotropic and metabotropic glutamate receptors to 
the initiation of intracellular events via Ras-mediated signalling cascades. Consistent 
with this hypothesis, it is reported that NMDA receptor mediated forms of synaptic 
plasticity are impaired in the hippocampus of Syngap heterozygous mice (Komiyama 
et al. 2002; Kim et al. 2003; Carlisle et al. 2008; Ozkan et al. 2014). As mentioned 
previously, CAMKII lies upstream of SynGAP and phosphorylates this protein at 
three sites, increasing its GAP activity (Oh et al. 2004). Once activated, SynGAP 
specifically binds and inactivates the Ras family of G-proteins that are required for 
the expression and maintenance mGluR-dependent LTD (Gallagher et al. 2004; Hou 
& Klann 2004).  
 
Interestingly, inhibition of CAMKII by KN-62, facilitates DHPG-induced mGluR-
dependent LTD at CA1 synapses (Schnabel 1999). One possible explanation of this 
finding is that in the presence of KN-62, CAMKII can no longer phosphorylate and 
activate SynGAP. This would mean that upon an LTD inducing stimulus, loss of 
CAMKII activity would leave SynGAP in its dormant state, which could 
consequently prolong the activity of Ras and its downstream targets due to the loss of 
inactivation by SynGAP. This could lead to the excessive removal of AMPA 
receptors from the postsynaptic terminal, potentially via protein synthesis dependent 
mechanism, leading to enhanced mGluR-dependent LTD. 
 
In support of SynGAPs role in AMPA receptor endocytosis, it has been observed in 
hippocampal cultures that overexpression of SynGAP suppresses AMPA receptor 
surface expression (Rumbaugh et al. 2006). Furthermore excitatory synaptic 
transmission is elevated in the hippocampus of Syngap heterozygous mice at P14 
suggesting that during early development SynGAP normally restricts AMPA 
receptor accumulation at the postsynaptic terminal, during a development period 
(<P21) where synapses gradually acquire AMPA receptors and increase their 
synaptic strength (Clement et al. 2012). This coincides with the peak expression of 
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SynGAP levels in this hippocampus, and may indicate a time-point at which 
synapses are most vulnerable to reduced SynGAP expression. 
 
Thus Syngap1 mutations lead to a derepression of synapse maturation leading to 
abnormally strong excitatory transmission that is functionally similar to adult-like 
levels of synaptic strength. By P21 basal synaptic transmission in WT synapses reach 
the same level of strength as Syngap heterozygous mice so there are no longer 
detectable differences in I/O function suggesting that at more mature synapses the 
expression of AMPA receptors is similar between Syngap heterozygous mutants WT 
mice (Clement et al. 2012). In this study, glutamatergic synaptic transmission in 
Syngap heterozygous mice at P25-32 was found to be intact, in agreement with 
previous reports (Komiyama et al. 2002; Clement et al. 2012). 
 
The comparable electrophysiological findings between Syngap heterozygous and 
Fmr1 KO mice lead us to predict that basal protein synthesis rates may too be 
elevated in the hippocampus of Syngap heterozygous mice. If so, this could account 
for our findings that mGluR-dependent LTD no longer requires new protein 
synthesis when SynGAP expression is reduced. In agreement with our prediction, 
basal protein synthesis rates are elevated in the hippocampus of the Syngap 
heterozygous mice. This result is consistent with increased protein synthesis rates in 
Syngap KD cortical cultures, which is accompanied by an increase in synaptic 
strength from increases in the expression of GluA1 containing AMPA receptors at 
the cell surface (Wang et al. 2013). However our findings reflect the consequence of 
reduced SynGAP expression, rather than total loss, and thus model Syngap 
haploinsufficiency more closely. Although it is unknown whether specific proteins 
are overexpressed, one would hypothesize that proteins involved in the removal of 
AMPA receptors are the most likely candidates. This would explain why Syngap1 
haploinsufficiency results in an excessive LTD, and would alleviate the need for new 





In Fmr1 KO mice elevated protein synthesis rates lie downstream of the ERK1/2 
MAPK signalling pathway, a pathway involved in the initiation of cap-dependent 
translation. Upstream of ERK1/2, is Ras, whose activity is regulated by synaptic 
GTPase activating proteins, such as SynGAP and neurofibromin (Ye & Carew 
2010). SynGAP reduces Ras activity by catalysing the hydrolysis of active Ras 
(GTP-bound) to its inactive form (GDP-bound). Thus when SynGAP expression is 
reduced, through loss of single functional copy of Syngap1, one would predict that 
the amount of time Ras remains in its active state is prolonged. Consequently this 
could lead to the persistent activation of cap-dependent translation via hyperactivity 
of Ras-mediated signaling cascades that include ERK1/2-MAPK and PI3K-Akt-
mTOR signaling leading to excessive translation of proteins involved in the 
expression and maintenance of long-lasting forms of synaptic plasticity.  
 
Interestingly, the magnitude of this increase in basal protein synthesis rates in 
Syngap heterozygous mice was far greater than that observed in Fmr1 KO mice. This 
may suggest that SynGAP regulates the translation of a greater subset of transcripts 
in the hippocampus than FMRP, which is known to bind to approximately 4% of 
mRNAs (Darnell et al. 2011). Thus increased protein synthesis levels may also be 
the core deficits underlying the pathophysiology of Syngap1 haploinsufficiency and 
it will be interesting to see whether the hippocampal deficits presented here can be 
corrected by the same pharmacological strategies used in mouse model of FXS.  
 
It should be noted by that an increase in 35S Met/Cys incorporation in hippocampal 
slice homogenates from Syngap heterozygous mice compared WT littermates could 
also reflect a reduction in the rate of protein degradation rather than an increase in 
protein synthesis. Both protein synthesis and degradation are important for synaptic 
plasticity and need to work in an orchestrated manner to regulate normal synaptic 
function (Tai et al. 2008; Steward & Schuman 2003). One way to test this alternative 
hypothesis would be via a pulse-chase method, in which slices are radiolabelled for 
45 minutes before being transferred back to fresh ACSF then slices collected at 
various time intervals to quantify the rate of 35S Met/Cys breakdown between Syngap 
heterozygous and WT mice. 
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Based on these initial findings that Syngap heterozygous and Fmr1 KO single 
mutants have a shared pathophysiology in the hippocampus, we wanted to directly 
test the hypothesis that these two genetically distinct causes of ID share a common 
pathophysiological axis. Thus a double transgenic was generated to investigate 
whether SynGAP and FMRP converge on the same molecular signalling mechanism 
that is involved in the expression of mGluR-dependent LTD. If SynGAP and FMRP 
utilised distinct pathways to modulate this form of synaptic plasticity then the 
magnitude of this depression would be further augmented in the Syngap 
heterozygous x Fmr1 KO cross. However, if SynGAP and FMRP converge on the 
same cellular mechanisms then Syngap1 haploinsufficiency would occlude the 
increase in mGluR-dependent LTD by the Fmr1 KO mutation. In the double mutant 
cross, mGluR-dependent LTD was enhanced compared to WT littermates but there 
was no further increase in magnitude of LTD than observed in the Fmr1 KO and 
Syngap heterozygous single mutants.  
 
To confirm that the magnitude of mGluR-dependent LTD in the double mutants was 
not caused by a “floor effect”, it was determined whether DHPG was inducing a 
saturating level of LTD for all four genotypes. Here it was observed that following a 
second application of DHPG, the magnitude of LTD was further increased in WT, 
Fmr1 KO and Syngap heterozygous mice, with double mutants showing a trend 
towards significance. This would suggest that DHPG induced LTD in double mutant 








3.9 Summary  
 
Thus to summarise, the data presented in this chapter demonstrate that two 
genetically distinct causes of ID, FXS and Syngap1 haploinsufficiency, share 
overlapping dysfunctions in cellular processes that are mediated by mGlu1/5 
receptors. Both mGlu1/5 receptor-mediated synaptic plasticity and protein synthesis 
are exaggerated in the hippocampus of Syngap heterozygous and Fmr1 KO mice. 
Together these findings suggest that FMRP and SynGAP may suppress steady-state 
levels of basal protein synthesis at CA1 synapses and in effect modulate AMPA 
receptor internalisation during periods of synaptic activation. Furthermore, it is 
shown that FMRP and SynGAP mediate their effects on synaptic strength via a 
common intracellular signalling cascade, most likely via Ras-ERK1/2 MAPK 
signalling, suggesting that mutations in Fmr1 and Syngap1 may share a common 
pathophysiological axis that results in excessive protein synthesis rates and 
exaggerated mGluR-dependent LTD. Thus Syngap1 lies on the same side of the 
pathological spectrum of synaptic function as Fmr1. This raises the intriguing 
possibility that synaptic abnormalities reported in the mouse model of Syngap1 
haploinsufficiency may be amenable to the same therapeutic strategies employed in 
the Fmr1 KO mouse.  
 




























Chapter 4  














4.1 Key findings 
 
1.) Western blot analysis reveals altered ERK1/2, Akt and S6 
signalling under steady-state conditions in the hippocampus of 
Syngap heterozygous mice. 
 
 
2.) Protein synthesis rates downstream of mGlu5 receptor activation 
are saturated in the hippocampus of Syngap heterozygous mice. 
 
 
3.) In contrast, western blot analysis of hippocampal homogenates 
and synaptoneurosome preparations reveal no significant 
differences in Ras mediated signalling or in the expression levels 











4.2 Introduction  
In Chapter 3 it was revealed that two monogenic causes of ID, FXS and Syngap1 
haploinsufficiency result in elevated basal protein synthesis in the hippocampus. 
Cellular functions, such as long-lasting forms of synaptic plasticity (e.g. mGluR-
dependent LTD, L-LTP) rely on the translation of specific proteins during periods of 
synaptic activity (Huber et al. 2000; Frey et al. 2003). Consistent with increases in 
translational rates, mGluR-dependent LTD at CA1 synapses was found to be 
enhanced and no longer dependent on new protein synthesis in Fmr1 KO and Syngap 
heterozygous mice. Furthermore investigations in the Fmr1 KO × Syngap 
heterozygous double mutants revealed that this exaggerated depression of excitatory 
synaptic transmission following an LTD–inducing stimulus likely involved the same 
intracellular signalling mechanism. These findings suggest that mutations in the 
Fmr1 and Syngap1 gene may converge on a common pathophysiological axis that is 
mediating increased protein synthesis rates in mouse models of FXS and Syngap1 
haploinsufficiency. 
Overall protein synthesis rates play an important role in neuronal function and must 
be tightly regulated. The process of mRNA translation, involves three main stages: 
initiation, elongation and termination. Translation factors and intracellular cascades 
target various components of this process and can determine gene expression in an 
activity-dependent manner. Upon mGlu1/5 receptor activation, both ERK1/2 and 
mTOR pathways stimulate cap-dependent mRNA translation by targeting 
components involved in initiation, the major rate-limiting step of mRNA translation 
(Banko et al. 2006; Ronesi & Huber 2008).  
The initiation of translation begins with the recognition of the 5’ mRNA cap by 
eukaryotic initiation factor 4E  (eIF4E) (Richter & Sonenberg 2005). This leads to 
the formation of the translation initiation complex, EIF4F that also includes EIF4A 
and EIF4G. Once the EIF4F complex is bound to the 5’ end of the mRNA, the small 
ribosomal subunit is recruited to the capped 5’ end of the mRNA transcript, where it 
traverses the 5’ untranslated region (UTR) in a 5’-3’ direction to identify the 
initiation codon AUG. Once initiation is complete, elongation factors are recruited to 
the ribosomal mRNA complex leading to the commencement of polypeptide 
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elongation and the production of newly synthesized proteins.  
Both ERK1/2 and mTOR signalling initiate translation by triggering the 
phosphorylation of eIF4E and 4E-BP, allowing the formation of EIF4F complex 
(Banko et al. 2006; Ronesi & Huber 2008; Richter & Sonenberg 2005; Proud 2007). 
In addition mGlu1/5 receptor activation of mTOR and ERK1/2 can stimulate 
translation by phosphorylating S6K1/2 and RSK, respectively, which activate the 
ribosomal protein S6 (Antion et al. 2008a). In turn S6 can phosphorylate and activate 
EIF4B, which potentiates EIF4A activity increasing EIF4F formation (Shahbazian et 
al. 2006). Furthermore S6 can increase the translation of a specific subset of 5’TOP 
mRNAs, which encode all ribosomal protein subunits and translation initiation 
factors, such as elongation factor 1A (EF1A), that enables a neuron to increase its 
overall translation capacity (Antion et al. 2008a; Figure 1.7). 
In CA1 of the hippocampus mGluR-dependent LTD is reliant on both ERK1/2 and 
mTOR activation, both of which have been shown to play an important role in the 
expression and maintenance of LTD and the regulation of mRNA translation 
(Gallagher et al. 2004; Hou & Klann 2004; Banko et al. 2006; Ronesi & Huber 
2008). It is suspected that mGlu1/5 receptors stimulate the synthesis of proteins, 
which participate in AMPA receptor endocytosis and trafficking, resulting in a 
depression of excitatory transmission. For this reason they are referred to as “LTD 
proteins” (Huber et al. 2000).   
In Fmr1 KO mutants, there is an overabundance of “LTD proteins” which include 
but are not limited to PSD-95 (Todd et al. 2003), APP (Westmark & Malter 2007), 
EF1A (Huang et al. 2005), MAP1b (Westmark & Malter 2007) and Arc (Chowdhury 
et al. 2006; Waung et al. 2008). Several of these proteins are directly implicated in 
the internalisation of AMPA receptors and their overexpression is thought to underlie 
the excessive reduction in synaptic strength following mGlu1/5 receptor activation. 
For these reasons both the ERK1/2 and mTOR pathways have been extensively 
studied in mouse model of FXS where mGlu1/5 mediated synaptic plasticity and 
protein synthesis are exaggerated. 
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It is reported that elevated basal protein synthesis in the Fmr1 KO hippocampus are 
corrected by targeting the Ras-ERK1/2 signalling pathway indicating that increased 
translational rates under steady-state conditions may lie downstream of Ras-ERK1/2-
MAPK signalling, rather than PI3K-Akt-mTOR signalling (Osterweil et al. 2010; 
Osterweil et al. 2013). The same study found that activity levels of ERK1/2 and 
mTOR signalling were intact and mGlu1/5 activation caused no further increase in 
elevated protein synthesis rates in the Fmr1 KO brain (Osterweil et al. 2010). Thus at 
rest mRNA translation is excessive and saturated downstream of mGlu5 receptor 
activation in the Fmr1 KO brain, resulting from a hypersensitivity of the mRNA 
translational machinery to Ras-ERK1/2 signalling due to the loss of translational 
repression by FMRP. 
In Syngap heterozygous mice, it has been reported that Ras and ERK1/2 activity 
levels are increased in the hippocampus (Carlisle et al. 2008; Komiyama et al. 2002; 
Ozkan et al. 2014), leading us to hypothesize that elevated protein synthesis rates in 
Syngap heterozygous mice arise from the hyperactivity of the Ras-ERK1/2 MAPK 
signalling pathway and moreover that they are saturated downstream of mGlu5 
receptor activation. In this chapter this hypothesis is tested, by measuring the 
phosphorylation status of key signalling components of the ERK1/2 and mTOR 
signalling cascades in hippocampal extracts from Syngap heterozygous mice. In 
addition, protein synthesis rates are measured in the presence DHPG, at a 
concentration that led to excessive mGluR-dependent LTD in the hippocampus of 
Syngap heterozygous mice. Furthermore the expression levels of key synaptic 
proteins, including “LTD proteins” that are involved in glutamatergic synaptic 
transmission, are quantified in hippocampal homogenates and synaptoneurosome 
preparations to determine whether steady-state levels are also increased in Syngap 
heterozygous mice. Thus this chapter sets out to examine the molecular mechanisms 
that may underlie elevated basal protein synthesis rates and enhanced mGluR-
dependent LTD in the hippocampus of Syngap heterozygous mice.  
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4.3 Results  
4.3.1 Basal levels of phosphorylated ERK, Akt and S6 are elevated in the 
hippocampus of Syngap heterozygous mice 
In Chapter 3 direct measurements of mRNA translation using a metabolic labelling 
approach revealed that protein synthesis rates were elevated in the dorsal 
hippocampus of Syngap heterozygous mice (P25-32). This is accompanied by 
enhanced mGluR-dependent LTD that is no longer dependent on new protein 
synthesis. At the synapse, SynGAP binds and inactivates Ras family members, which 
converge on intracellular signalling cascades that include ERK1/2 and mTOR. Both 
of these pathways are linked to the initiation of cap-dependent mRNA translation, 
which is crucial for the expression of mGluR-dependent LTD at CA1 synapses 
(Gallagher et al. 2004; Hou & Klann 2004). In Syngap heterozygous mutants, where 
SynGAP expression is reduced by 50%, Ras and ERK1/2 activity are reportedly 
increased in the hippocampus (Komiyama et al. 2002; Carlisle et al. 2008). Thus we 
suspect that the abnormal mGlu1/5 mediated phenotypes might arise from increased 
levels of Ras activation that could consequently lead to the hyperactivation of 
downstream signalling components that mediate mRNA translation.  
To test this hypothesis steady-state levels of phosphorylated and total ERK1/2 were 
quantified through western blot analysis using infrared fluorescence in the same 
dorsal hippocampal slices where elevated protein synthesis rates were measured 
(Figure 4.1A). In agreement with existing findings, levels of phosphorylation at sites 
Thr202/Tyr204 on ERK1/2 were elevated in hippocampal slices from Syngap 
heterozygous mice compared to WT littermates (Komiyama et al. 2002; Ozkan et al. 
2014). This was observed in the absence of any detectable differences in total 
ERK1/2 protein levels (phospho/total ERK1/2: WT 100 ± 7%; Het 162 ± 15%; n = 8, 
t-test *p = 0.003; phospho/total ERK1: WT 100 ± 7%; Het 176 ± 22%; n = 8, t-test 





To determine whether mTOR signalling was also hyperactive, basal levels of 
phosphorylated and total Akt and p70 S6 kinase were quantified in hippocampal 
slices from Syngap heterozygous mice. Phosphorylated Akt was found to be 
significantly elevated in Syngap heterozygous slices compared to WT controls with 
no change in total Akt levels (p-Akt/Akt: WT 100 ± 11%; Het 124 ± 8%; n = 7, t-test 
*p = 0.02; Figure 4.1B). However using an antibody that recognised the 
phosphorylation site Thr389 on p70 S6 kinase failed to provide a detectable 
fluorescent signal in hippocampal slices. 
One downstream target of both activated ERK1/2 and mTOR is the S6 ribosomal 
protein, a subunit of the small 40S ribosome (Nygård & Nilsson 1990). S6 is 
phosphorylated at several serine residues (Ser235, Ser236, Ser240, Ser244 and Ser247) by 
two classes of protein kinases, S6K1/2 and RSK that are in turn activated by mTOR 
and ERK1/2 signalling respectively (Roux et al. 2007). Phosphorylation of S6 was 
quantified using two antibodies that recognize S6 when dually phosphorylated at 
either Ser235/236 (S6235/236) or Ser240/244 (S6240/244). In Syngap heterozygous mice, 
phospho-S6235/236 levels were significantly elevated compared to WT littermates with 
no change in the levels of total S6 (pS6235/236/S6: WT 100 ± 7%; Het 121 ± 8%; n = 
8, t-test *p = 0.03; Figure 4.1C). In contrast there were no detectable differences 
observed in phospho-S6240/244 between Syngap heterozygous and WT mice 
(pS6240/244/S6: WT 100 ± 4%; Het 106 ± 7%; n = 8, t-test p > 0.05; Figure 4.1D) 
indicating that under steady state conditions S6 is overactive in the Syngap 





Figure 4.1 Western blots reveal activity levels of key signalling proteins are elevated in 
hippocampal slices from Syngap heterozygote mice. Basal activation states of ERK1/2, Akt and S6 
were quantified in hippocampal slices from Syngap heterozygous mice (het, SG+/-) and expressed as a 
percentage of their WT pair. (A) Levels of phosphorylated ERK1/2 to total ERK1/2 were increased in 
Syngap heterozygous mice compared to WT littermates (Phospho/total ERK1/2: WT 100 ± 7%; SG +/-
162 ± 15%, n = 9, t-test *p = 0.004). (B) Similarly phosphorylated forms of Akt/total Akt were 
elevated in hippocampal slices from Syngap het mice compared WT littermates (Phospho/total Akt: 
WT 100 ± 11%; SG +/-124 ± 8%, n = 7, t-test *p = 0.001). (C) The basal activation state of S6 at 
Ser235/236 was also significantly increased in Syngap heterozygous mice compared to WT controls 
(Ser235/236 /S6: 100 ± 5%; SG +/- 121 ± 8%, n = 8, t-test *p = 0.03), whilst phosphorylation of S6 at 
Ser240/244 was indistinguishable from WT littermates (Ser240/244/S6: 100 ± 5%; SG +/- 121 ± 8%; n = 8, 
t-test p > 0.05). 
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4.3.2 mGluR-dependent protein synthesis is saturated in the hippocampus of 
Syngap heterozygous mice 
In Syngap heterozygous mice, the activation of Gp1 mGlu receptors with DHPG 
induces a depression of synaptic responses that is greater in magnitude than WT 
littermates and no longer sensitive to protein synthesis inhibitors. These findings 
suggest that the proteins required for the stabilizing LTD expression, which are 
normally synthesized in response to mGlu1/5 receptor activation, are already present 
at Syngap heterozygous synapses. In the Fmr1 KO brain, DHPG failed to increase 
elevated protein synthesis rates in hippocampal slices suggesting that mRNA 
translation is saturated downstream of mGlu1/5 receptor activation (Osterweil et al. 
2010). 
 
Here, we investigated whether translational rates downstream of mGlu1/5 receptor 
activation are elevated in Syngap heterozygous under experimental where 
exaggerated mGluR-dependent LTD is obtained. The application of an mGluR-
inducing LTD stimulus, DHPG (100 µM; 5 mins), significantly increased 
translational rates in WT hippocampal slices by ~40% when normalised to WT 
vehicle treated slices (WT veh 100 ± 5%; WT DHPG 138 ± 14%; n  = 6; *p = 0.008; 
Figure 4.2). However measurements of 35S incorporation in hippocampal slices from 
Syngap heterozygous revealed that DHPG failed to significantly increase elevated 
protein synthesis levels further in hippocampal slices from Syngap heterozygous 
mice (Het veh 135 ± 7%; Het DHPG %, 148 ± 15% n  = 6, p = 0.43). These findings 
suggest that in WT slices mGlu1/5 activation leads to a significant increase in mRNA 
translation, whilst in Syngap heterozygous slices DHPG has no effect on protein 
synthesis rates because they are already saturated downstream of mGlu5 receptor 













Figure 4.2 Protein synthesis rates are saturated downstream of mGlu1/5 receptor activation in 
Syngap heterozygous mice. (A) Schematic of experimental timeline for 35[S]-Methionine/Cysteine 
metabolic labeling in the presence of DHPG (100 µM). (B) Protein synthesis levels were significantly 
elevated in vehicle (veh) treated dorsal hippocampal slices from Syngap+/- (het, SG +/-) versus wild 
type mice (SG +/- veh: 135 ± 7%; WT veh: 100 ± 7%; n = 6; ANOVA *p = 0.02). DHPG treatment 
significantly increased protein synthesis rates in WT slices but did not further increase 35S 
incorporation in Syngap heterozygous mice (WT DHPG: 138 ± 14%; SG +/- DHPG: 148 ± 15%; 





4.3.3 No detectable differences in protein expression levels of key synaptic 
proteins in hippocampal homogenates from Syngap heterozygous mice 
In Fmr1 KO mice, elevated protein synthesis rates are accompanied by increases in 
steady state levels of synaptic proteins, which include CAMKII, Arc, and PSD-95 
(Todd & Malter 2002; Chowdhury et al. 2006; Roux et al. 2007; Waung et al. 2008; 
Zalfa et al. 2003). Here the expression levels of a specific subset of synaptic proteins 
were quantified in hippocampal homogenates from Syngap heterozygous and WT 
mice (P25-32). The aim of this experiment was to examine whether key synaptic 
proteins, implicated in mGlu1/5 receptor signalling and known to be overabundant at 
Fmr1 KO synapses, are overexpressed in the hippocampus of Syngap heterozygous 
mutants.  
Using an alternative method of detection, enhanced chemiluminescence (ECL), it 
was observed that protein expression levels of PSD-95, CAMKII and Arc, were not 
significantly different in hippocampal homogenates from Syngap heterozygous and 
WT controls (Figure 4.3). Similarly, no detectable genotype differences were 
observed in the expression of glutamatergic receptor subunits in hippocampal 
homogenates. These included the expression of mGlu5 receptors (mGlu5: WT 100 ± 
5%; Het 80 ± 10%; n = 4, t-test p = 0.16), AMPA receptor subunits GluA1 and 
GluA2 (GluA1: WT 100 ± 5%; Het 90 ± 14%; n = 4, t-test p = 0.89; GluA2: WT 100 
± 19 %; Het 78 ± 15%; n = 4, t-test p = 0.23), and the GluN2A and GluN2B subunits 
of the NMDA receptor (GluN2A: WT 100 ± 8%; Het 98 ± 10%; n = 5, t-test p = 
0.83; GluN2B: WT 100 ± 3%; Het 102 ± 9%; n = 5, t-test p = 0.83). However, high 
levels of variability were observed in the expression of certain proteins, such as 
GluA2, which would require a greater n to determine any significant phenotypic 
differences in protein expression.  
 
4.3.4 mGlu5 receptor expression is downregulated in hippocampal 
synaptoneurosomes preparations from Syngap heterozygous mice 
Synaptoneurosome preparations prepared from Syngap heterozygous and WT 
hippocampi were probed for the same subset of proteins (Figure 4.4). There were no 
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significant differences in the expression profiles of PSD-95, CAMKII or Arc in 
synaptoneurosomes prepared from Syngap heterozygous and WT hippocampi. 
Similarly no significant differences were observed in protein expression of NMDA 
receptor subunits GluN2A or GluN2B (GluN2A: WT 100 ± 15%; Het 76 ± 15%; n = 
5, t-test p = 0.17; GluN2B: WT 100 ± 17%; Het 92 ± 28%; n = 5, t-test p = 0.80), or 
AMPA receptor subunits GluA1 or GluA2 (GluA1:  WT 100 ± 7%; Het 83 ± 11%; n 
= 5, t-test p = 0.20; GluA2: WT 100 ± 23%; Het 77 ± 18%; n = 5, t-test p = 0.27), 
however again there was a significant level of variability observed. Interestingly, the 
only significant finding was that levels of mGlu5 receptor expression were 
significantly lower in Syngap synaptoneurosome preparations (mGlu5: WT 100 ± 







































Figure 4.3 Western blots of PSD protein expression levels in hippocampal homogenates from 
Syngap heterozygous and WT mice. (A) Bar plot showing protein expression levels in whole 
hippocampal homogenates from Syngap heterozygous (het, SG+/-) mice, quantified by western 
blotting and expressed as a percentage of wild-type (WT) pair. For all proteins examined no 



















Figure 4.4 Western blots of PSD protein levels in hippocampal synaptoneurosome preparations 
from Syngap heterozygote and WT mice. (A) Bar plot showing protein expression levels in whole 
hippocampal homogenates from Syngap heterozygous (het, SG+/-) mice, quantified by western 
blotting and expressed as a percentage of wild-type (WT) pair. The only significant difference 











4.3.5 Western blot analysis of hippocampal homogenates and 
synaptoneurosome preparations do not reveal elevations in ERK1/2 or mTOR 
signalling 
Next, we investigated whether the elevation in basal levels of ERK1/2 and Akt 
measured in Syngap heterozygous hippocampal slices could be reproduced in 
hippocampal homogenates and synaptoneurosome preparations at the same 
developmental time point (P25-32) via ECL methodology. Here protein 
phosphorylation levels of several components of the ERK and mTOR signalling 
cascades were quantified in hippocampal tissue that had been rapidly dissected and 
immediately frozen from Syngap heterozygous and WT mice. Contradicting our 
previous findings in hippocampal slices, no significant differences were observed in 
any of components of the Ras-mediated signalling cascade in either hippocampal 
homogenates (Figure 4.5), or synaptoneurosome preparations from Syngap 













































Figure 4.5 Western blots of intracellular signalling proteins in hippocampal homogenates from 
Syngap heterozygote and WT mice. Bar plot relative protein expression levels in whole 
hippocampal homogenates from Syngap heterozygous (het, SG+/-) mice, quantified by western blotting 



























Figure 4.6 Western blots of intracellular signalling proteins in hippocampal synaptoneurosome 
preparations from Syngap heterozygote and WT mice. Bar plot relative protein expression levels 
in whole hippocampal synaptoneurosomes from Syngap heterozygous (het, SG+/-) mice, quantified by 















In Chapter 3 it was shown that mutations in two ID-related genes, Fmr1 and 
Syngap1, lead to similar phenotypic manifestations in the hippocampus of Fmr1 KO 
and Syngap heterozygous mice. These findings suggest that both FMRP and 
SynGAP form part of the same intracellular signalling cascade that link mGlu1/5 
receptor activation to mRNA translation. Thus this chapter was dedicated to 
investigating the intracellular signalling mechanisms that may be disrupted in Syngap 
heterozygous mice, which could consequently lead to excessive protein synthesis and 
enhanced mGluR-dependent LTD. 
 
The activation of Gp1 mGlu receptors at CA1 synapses in the hippocampus 
stimulates the translation of pre-existing mRNA transcripts at local dendritic sites 
(Weiler et al. 1997; Huber et al. 2000). Here, mGlu1 and mGlu5 receptors do not 
signal through the canonical pathway associated with Gq/11 coupled GPCRs but 
instead utilize Ca2+-independent signalling mechanisms to target the initiation and 
elongation phase of translation. The two major signalling cascades that couple 
mGlu1/5 receptors to the translational apparatus are the ERK1/2-MAPK and PI3K-
Akt-mTOR pathways (Banko et al. 2006; Ronesi & Huber 2008a). Both of these 
signalling cascades are activated by mGlu1/5 receptors and are crucial for long-lasting 
forms of synaptic plasticity (Gallagher et al. 2004; Hou & Klann 2004). Thus 
ERK1/2 and mTOR signalling have been extensively studied in the mouse model of 
FXS and were the primary focus in this study.  
 
4.4.1 Hyperactivity of ERK1/2 and Akt lead to elevated protein synthesis rates 
in Syngap heterozygous mice 
Although mGlu1/5 receptor mediated synaptic plasticity and protein synthesis are 
aberrant in the Fmr1 KO mouse, until recently there was no evidence to directly link 
either the ERK1/2 or mTOR pathway to elevated protein synthesis rates in the 
hippocampus. However, a recent study by Osterweil et al. (2010) directly measured 
mRNA translational rates in Fmr1 KO mice and quantified activation states of key 
signalling components of the ERK1/2 and mTOR signalling cascade under similar 
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conditions in which exaggerated LTD was observed. Here elevated protein synthesis 
rates in Fmr1 KOs were not accompanied by the hyperactivation of either pathway 
but were caused by a hypersensitivity of the translational machinery to mGlu1/5 
signalling. Furthermore, the same study found that inhibitors of ERK1/2, but not 
mTOR, normalized elevated protein synthesis rates to WT levels suggesting that the 
saturation of mGluR-dependent mRNA translation in the Fmr1 KO brain was 
downstream of the ERK1/2-MAPK pathway.  
 
By employing a similar experimental approach it was shown in this chapter that 
elevated protein synthesis rates in the hippocampus of Syngap heterozygous mice are 
accompanied by significant increases in the activation state of both ERK1/2 and Akt. 
Although a more detailed biochemical analysis of these two pathways is required, the 
hyperactivity of ERK1/2 and Akt are consistent with SynGAPs role as a negative 
regulator of Ras activity. Ras family members include Ras, Rap1 and Rap2. Both 
Ras and Rap1 can activate the ERK1/2 and mTOR pathways through a distinct series 
of phosphorylation steps (Ye & Carew 2010).  The mGlu5 receptor can activate the 
PI3K-Akt-mTOR through its interaction with homer (Rong et al. 2003), or through 
activation of Ras. The mechanism by which mGlu5 receptors are linked to Ras 
mediated signalling, including activation of ERK-MAPK pathway, is not known. 
However there is evidence to suggest that it may involve scaffolding proteins, such 
as the β-arrestins or the kinase suppressor of Ras1 (KSR) (Shalin et al. 2006; DeWire 
et al. 2008). 
 
Substrates of both ERK1/2 and mTOR signalling are known to be involved in the 
translational control of gene expression, and include: Mnk1, S6 protein kinases, eIFs, 
4E-BPs and eukaryotic elongation factor 2 (Richter & Sonenberg 2005). Here the 
activation state of an S6K kinase substrate, ribosomal protein S6, was examined in in 
the hippocampus of Syngap heterozygous mice. S6 is the subunit of the small 40S 
ribosome that directly interacts with mRNA, tRNA and translational initiation factors 
(Nygård & Nilsson 1990). Western blot analysis revealed that phosphorylation levels 
of S6 at Ser235/236 were elevated in hippocampal slices from Syngap heterozygous 
mutants, whilst phosphorylation at Ser240/244 was unaffected. S6 is phosphorylated at 
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several serine residues (Ser235/236, Ser240/244 and Ser247) by two classes of protein 
kinases, S6K1/2 and RSK, which are activated by mTOR and ERK1/2 respectively 
(Frödin et al. 2000). Ras signalling is specifically linked the phosphorylation of S6 at 
Ser235/236 but not Ser240/244 (Richter & Sonenberg 2005; Roux et al. 2007). In contrast, 
mTOR signalling via S6K1/2 leads to the phosphorylation of S6 at all five serine 
sites (Roux & Blenis 2004; Pende et al. 2004).  
 
In addition to cap-dependent translation, the activation of S6 is associated with the 
translation of 5’TOP mRNAs that encode translation initiation factors and ribosomal 
protein subunits (Antion et al. 2008a).  Thus hyperactivation of S6 may increase the 
translation capacity of hippocampal neurones exacerbating protein synthesis rates in 
Syngap heterozygous mice under basal conditions. Interesting, DHPG-induced 
increases in S6 phosphorylation and 5’TOP mRNAs persist in the absence S6K1/2 
(Antion et al. 2008b). Furthermore the same study reported that S6K2 KOs exhibit 
enhanced mGluR-dependent LTD. This may point towards a mechanism, in which 
mGlu1/5 signals through RSK to activate S6, rather than S6K1/2 to initiate mGluR-
dependent mRNA translation. Alternatively, S6K2 activation could lead to the 
functional repression of translation during an LTD stimulus. Thus, one potential 
signalling mechanism that may result in excessive basal protein synthesis rates in the 
hippocampus of Syngap heterozygous mice may involve Ras signalling through 
ERK1/2 to activate RSK which phosphorylates S6 at Ser235/236 leading to 5’TOP 
mRNA translation as well as the initiation of cap-dependent translation via the 












Figure 4.7 mGluR-dependent mRNA translation in the hippocampus. Activation of Gp1 mGlu 
receptors leads to the activation of Ras signalling. Targets of Ras include both ERK1/2 and PI3K-Akt-
mTOR signalling cascade. ERK1/2 can initiate mGluR-dependent translation by targeting the p90 
S6K, RSK, which targets ribosomal protein S6, which is linked to the 5TOP mRNA translation. In 
addition RSK can target EIF4B, which potentiates the activity EIF4A, facilitating the formation of the 
EIF4F complex leading to the initiation of cap-dependent translation. In response to mTOR, Ras may 
also signal through mTOR, which targets 4E-BP, leading to the release of EIF4E, which binds to 
EIF4G. Once EIF4E is bound to the EIF4F, Mnk1 phosphorylates EIF4E through activation of ERK 




Another downstream target of ERK1/2 and mTOR is 4E-BP (Kelleher et al. 2004; 
Banko et al. 2006). Similarly to S6K2 KOs, the genetic deletion of 4E-BP2 also 
results in elevated mGluR-dependent LTD that is sensitive to U0126 but insensitive 
to rapamycin (Antion et al. 2008b). This suggests that mTOR may lie upstream of 
4E-BP2, signalling through this protein to regulate mGluR-dependent LTD (Figure 
4.7). Previously it has been shown that inhibition of mTOR, not ERK1/2, prevents 
DHPG-induced phosphorylation 4E-BP2 (Banko et al. 2006). At the synapse 4E-BP 
family members are bound to eIF4E inhibiting the formation of the EIF4F complex 
and preventing the initiation of mRNA translation (Richter & Sonenberg 2005). 
Consequently, the loss of 4E-BP is thought to lead to an increase in the availability 
of EIF4E, permitting EIF4E to bind EIF4G, leading to the formation of the EIF4F 
initiation complex. Once EIF4E is bound to EIF4G, Mnk1 can phosphorylate this 
protein, in an ERK-dependent manner, and initiate cap-dependent translation (Banko 
et al. 2006). Thus increases in basal protein synthesis rates in Syngap heterozygous 
mice could also arise through ERK1/2 and mTOR inhibiting 4E-BP.  
 
Collectively, these intracellular signalling cascades may contribute to elevated 
translational rates in the hippocampus of Syngap heterozygous mice. In the mouse 
model of FXS many of symptoms are thought to arise from an increase in synaptic 
protein synthesis, which could be applicable to the mouse model of Syngap 
haploinsufficiency. Importantly, increased protein synthesis rates in Fmr1 KO mice 
can be restored in adulthood (Dölen et al. 2007; Osterweil et al. 2010; Osterweil et 
al. 2013). This raises the intriguing possibility that pharmacologically strategies used 
in the treatment of FXS, may also correct the hippocampal pathophysiology we 




4.4.2. Translational rates are saturated downstream of mGlu5 receptor 
activation in Syngap heterozygous mice 
The activation of Gp1 mGlu receptors with DHPG, at a concentration that induces a 
persistent depression of synaptic responses, did not cause a further increase in 
mRNA translational rates in Syngap heterozygous hippocampal slices. This suggests 
that genetic reduction of SynGAP expression mimics and occludes the effect of 
DHPG on protein synthesis. Thus it appears that in the hippocampus of Syngap 
heterozygous mice mRNA translational rates downstream of mGlu1/5 activation are 
saturated and no longer regulated in an activity-dependent manner.  
 
In CA1 of the hippocampus the expression of mGluR-dependent LTD is dependent 
on cap-dependent translation to maintain reduced AMPA receptor expression at the 
postsynaptic terminal (Huber et al. 2000). Thus it was hypothesized that proteins 
normally up regulated in response to mGlu1/5 receptor activation may be present in 
the Syngap heterozygous brain at rest. However, western blot analysis of 
hippocampal extracts from Syngap mutant mice revealed that there were no 
significant differences in the expression of PSD-95, CAMKII and Arc. This was 
unexpected as elevated protein synthesis rates in the hippocampus of Syngap 
heterozygous mice are accompanied by the enhanced levels of mGluR-dependent 
LTD, which we predicted would arise from the overexpression of proteins that 
facilitate AMPA receptor removal.  
 
One explanation for these apparently conflicting findings is that there may also be 
alterations in protein degradation in the hippocampus of Syngap heterozygous mice. 
For mGluR-dependent protein expression to be consistent between Syngap 
heterozygous and WT mice, when translational rates are increased in Syngap 
mutants, newly synthesized proteins would have to be broken down at a similar rate 
to which they were made. This could indicate that the protein degradation pathway is 
also hyperactive under basal conditions in the Syngap heterozygous brain. However 
if protein synthesis and degradation rates were matched this wouldn’t explain why 
LTD is enhanced and independent of new protein synthesis, unless mGlu receptor 
activation puts a brake on protein degradation. Inhibition of the proteasome 
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degradation pathway would lead to a rapid build up of “LTD proteins” at CA1 
synapses due to enhanced mRNA translation rates in the Syngap heterozygous brain. 
The sudden overabundance of “LTD proteins” could contribute to exaggerated 
AMPA receptor removal. In order to test this idea, mRNA translational rates could 
be measured in the presence of a proteasome inhibitor, such as Mg132, and western 
blot analysis performed on the same slice homogenates. This will determine whether 
the proteasome degradation pathway impacts basal protein synthesis rates in both 
WT and Syngap heterozygous mice and allow quantification of proteins 
overtranslated in the Syngap heterozygous brain.  
 
Another possibility is that targets of “LTD proteins”, which include components of 
the AMPA receptor endocytotic machinery, are somewhat hypersensitive to their 
expression. This could occur if ERK1/2 and/or mTOR activation have additional 
functional effects at the synapse, for example priming proteins that are involved in 
the mGluR-dependent depression of synaptic responses (e.g. STEP, MAP1b, Arc). 
As observed in Fmr1 KO and Syngap heterozygous mice, increases in basal protein 
synthesis only impact synapse function when mGlu1/5 receptors are activated. Basally 
there is no reduction in AMPA receptor content at the synapse as measured by I/O 
function and western blot analysis. This suggests that a stimulus is still required in 
order to trigger AMPA receptor removal, even though in Fmr1 KO mice there is an 
overabundance of “LTD proteins”. Thus it will be important to access whether 
inhibitors of ERK or mTOR impress on mGluR-dependent LTD in the hippocampus 
of Syngap heterozygous mice. It is already known from Chapter 3 that this form of 
synaptic plasticity is insensitive to translation inhibitors in the Syngap heterozygous 
brain, thus if ERK1/2 and mTOR are altering synapse function solely through 
mRNA translation then they are unlikely to effect the expression of LTD in Syngap 
heterozygous hippocampal slices.    
 
In addition we detected no significant differences in the activation states of proteins 
that compose the ERK1/2 or mTOR pathway in hippocampal homogenates or 
synaptoneurosomes from Syngap heterozygous mice. This data was in stark contrast 
to findings observed in hippocampal slice homogenates. This could arise from a 
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caveat associated with our experimental approach because protein expression levels 
were not quantified in conditions where elevated protein synthesis and mGluR-
dependent LTD were observed. Quantification of Ras-mediated signalling 
components were initially performed in single dorsal hippocampal slices, which were 
left to recover for at least 4 hours following tissue preparation and quantified using 
infrared fluorescence. Previously Osterweil et al. (2010) has shown that protein 
synthesis rates in the hippocampus require a recovery period of at least 4 hours 
before mRNA translational rates stabilize. In contrast, here western blot analysis was 
performed on whole hippocampi that were rapidly dissected and processed. This 
method of tissue preparation may only capture early post-mortem differences in 
protein metabolism, rather than alterations in protein expression under stable slice 
conditions where electrophysiological recordings were performed (Osterweil et al. 
2010).  
 
This may explain why we did not observe significant increases in ERK1/2 or mTOR 
signalling or in “LTD protein” expression in hippocampal extracts from Syngap 
heterozygous mice. The only significant difference observed was in the expression of 
mGlu5 receptors, which were markedly reduced in Syngap heterozygous 
synaptoneurosomes but not in homogenate. This may suggest total mGlu5 expression 
in the hippocampus is unaffected but there is a reduction of mGlu5 receptors at the 
postsynaptic terminal. Altered mGlu5 receptor levels have also been detected in PSD 
fractions prepared from Fmr1 KO mice with no detectable change in total mGlu5 
receptor expression in forebrain homogenates (Giuffrida et al. 2005). These findings 
may reflect a compensatory effect due to the functional consequences mGlu5 
receptor activation imposes at Syngap heterozygous and Fmr1 KO synapses. 
Furthermore, our findings that GluN2A and GluN2B were unchanged in the Syngap 
hippocampal extracts is in agreement with a previous study, which found no 
significant differences in NMDA receptor expression in the hippocampus of mature 




In retrospect, quantification of mGlu5-related proteins, particularly of those encoded 
by cap- and TOP- mRNAs, in metabolically stable slices would have allowed a more 
comparable assessment of protein expression under conditions where we observe 
abnormal mGluR-dependent synaptic plasticity and protein synthesis. Although this 
would be possible for highly abundant proteins, such as PSD-95 and CAMKII, it 
may not be feasible for low abundant proteins such as p70S6K unless multiple 
hippocampal samples were pooled together. As previously mentioned, when 
quantifying phospho-p70S6K in single hippocampal slice homogenates, using 
infrared fluorescence, there was no quantifiable signal. Thus experimental conditions 
need to be optimised to obtain a robust readout of protein expression in order to 
examine the activation status of key signalling proteins implicated in the 
pathophysiology of FXS and Syngap1 haploinsufficiency. Furthermore it should be 
noted that western blot analysis only captures alterations in protein expression that 
differ by 20% or more (Personal communication Professor Kind). Thus, perhaps this 
method of quantification is not sensitive enough to identify proteins overtranslated in 
Syngap heterozygous brain. An alternative approach could be to use a translating 
ribosome affinity protocol (TRAP) assay, to determine which mRNA transcripts are 
bound to the actively transcribing polyribosomes in the hippocampus of Syngap 
heterozygous mice under basal conditions.  This would allow the identification of 
potential pathogenic proteins that may contribute to the underlying synaptic function 












4.5 Summary  
 
Although phenotypically, Syngap heterozygous and Fmr1 KO mice share a similar 
hippocampal pathophysiology, data presented in this chapter reveals that there are 
clear distinctions between these two models of ID at the molecular level. Firstly, in 
the Fmr1 KO hippocampus elevations in basal protein synthesis were observed in the 
absence of any alterations in either ERK1/2 or mTOR signalling. Yet the deletion of 
Fmr1 occluded any further increase in mRNA translation induced by Gp1 mGlu 
receptor activation and inhibitors of either mGlu5 or the Ras-ERK1/2 signalling 
pathway (but not mTOR) corrected increased basal protein synthesis raised 
(Osterweil et al. 2010; Osterweil et al 2013). These findings indicated that increased 
translational rates in Fmr1 KO mice resulted from a hypersensitivity of the mRNA 
translational machinery to constitutive mGlu5–ERK1/2 signalling that was direct 
effect of the loss of translational repression in the absence of FMRP. In this chapter 
the same experimental conditions, as used in Fmr1 KO mice, revealed an increase in 
the activity of ERK1/2 and Akt in the hippocampus of Syngap heterozygous mice 
suggesting that elevations in translational rates may arise from hyperactivity in 
ERK1/2 and mTOR signalling under steady state conditions. Thus, there is a 
possibility that inhibition of ERK1/2 or mTOR signalling may restore elevated 














Chapter 5  
Rescue of the Hippocampal Pathophysiology 








Chapter 5: Rescue of Hippocampal Pathophysiology in the 
Mousel of Syngap1 Haploinsufficiency  
5.1 Key findings  
 
1.) Elevated protein synthesis rates in Syngap heterozygous mice are 
selectively reduced to WT levels by acute inhibition of either 
mGlu5, Ras or ERK1/2. 
 
2.) U0126 & Lovastatin lower overactive ERK1/2 and S6235/236 
phosphorylation in Syngap heterozygous hippocampal slices. 
 
3.) U0126 & rapamycin reduce mGluR-dependent LTD in Syngap 
heterozygous mice via a protein synthesis independent 
mechanism. 
 
4.) Rapamycin reduces elevated protein synthesis rates, normalizes 
elevated mGluR-dependent LTD and restores the protein synthesis 

















5.2 Introduction  
Altered mGlu1/5 receptor signalling appears to be a shared dysfunction in the mouse 
model of FXS and Syngap1 haploinsufficiency. In Chapters 3 and 4 it was observed 
that Syngap heterozygous mice share a similar hippocampal pathophysiology to FXS 
mutants, including enhanced mGluR-dependent LTD and increased translational 
rates that are saturated downstream of mGlu1/5 receptor activation. In Fmr1 KO mice 
elevated basal protein synthesis rates are observed in the absence of altered ERK1/2 
or mTOR signalling, suggesting that mRNA translational apparatus are 
hypersensitive to constitutive mGlu5 receptor activity due to the loss of steady-state 
translational repression by FMRP. In contrast, both ERK1/2 and mTOR signalling 
appear overactive in the Syngap heterozygous mutants when examined under similar 
experimental conditions. This suggests that increased translation rates, associated 
with Syngap1 haploinsufficiency, may arise from a hyperactivity of Ras-mediated 
intracellular signalling. 
 
Normally SynGAP binds and inactivates Ras family members suppressing the 
activation of downstream signalling cascades that include both ERK1/2 and mTOR 
(Ye & Carew 2010). However in Syngap heterozygous mice, where SynGAP 
expression is reduced by at least 50%, there is a loss of Ras inactivation that 
consequently leads to the overactivation of ERK1/2 and mTOR signalling under 
steady-state conditions. At CA1 synapses both ERK1/2 and mTOR can trigger the 
initiation of cap-dependent and 5’TOP mRNA translation by regulating translation 
factors and RNA binding proteins (Banko et al. 2006; Ronesi & Huber 2008; Antion 
et al. 2008a). They are both activated in response to mGlu1/5 receptor stimulation and 
play a crucial role in the expression and maintenance of mGluR-dependent LTD 







Based on this evidence, overactivation of ERK and mTOR signalling may underlie 
increased translational rates and enhanced mGluR-dependent LTD that is observed in 
the Syngap heterozygous brain. In Fmr1 KO mice, elevated protein synthesis rates 
are restored to WT levels by inhibitors of either mGlu5, Ras or ERK1/2, but not 
mTOR (Dölen et al. 2007; Osterweil et al. 2010; Osterweil et al. 2013; Michalon et 
al. 2012). Thus the focus of this chapter is to assess whether the hippocampal 
pathophysiology associated with Syngap1 haploinsufficiency can be reversed using 
similar pharmacological strategies known to be effective at correcting hippocampal-
based phenotypes in mouse models of ID (Figure 5.1). 
 
CTEP a highly specific & long-lasting negative allosteric modulator of the mGlu5 
receptor 
Recently CTEP, a novel, long lasting (Kd = 1.8 nM for mouse) and orally 
bioavailable NAM of mGlu5 was developed. CTEP is 1000 times more selective for 
the mGlu5 receptor than its predecessor MPEP (Lindemann et al. 2011). 
Furthermore, unlike MPEP and fenobam, which are extremely short acting (half-life 
approximately 15 minutes in the brain), a single-dose of CTEP administered every 
48 hours achieves consistent receptor occupancy of 81%. In Fmr1 KO mice, chronic 
treatment with CTEP starting at 4-5 weeks corrected: learning and memory deficits, 
hyperactivity to sensory stimulus, elevated locomotor activity, increased dendritic 
spine density, increased AGS susceptibility, excessive mGluR-dependent LTD and 
elevated protein synthesis (Michalon et al. 2012).   
 
Lovastatin reduces Ras-ERK signalling 
Similarly, lovastatin is a promising therapeutic strategy for the correction of synaptic 
dysfunction associated with mouse models of ID. Previous work in NF1 
heterozygous mice has shown that lovastatin, an inhibitor of HMG-CoA reductase, 
rescues cognitive abnormalities and impaired LTP associated with the hyperactivity 
of Ras (Li et al. 2005). In Fmr1 KO mice, lovastatin corrected elevated protein 





Figure 5.1 CTEP, lovastatin, U0126 & rapamycin target components of mGlu5 receptor 
signalling that converge on mRNA translation. mGlu5-Ras-mediated signalling can be reduced in 
the hippocampus by targeting various components of the intracellular signalling cascade. CTEP 
selectively targets mGlu5, lovastatin causes a subtle reduction in Ras activity, U0126 inhibits MEK1/2 
reducing ERK1/2 signalling whilst rapamycin targets mTOR. Both ERK and mTOR signalling 










with in vivo and in vitro epilepsy phenotypes (Osterweil et al. 2013). Lovastatin 
indirectly reduces Ras activity by targeting the mevalonate pathway involved in 
farnesylating the C-terminal tail of Ras, which is required for Ras to translocate to 
the plasma membrane where it is activated and functional (Li et al. 2005). Thus in 
Syngap heterozygotes where SynGAP expression is reduced, lovastatin may provide 
a potential pharmacological tool to reduce Ras activity.  
 
Direct inhibition of ERK & mTOR activity 
Downstream of Ras lies ERK1/2 and mTOR signalling, which can be targeted with 
U0126 and rapamycin respectively. U0126 inactivates the MAPK signalling pathway 
by selectively targeting the upstream activator of ERK1/2, MEK1/2 (Duncia et al. 
1998). Previously, U0126 has been shown to correct elevated protein synthesis rates 
in the hippocampus of Fmr1 KO mice. Rapamycin targets mTORC1 complex that 
consists of mTOR in complex with Raptor and LST8/GβL. 
 
This chapter will set out to examine whether the cellular deficits observed in the 
hippocampus of young adult Syngap heterozygous mice can be restored 
pharmacologically following phenotypic onset. These findings will establish whether 
alterations in hippocampal pathophysiology associated with Syngap1 
haploinsufficiency are due to an ongoing overactivation of mGlu5-Ras signalling, 
which if downregulated can restore normal synaptic function. If successful, then this 
study will provide further evidence to support the hypothesis that mutations in Fmr1 
and Syngap1 converge on the same pathophysiological axis and would raise the 
intriguing possibility that therapeutics currently in clinical trials for the treatment of 












In Syngap heterozygous mice, mGluR-dependent LTD is enhanced and insensitive to 
protein inhibitors. This is accompanied by hyperactive ERK1/2 and mTOR 
signalling and elevated basal protein synthesis rates that are saturated downstream of 
mGlu5 receptors. To assess whether these hippocampal deficits are amenable to 
pharmacological rescue, a biochemical approach was initially taken to determine 
whether these compounds could restore elevated protein synthesis rates in the 
Syngap heterozygous brain. Hippocampal slices from juvenile (P25-32) Syngap 
heterozygous and WT mice were prepared and translational rates were quantified by 
measuring 35S incorporation in the presence of either a vehicle (DMSO) or one of the 
following inhibitors: CTEP (10 µM), lovastatin (50 or 100 µM), U0126 (5 µM) or 
rapamycin (20 nM). Slices were preincubated in actinomycin D and either 
vehicle/inhibitor for 30 minutes and then protein synthesis rates were measured for a 
further 45 minutes in the presence of vehicle or inhibitor, initially at a drug 






Figure 5.2 Metabolic labelling of hippocampal slices from Syngap heterozygous mice in the 
presence of inhibitors. Experimental timeline for 35[S]-Met/Cys metabolic labeling in the presence of 
CTEP, lovastatin, U0126 and rapamycin, which target either mGlu5 receptors, Ras, ERK1/2 and 
mTOR respectively. Dorsal hippocampal slices are left to recover for 4 hours in ACSF, new 
transcription is blocked with actinomycin D (Act D, 25 µM) ± inhibitor for 30 minutes before slices 
are transferred to 35S Met/Cys protein labelling mix ± inhibitor for 45 minutes. 
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5.3.1 Inhibition of mGlu5 receptors reduces elevated basal protein synthesis 
rates in the hippocampus of Syngap heterozygous mice  
As altered mGlu5 receptor signalling appears to be a crucial component of the 
pathogenesis underlying Syngap1 haploinsufficiency, we examined whether the 
acute application of CTEP, a highly selective NAM of mGlu5, could restore elevated 
protein synthesis rates in the hippocampus of Syngap heterozygous mice. 
Hippocampal slices from young adult Syngap heterozygous and WT mice were 
preincubated in CTEP (10 µM) and protein synthesis rates were directly measured by 
quantifying 35S incorporation. In WT slices, basal protein synthesis levels were 
unaffected by CTEP treatment indicating that mGlu5 receptor activity does not 
contribute to steady-state rates of mRNA translational (WT veh 100 ± 3%; WT 
CTEP 106 ± 5 %, n = 9; Figure 5.3). Consistent with findings in Fmr1 KO mice 
(Osterweil et al. 2010); CTEP normalized elevated translational rates in the 
hippocampus of Syngap heterozygous mice (Het veh 125 ± 4%; Het CTEP 102 ± 8% 
n = 9; ANOVA genotype p = 0.06). Thus, it appears that increased translational rates 













































Figure 5.3 CTEP corrects elevated protein synthesis in the hippocampus of Syngap heterozygous 
mice. In vehicle treated slices protein synthesis rates are elevated in dorsal hippocampal slices from 
Syngap heterozygous mice compared to wild-type (WT) littermates. In the presence of CTEP, 
increased protein synthesis levels are reduced to WT levels (WT: veh 100 ± 3%, 10 µM 106 ± 5%; 







5.3.2 Lovastatin normalises excessive protein synthesis rates in the hippocampus 
of Syngap heterozygous mice 
 
Both the ERK1/2-MAPK and PI3K-Akt-mTOR signalling cascades converge on 
translational factors and RNA bindings proteins that initiate cap-dependent and 
5’TOP mRNA translation, in response to mGlu1/5 receptor activation (Banko et al. 
2006; Antion et al. 2008). At the top of these intracellular signalling cascades lies 
Ras.  Similarly to NF1 mutants, Ras activity is increased in two-fold in forebrain 
homogenates from Syngap heterozygous mice, indicating that it may also be a key 
component of pathophysiological axis underlying Syngap1 haploinsufficiency (Li et 
al. 2005; Carlisle et al. 2008). Furthermore we observed that substrates of Ras 
signalling, including ERK1/2 and Akt were significantly elevated in hippocampus of 
Syngap heterozygous mice and were accompanied by elevated protein synthesis rates 
that were saturated downstream of mGlu5 receptor activation.   
 
In the mouse model of NF1 and FXS, inhibitors of Ras activity (e.g. farnesyl 
thiosalicyclic acid and lovastatin) restored hippocampal pathophysiology, cognitive 
deficits and abolished epileptogenesis (Li et al. 2005; Osterweil et al. 2013). Thus we 
hypothesized that downregulation of Ras activity with the acute application of 
lovastatin may restore protein synthesis rates in the hippocampus of Syngap 
heterozygous mice. To test this hypothesis, hippocampal slices were pre-incubated in 
lovastatin during metabolic labelling. Here it was observed that 50 µM lovastatin 
caused a small, albeit significant, reduction of translational rates in Syngap 
heterozygous slices (WT: veh 100 ± 2%, 50 µM lovastatin 102 ± 12%; Het: veh 128 
± 5%; 50 µM lovastatin 115 ± 3%; ANOVA genotype *p = 0.01, n = 4; Figure 
5.4A), therefore, the concentration of lovastatin was increased from 50 µM to 100 
µM. Incubation of hippocampal slices in 100 µM lovastatin normalized protein 
synthesis rates to a level that was indistinguishable from WT controls (WT: veh 100 
± 4%, 100 µM 92 ± 7; Het: veh 142 ± 9%, 100 µM 106 ± 9%; ANOVA genotype *p 
= 0.0007, treatment *p = 0.006; n = 7; Figure 5.4B) suggesting increased translation 

















Figure 5.4 Lovastatin corrects elevated protein synthesis in Syngap heterozygous mice. (A) In the 
presence of lovastatin (50 µM), elevated protein synthesis rates were subtly reduced but not corrected 
to WT levels in dorsal hippocampal slices from Syngap heterozygous (het, SG +/-) mice (WT: veh 100 
± 2%, 50 µM 102 ± 12%; SG+/-: veh 128 ± 5%; 50 µM 115 ± 3%; ANOVA genotype *p = 0.01, n = 
4). (B) Increasing the concentration of lovastatin (100 µM) normalised excessive translational rates to 
WT levels in hippocampal slices from Syngap+/- mice (WT: veh 100 ± 4%, 100 µM 92 ± 7; SG+/-: veh 









5.3.3 Lovastatin reduces ERK1/2 activity in the hippocampus of Syngap 
heterozygous mice 
To examine whether lovastatin elicits its actions via Ras-ERK1/2 signalling, 
phosphorylated and total ERK1/2 and S6235/236 were quantified in a subset of 
hippocampal slices that underwent metabolic labelling. Western blot analysis of 
hippocampal slices, treated with either vehicle or lovastatin (100 µM), revealed that 
lovastatin significantly reduced ERK1/2 activation in both WT and Syngap 
heterozygous mice (phospho/total ERK1/2: WT veh 100 ± 12%; WT 100 µM 67 ± 
6%; Het veh 154 ± 30%; Het 100 µM 56 ± 4%; ANOVA treatment *p =0.005; 
Figure 5.5A; phospho/total ERK1: WT veh 100 ± 20%; WT 100 µM 83 ± 23%; Het 
veh 171 ± 38%; Het 100 µM 130 ± 7%; phospho/total ERK2: WT veh 100 ± 29%; 
WT 100 µM 123 ± 34%; Het veh 137 ± 20%; Het 100 µM 152 ± 49%). However, 
S6235/236/S6 was only significantly reduced in Syngap heterozygous slices, not WT 
slices (S6235/236/S6:  WT veh 100 ± 13%, WT 100 µM 79 ± 8%; Het veh 109 ± 7%; 
Het 100 µM 66 ± 4%; ANOVA treatment *p =0.003, n = 5; Figure 5.5B). In Syngap 
heterozygous mice the reduction in S6235/236/S6 was caused by a reduction in S6235/236 
phosphorylation and by an increase in total S6. These findings indicate in the 
presence of lovastatin, the remaining levels of active ERK1/2 in WT hippocampal 
slices are sufficient to maintain S6235/236 phosphorylation at control levels. Whilst in 
Syngap heterozygous hippocampal slices Ras activity is required to maintain 





























Figure 5.5 Lovastatin inhibits ERK1/2 signalling. (A) Lovastatin downregulates ERK1/2 activity in 
the hippocampus of Syngap heterozygous and WT mice (pERK/ERK: WT veh 100 ± 12%; WT 100 
µM 67 ± 6%; SG+/- veh 154 ± 30%; SG+/- 100 µM 56 ± 4%; ANOVA treatment *p = 0.005, n = 4). 
(B) In Syngap heterozygous mice S6235/236 activity is also significantly reduced (pS6235/236 /S6: WT veh 
100 ± 13%; WT 100 µM 109 ± 7; SG+/- veh 79 ± 8%, SG+/- 100 µM 66 ± 4%; ANOVA treatment *p 





5.3.4 U0126 corrects excessive protein synthesis rates in the hippocampus of 
Syngap heterozygous mice 
So far our findings indicate that inhibiting Ras with lovastatin significantly reduces 
elevated ERK1/2 activity and restores increased translational rates in the 
hippocampus of Syngap heterozygous mice. In Fmr1 KO mice elevated protein 
synthesis rates lie downstream of Ras-ERK1/2 activity, not mTOR, and are corrected 
with either lovastatin or U0126 (Osterweil et al. 2010; Osterweil et al. 2013). To 
determine whether lovastatin is mediating its effect via downregulation of ERK1/2 
signalling, an inhibitor of ERK1/2s upstream activator was used to examine whether 
inhibition of ERK1/2 signalling could also restore protein synthesis rates to normal 
levels. Metabolic labelling was performed in hippocampal slices from WT and 
Syngap heterozygous mice in the presence of 5 µM U0126.  Here it was observed 
that inhibition of ERK1/2 signalling with U0126 (5 µM) was sufficient to correct 
elevated protein synthesis rates to WT levels (WT: veh 100 ± 4%, 5 µM 99 ± 8%; 
Het: veh 130 ± 9%, 5 µM 94 ± 9%; ANOVA genotype *p = 0.018, treatment *p = 
0.03, genotype x treatment *p < 0.05; n = 9; Figure 5.6).  Thus it appears that the 
elevated protein synthesis rates in Syngap heterozygous mutants are mediated via 
increased Ras-ERK1/2 signaling. 
 
Interestingly U0126 does not affect basal protein synthesis rates in WT mice. 
Similarly in Syngap heterozygous mice, abolishing ERK1/2 activity only reduces the 
elevated component, without affecting normal levels of protein synthesis. These 
findings suggest the Ras-ERK1/2 signalling cascade is not crucial for regulating 
basal protein synthesis rates. Thus in the hippocampus, translational rates are being 





























Figure 5.6 U0126 normalises elevated protein synthesis rates in Syngap heterozygous mice. In 
vehicle treated slices, protein synthesis rates were significantly elevated in dorsal hippocampal slices 
from Syngap heterozygous slices. In the presence of U0126 (5 µM) increased protein synthesis levels 
are reduced to WT levels (WT: veh 100 ± 4%, 5 µM 99 ± 8%; SG+/-: veh 130 ± 9%, 5 µM 94 ± 9%; 






5.3.5 U0126 abolishes elevated ERK1/2 signalling in Syngap heterozygous mice 
To confirm that U0126 at 5 µM was effectively inhibiting ERK1/2 activity in Syngap 
heterozygous and WT slices, phosphorylated and total ERK1/2 and S6235/236 were 
quantified biochemically. Western blot analysis of hippocampal slice homogenates 
revealed U0126 (5 µM) completely abolishes ERK1/2 activation in both Syngap 
heterozygous and WT slices (phospho/total ERK1/2: WT veh 100 ± 9%; WT U0126 
8 ± 1%; Het veh 171 ± 9%; SG+/- U0126 11 ± 1%; ANOVA genotype *p = 3 × 10-7, 
treatment *p = 2 × 10-13, n = 4, Figure 5.7A; phospho/total ERK1: WT veh 100 ± 
3%; WT U0126 17 ± 7%; Het veh 157 ± 28%; SG+/- U0126 23 ± 5 %; phospho/total 
ERK2: WT veh 100 ± 7%; WT U0126 8 ± 2%; Het veh 220 ± 18%; SG+/- U0126 11 
± 3%). Similarly S6235/236 activity was significantly reduced in hippocampal slices 
WT and Syngap heterozygous (S6235/236/S6: WT veh 100 ± 12%, WT U0126 31 ± 
7%; Het veh 136 ± 9%; Het U0126 36 ± 5%; ANOVA genotype *p =0.007, 
treatment *p = 1 × 10-8, n = 4; Figure 5.7B). Thus U0126 (5 µM) significantly 
reduces phosphorylation of both ERK1/2 and S6235/236 activity suggesting that 
MEK1/2 signals through ERK1/2 to phosphorylates S6235/236. Down regulation of 
ERK1/2 and S6235/236 corrects elevated protein synthesis rates in the hippocampus of 
Syngap heterozygous mice suggesting that Ras-ERK1/2, possibly via S6235/236, 






















Figure 5.7. U0126 inhibits ERK1/2 and S6 activation. Western blot analysis of phosphorylated and 
total ERK1/2 and S6235/236 levels in Syngap heterozygous (SG+/-) and wild type (WT) hippocampal 
slices treated with either vehicle (DMSO) or U0126 (5 µM). (A) In vehicle treated slices ERK1/2 
activity is significantly elevated in Syngap heterozygous slices compared to WT controls. In the 
presence of U0126 ERK1/2 activity is abolished in both WT and Syngap heterozygous mice 
(pERK/ERK: WT veh 100 ± 9%; WT U0126 8 ± 1%; SG+/- veh 171 ± 9%; SG+/- U0126 11 ± 1%; 
ANOVA genotype *p = 3 × 10-7, treatment *p = 2 × 10-13; n = 4). (B) S6235/236 activity is significantly 
elevated in vehicle treated Syngap heterozygous slices compared to WT mice. In the presence of 
U0126 S6235/236 activity is significantly reduced in both WT and Syngap heterozygous slices 
(pS6235/236/S6: WT veh 100 ± 12%, WT U0126 31 ± 7%; SG+/- veh 136 ± 9; SG+/- U0126 36 ± 5%; 





5.3.6 U0126 reduces mGluR-dependent LTD in the hippocampus of Syngap 
heterozygous mice 
It has been previously shown that inhibition of ERK1/2 signalling with U0126 
(Gallagher et al. 2004) abolishes mGluR-dependent LTD at CA1 synapses. Upon 
activation of mGlu1 and mGlu5 receptors, ERK1/2 activity is significantly increased 
along with the its downstream targets Mnk1, EIF4E and S6235/236 (Banko et al. 2006), 
which imitate cap-dependent and 5’TOP mRNA translation that is crucial for the 
maintenance of long lasting forms of synaptic plasticity, which include mGluR-
dependent LTD (Huber et al. 2000). 
 
As elevated protein synthesis rates were corrected by U0126 (5 µM) in the 
hippocampus of Syngap heterozygous mice, we wanted to determine 
electrophysiologically whether the same treatment could restore exaggerated mGluR-
dependent LTD. Extracellular recordings were performed in CA1 where it was 
observed that U0126 (5 µM) had no significant effect on basal synaptic transmission 
with baseline responses remaining consistent throughout an 80 minutes recording in 
the presence of this compound (Figure 5.13A). Hippocampal slices form WT and 
Syngap heterozygous mice were preincubated in either vehicle or U0126 (5 µM) for 
at least 20 minutes prior to inducing LTD with the Gp1 mGluR agonist DHPG (50 
µM). In WT mice, U0126 (5 µM) had no significant effect on the magnitude of 
mGluR-dependent LTD (WT: veh 77 ± 3%, n = 18; U0126 86 ± 6%, n = 8, t-test p = 
0.16; Figure 5.7A). In contrast, U0126 (5 µM) significantly reduced exaggerated 
mGluR-dependent LTD in Syngap heterozygous mice (Het: veh 62 ± 5%, n = 15; 
U0126 83 ± 6%, n = 6; t-test *p = 0.04; Figure 5.8B) to a level that was not 
significantly different from WT vehicle treated slices or baseline responses. These 
findings support the biochemical data and indicate that restoring elevated protein 
synthesis rates in Syngap heterozygous mice normalizes enhanced mGluR-dependent 






Figure 5.8 U0126 reduces enhanced mGluR-dependent LTD in Syngap heterozygous mice. 
Extracellular recordings were performed in CA1 of hippocampal slices from Syngap heterozygous 
(Het, SG+/-) and wild type (WT) mice. (A) Induction of mGluR-dependent LTD (50 µM) in the 
presence of U0126 (5 µM) did not significantly affect the magnitude of LTD in WT hippocampal 
slices (WT: veh 77 ± 3%, n = 18; U0126 85 ± 6%, n = 8, t-test p = 0.16). (B) In Syngap 
heterozygous mice, U0126 reduced the magnitude of mGluR-dependent LTD in the hippocampus of 
Syngap heterozygous to a level not significantly different from WT or baseline responses (SG+/-: veh 
62 ± 5%, n = 15; U0126 83 ± 6%, n = 10; t-test *p = 0.01) (C) Comparison of mGluR-dependent 
LTD in the presence of U0126 in WT and Syngap heterozygous mice.  
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In addition, we examined the effect of U0126 5 µM on mGluR-dependent LTD using 
a higher concentration of DHPG (100 µM). Although statistically U0126 (5 µM) had 
no significant effect on mGluR-dependent LTD in WT mice, a comparison of LTD 
versus predrug baseline revealed that LTD was no longer significantly different from 
baseline (Figure 5.9A). Consistent with Gallagher et al. (2004) increasing the 
concentration of U0126 to 20 µM completely abolished mGluR-dependent LTD in 
WT slices (WT: veh 74 ± 6%, n = 12; 5 µM 87 ± 7%, n = 5; 20 µM 100 ± 6%, n = 7; 
ANOVA *p = 0.02; Figure 5.9B). In Syngap heterozygous mice, 5 or 20 µM U0126 
had no significant effect on mGluR-dependent LTD  (Het: veh 56 ± 5%, n = 14; 5 
µM 70 ± 9%, n = 7; 20 µM 72 ± 3%, n = 5; ANOVA p > 0.05; Figure 5.9 C & D). 
Comparison of mGluR-dependent LTD (100 µM) in the presence of U0126 (5 & 20 
µM) between Syngap heterozygous and WT mice revealed that LTD was no longer 
significantly different between genotypes at 5 µM U0126, but not at 20 µM U0126 





Figure 5.9 U0126 reduces enhanced mGluR-dependent LTD in Syngap heterozygous mice. 
Extracellular recordings were performed in CA1 of hippocampal slices from Syngap heterozygous 
(Het, SG+/-) and wild type (WT) mice. (A) Induction of mGluR-dependent LTD (100 µM) in the 
presence of 5 µM U0126 did not significantly affect the magnitude of LTD in WT hippocampal slices 
but LTD was no longer significantly difference from baseline whilst 20 µM U0126 significantly 
reduced LTD compared to vehicle treated slices (WT: veh 74 ± 6%, n = 12; 5 µM 87 ± 7%, n = 5; 
20 µM 100 ± 6%, n = 7; ANOVA *p = 0.02). (C, D) U0126 (5 µM and 20 µM) had no significant 
effect on the magnitude of LTD compared to vehicle treated slices (B) In Syngap heterozygous mice, 
U0126 reduced the magnitude of mGluR-dependent LTD in the hippocampus of Syngap heterozygous 
mutants to a level not significantly different from WT or baseline responses (SG+/-: veh 56 ± 5%, n = 
14; 5 µM 70 ± 9%, n = 7; 20 µM 72 ± 3%, n = 5; ANOVA p > 0.05). (C) Comparison of mGluR-
dependent LTD in the presence of U0126 in WT and Syngap heterozygous mice.  
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5.3.7 Rapamycin restores elevated protein synthesis rates in the hippocampus of 
Syngap heterozygous mice 
In response to mGlu1/5 receptor activation the mTOR signaling pathway initiates 
translation of new protein synthesis at CA1 synapses (Banko et al. 2006). In Syngap 
heterozygous mice, basal levels of phosphorylated Akt are elevated compared to WT 
littermates. To examine whether altered mTOR signaling contributes to excessive 
protein synthesis rates in the hippocampus of Syngap heterozygous mice, 
translational rates were measured in the presence of the mTOR inhibitor rapamycin 
(20 nM). Again, we observed a significantly elevation in 35S incorporation in 
vehicle-treated Syngap heterozygous hippocampal slices compared to WT controls 
(t-test *p = 0.04). Rapamycin (20 nM) had no significant effect on basal protein 
synthesis levels in WT slices, however inhibition of mTOR reduced protein synthesis 
rates in Syngap heterozygous slices to a level that was not significantly different 
from WT controls (WT: veh 100 ± 3%, 20 nM 106 ± 7%; Het: veh 124 ± 6%, 20 nM 
































Figure 5.10 Rapamycin reduces elevated protein synthesis rates in Syngap heterozygous mice. In 
vehicle treated slices, protein synthesis rates were significantly elevated in dorsal hippocampal slices 
from Syngap heterozygous slices. In the presence of rapamycin (20 nM) exaggerated protein synthesis 
levels are reduced to a level that is not significantly different from WT values (WT: veh 100 ± 3%, 20 









5.3.8 Rapamycin corrects elevated mGluR-dependent in the hippocampus of 
Syngap heterozygous mice 
At CA1 synapses mGluR-dependent LTD requires both PI3K and mTOR activity to 
be sustained for at least 1 hour following LTD induction (Hou & Klann 2004; 
Sharma et al. 2010). mGlu5 receptors can couple to the mTOR pathway via the 
scaffolding protein Homer, and also through activating Ras G-proteins. Together 
Homer and Ras can regulate mTOR signaling through the activation of PI3K. In 
Chapter 4 the activation state of Akt was significantly elevated in Syngap 
heterozygous hippocampal slices compared to WT littermates. This is accompanied 
by an increase in translational rates in the hippocampus of Syngap heterozygous 
mutants that is sensitive rapamycin.  
 
To determine whether elevated mTOR signaling contributes to enhanced mGluR-
dependent LTD at CA1 synapses in the hippocampus of Syngap heterozygous, slices 
were preincubated in the mTOR inhibitor rapamycin (20 nM) for at least 20 minutes 
prior to the induction of mGluR-dependent LTD (DHPG 50 µM). Using extracellular 
recordings in CA1 it was observed that rapamycin had no significant effect on basal 
synaptic transmission with baseline responses remaining consistent throughout an 80 
minutes recording in the presence of this compound (Figure 5.13B). In WT slices, 
rapamycin had no significant effect on the magnitude of mGluR-dependent LTD 
compared to vehicle treated slices (WT control: 77 ± 3%, n = 18; WT rapamycin 85 
± 3%, n = 7, t-test p = 0.16; Figure 5.11A). Although this finding is consistent with 
Auerbach et al. (2011), there are several other studies that report rapamycin inhibits 
mGluR-dependent LTD in WT slices (Hou & Klann 2004; Sharma et al. 2010). In 
Syngap heterozygous slices rapamycin prevented exaggerated mGluR-dependent 
LTD that result in a magnitude of LTD that was comparable to WT levels (Syngap 
control 62 ± 5%, n = 15; Het rapamycin 83 ± 6%, n = 10; t-test *p = 0.01; Figure 
5.11B). Thus inhibition of mTOR restores elevated mGluR-dependent LTD in 
Syngap heterozygous mice to a magnitude that is indistinguishable from WT controls 
(p = 0.342; Figure 5.11C).   
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Figure 5.11 Rapamycin normalises elevated mGluR-dependent LTD in Syngap heterozygous 
mice. Field excitatory postsynaptic potentials (fEPSPs) were recorded at 30 ◦C in CA1 region of 
hippocampal slices from Syngap heterozygous (Het, SG+/-) and WT littermates. (A) In WT mice, the 
mTOR inhibitor (20 nM) did not affect the magnitude of DHPG-induced (5 mins, 50 µM) mGluR-
dependent LTD in WT hippocampal slices (WT control: 77.0 ± 3%, n = 18; WT rapamycin 85 ± 3%, 
n = 7, t-test p = 0.157). (B) In contrast, rapamycin significantly reduced the magnitude of mGluR-
dependent LTD in Syngap het slices (SG+/- control 62 ± 5%, n = 15; SG+/- rapamycin 83 ± 6%, n = 10; 
t-test *p = 0.01). (C) Comparison of mGluR-dependent LTD in the presence of rapamycin in 
hippocampal slices from WT and Syngap heterozygous mice. In the presence of rapamycin the 
magnitude of mGluR-dependent LTD in Syngap mutants is indistinguishable from WT mice (t-test p 
= 0.76). 
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5.3.9 Inhibition of mTOR restores protein synthesis dependency to mGluR-
dependent LTD in Syngap heterozygous mice 
In Syngap heterozygous mice, increases in mGluR-dependent LTD are accompanied 
with qualitative differences; this form of LTD is no longer sensitive to protein 
synthesis inhibitors. This suggests that the proteins required for the expression and 
maintenance of this form of plasticity are already present at CA1 synapses in the 
Syngap heterozygous brain. As rapamycin reduced elevated protein synthesis rates 
and normalized mGluR-dependent LTD to WT levels, this led us to hypothesize that 
inhibition of mTOR in Syngap heterozygous hippocampal slices may also restore the 
protein synthesis dependency of this form LTD in mutant slices.  
 
Although corrections of mGluR-dependent LTD in mouse models of ID have been 
reported (Osterweil et al. 2013), these studies have failed to show whether the 
protein synthesis dependent component of this form of LTD is reestablished. Here 
we examined whether rapamycin would return protein synthesis-dependence to LTD. 
Hippocampal slices from Syngap heterozygous mice were incubated in ACSF 
containing rapamycin (20 nM) plus vehicle for 10 minutes and either remained in 
this solution or swapped to ACSF containing rapamycin (20 nM) and the 
translational inhibitor anisomycin (20 µM). Consistent with our findings in 5.3.7, 
preincubation of Syngap heterozygous slices in rapamycin (20 nM) reduced the 
magnitude of mGluR-dependent LTD in Syngap heterozygous slices (Het rapamycin 
+ vehicle 74 ± 8%, n = 3; Figure 5.12A). Furthermore, in the presence of both 
rapamycin (20 nM) and anisomycin (20 nM) the expression of mGluR-dependent 
LTD (50 µM DHPG) was inhibited (Het rapamycin + anisomycin: 97 ± 7%, n = 5) to 
a level that wasn’t significantly different from baseline (t-test p = 0.72). These 
findings are summarized in Figure 5.12B and suggest that inhibition of mTOR may 
restore elevated mGluR-dependent LTD and the protein synthesis dependency of 
















Figure 5.12 Rapamycin restores protein synthesis dependency to mGluR-dependent LTD in 
Syngap heterozygous mice. (A) Extracellular recordings in CA1 reveal that in Syngap heterozygous 
(Het, SG+/-) hippocampal slices, treatment with rapamycin (20 nM) reduces enhanced mGluR-
dependent LTD (50 µM DHPG) to WT levels and restores the protein synthesis dependency of 
mGluR-dependent LTD. (B) Bar chart represents the mean (± S.E.) depression of fEPSP relative to 
pre-drug baseline (Het: rapa + veh 74 ± 8%, n = 3; rapa + aniso: 97 ± 7%, n = 5, t-test treatment p = 
0.08). (B) Comparison of mGluR-dependent LTD induced by 50 µM in the presence of rapamycin (20 
nM) ± DMSO or anisomycin (20 µM) to mGluR-dependent LTD (50 µM) in WT and Syngap 





















Figure 5.13 Baseline responses obtained in the presence of U0126 and rapamycin. Extracellular 
recordings reveal stable baseline responses for 80 minutes in the presence of either U0126 (5 µM; A) 


















5.4 Discussion  
The mouse model of Syngap1 haploinsufficiency closely phenocopies the 
hippocampal plasticity deficits reported in the Fmr1 KO mouse including: enhanced 
mGluR-dependent LTD, which is independent of new protein synthesis; and elevated 
basal protein synthesis rates, that are saturated downstream of mGlu5 receptor 
activation. Dissimilarly to Fmr1 KO mice ERK1/2, Akt and S6 activity are elevated 
in hippocampal slice homogenates, indicating that the Syngap1 haploinsufficiency 
may arise from hyperactivity, rather than a hypersensitive response, to Ras-mediated 
signalling (Osterweil et al. 2010). Irrespective of this, loss of FMRP and reduced 
SynGAP expression result in similar phenotypic outcomes in the hippocampus via a 
common mechanism, which led us to hypothesize that they may be amenable to same 
pharmacological strategies shown to correct the hippocampal pathophysiology in the 
mouse model of FXS. To test this hypothesis, biochemical and electrophysiological 
investigations were repeated in the presence of inhibitors that target mGlu5, Ras or 
their downstream targets, to determine whether the synaptic pathophysiology could 
be restored in the mouse model of Syngap1 haploinsufficiency.   
 
5.4.1 Elevated protein synthesis rates in Syngap heterozygous mice lie 
downstream of mGlu1/5 receptors and Ras-mediated signalling 
CTEP, U0126 and lovastatin all normalised elevated protein synthesis rates to WT 
levels in Syngap heterozygous hippocampal slices, whilst rapamycin led to a 
reduction in basal protein synthesis. Together these findings suggest that increased 
translational rates in the hippocampus of Syngap heterozygous mice lie downstream 
of hyperactivate Ras-signalling signalling. It is well documented that the ERK1/2 
and mTOR pathway converge on various components of the translational apparatus 
that initiate mRNA translation in response to synaptic activity (Figure 5.14). 
However our findings suggest that in the Syngap heterozygous brain, ERK1/2 and 
mTOR signalling may be overactive in response to constitutive mGlu5 receptor 
activation, stimulating mRNA translation under basal conditions.  
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In WT mice, the acute application of DHPG leads to an increase in translational rates 
suggesting that mGlu5 receptors play a major role in activity-dependent protein 
synthesis. Activation of mGlu1/5 receptors is correlated with increases in 
phosphorylation levels of Mnk1, S6 and the cap-dependent translation initiation 
factor EIF4E, which are dependent on ERK1/2 activation (Banko et al. 2006; Antion 
et al. 2008). Furthermore mGlu5 receptor activity is associated with mTOR-induced 
phosphorylation of 4E-BP, which increases EIF4E availability for EIF4F complex 
formation (Banko et al 2006). Thus in the Syngap heterozygous brain where ERK1/2 
and mTOR are hyperactive under steady state conditions it is likely these two 
pathways are increasing translation by overactivating downstream targets including 
Mnk1, EIF4E and 4E-BP.  
 
In this chapter it was observed that both U0126 and lovastatin normalised protein 
synthesis rates to WT levels in the hippocampus of Syngap heterozygous mice and 
this was accompanied by a significant reduction in increased ERK1/2 
phosphorylation. This suggests that elevated protein synthesis rates in the 
hippocampus of Syngap heterozygous mice may arise through ERK-induced mRNA 
translation. One possible mechanism by which lovastatin and U0126 reduce 
translation might be via targeting ERK-induced Mnk1 phosphorylation of EIF4E 
halting the initiation of cap-dependent mRNA translation. 
 
In addition rapamycin, and perhaps lovastatin and CTEP, may reduce protein 
synthesis rates in the hippocampus of Syngap heterozygous mice by inhibiting PI3K-
Akt-mTOR signalling, which targets 4E-BP in response to mGlu5 receptor activation 
(Banko et al. 2006). The interaction between 4E-BP and EIF4E prevents the 
assembly of the EIF4F complex that is crucial for the initiation of mRNA translation 
(Raught & Gingras 1999). Thus inhibition of PI3K-Akt-mTOR may conserve the 4E-
BP-eIF4E interaction reducing EIF4E availability. Moreover this will preclude Mnk1 




In addition both the ERK1/2-MAPK and PI3K-Akt-mTOR signalling pathway target 
the ribosomal S6 kinases (Antion et al. 2008a). ERK1/2 activity is coupled to RSK 
family members, whilst mTOR signalling targets S6K1/2, both of which lead to the 
activation of eIF4B (Shahbazian et al. 2006). This initiation factor stimulates EIF4F 
activity by potentiating the RNA helicase activity of EIF4A, that together with 
EIF4G and EIF4E form the EIF4F complex required for cap-dependent mRNA 
translation (Roux & Blenis 2004). Both RSK and S6K1/2 also target the ribosomal 
S6 protein, which is also associated with the 5’TOP mRNA translation (Antion et al. 
2008a).  
 
A previous study has shown that mGlu1/5 activation increases S6 phosphorylation, 
which persists in the absence of S6K1/2, and leads to an increase in expression of a 
5’TOP mRNA transcript EF1A (Antion et al. 2008). Thus inhibition of ERK1/2 and 
mTOR may reduce elevated protein synthesis rates by not only preventing the 
initiation of cap-dependent translation but also 5’TOP mRNA translation. This could 
reduce the synthesis of proteins required for the expression and maintenance of 
mGluR-dependent LTD, and reduce translational competence in neuronal cells by 
preventing the synthesis of ribosomal subunits and translation factors in the Syngap 
heterozygous brain (Huber et al. 2000; Antion et al. 2008a).    
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Figure 5.14. CTEP, lovastatin, U0126 and rapamycin reduce translational rates in the Syngap 
heterozygous brain. The potential intracellular signalling mechanisms targeted by inhibitors of 
mGlu5 receptors, Ras, ERK and mTOR. 
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5.4.2 Basal protein synthesis rates may be independent of ERK1/2 and PI3K 
activity in the hippocampus of WT mice 
In WT hippocampal slices neither CTEP, U0126, lovastatin or rapamycin treatment 
significantly affected basal protein synthesis rates consistent with previous findings  
(Osterweil et al. 2010; Michalon et al. 2012; Osterweil et al. 2013). This could 
suggest: (1) constitutive activity of mGlu5, Ras, ERK1/2 or PI3K do not regulate 
mRNA translation under steady state conditions, or (2) ERK1/2 and mTOR 
signalling are able to compensate for one another when either cascade is inhibited. 
To test this, protein synthesis rates would have to be quantified in the presence of 
both U0126 and rapamycin to determine whether ERK1/2 and mTOR signalling can 
counteract each other to maintain mRNA translation at a constant rate, or if neither 
are essential for the maintenance of basal protein synthesis.  
 
A previous study has reported that p38 MAPK signalling controls the 
phosphorylation levels of Mnk1 and EIF4E under steady-state conditions (Bank et al. 
2006). Inhibition of p38 MAPK significantly reduced the basal phosphorylation 
levels of Mnk1 and EIF4E, whilst U0126 treatment had no significant effect. 
However activation of mGlu1/5 receptors triggers an increase in the phosphorylation 
levels of both Mnk1 and EIF4E, which are abolished by U0126 (Banko et al. 2006). 
This suggests that at rest p38 MAPK activity controls activity levels of Mnk1 and 
EIF4E, however under stimulated conditions mGlu1/5 receptors signals through 
ERK1/2 and Mnk1 to target eIF4E, facilitating EIF4F complex formation and the 
initiation of mRNA translation that is crucial for the expression and maintenance of 









5.4.3 MEK1/2 maintains steady-state levels of ERK and S6 
Here it was observed that inhibition of MEK1/2 with U0126 (5 µM) dramatically 
reduces basal phosphorylation levels of ERK1/2 and S6235/236 by ~90% and ~70%, 
respectively, in both WT and Syngap heterozygous hippocampal slices. This 
indicates that MEK1/2 signals through ERK1/2 to phosphorylate S6235/236, under 
steady-state conditions. Comparatively, lovastatin caused a more subtle reduction in 
phosphorylation levels of ERK1/2, whilst S6235/236 levels were not significantly 
affected in WT slices suggesting that either the residual activity of ERK1/2 was 
sufficient to maintain normal levels of S6235/236 activity or there was compensation 
from an alternative pathway.  
 
Ras can target S6 by either activating the ERK1/2 or mTOR signalling cascades. 
Although the function of S6 is not firmly established, phosphorylation levels of this 
protein are correlated with increased protein synthesis rates including translation of 
5’ TOP mRNA translation (Antion et al. 2008). To determine whether this form of 
mRNA translation is upregulated in the Syngap heterozygous brain, proteins encoded 
by 5’TOP mRNA transcripts (e.g. EF1A) would need to be quantified in 
hippocampal slice homogenates to see if expression levels were upregulated in the 
Syngap heterozygous brain. This would determine whether this particular form of 
mRNA translation is contributing to hippocampal pathophysiology associated with 
Syngap1 haploinsufficiency. Although U0126 and lovastatin significant inhibited 
ERK1/2 and or S6 signalling neither had a significant effect on basal protein 
synthesis rates. Thus in agreement with Banko et al. (2006) it appears that MEK1/2-
ERK1/2-S6 pathway is not the predominant mechanism mediating steady-state 








5.4.4 U0126 abolishes mGluR-dependent LTD in Syngap heterozygous mice  
Our electrophysiological recordings reveal that although preincubating WT 
hippocampal slices in U0126 (5 µM) does not lead to a significant reduction in 
mGluR-dependent LTD, the magnitude of LTD is not always significantly different 
from baseline. Thus our findings are not conclusive as to the impact of 5 µM U0126 
on mGluR-dependent LTD. Only when the concentration of U0126 was raised to 20 
µM was mGluR-dependent LTD completely abolished. As U0126 (5 µM) is 
sufficient to block the majority of ERK1/2 activity, this raises the question as to 
whether higher concentrations of U0126 are targeting additional pathways that lead 
to the full inhibition of mGluR-dependent LTD or are just causing a greater 
reduction in the activation states of ERK1/2s downstream targets such as S6235/236. 
To address this question, western blot analysis of ERK1/2 and its downstream targets 
need to be examined in hippocampal slices preincubated in both 5 and 20 µM U0126. 
 
 
5.4.5 Inhibitors of mTOR and ERK may correct mGluR-dependent LTD via a 
mechanism independent of new protein synthesis  
In Syngap heterozygous mice, elevated mGluR-dependent LTD (50 µM) was 
dramatically reduced in the presence of U0126, to a level not significantly different 
from WT controls or baseline responses. This indicates that ERK1/2 signalling 
contributes to elevated mGluR-dependent LTD levels at CA1 synapses. However, it 
also highlights that ERK1/2 is regulating synaptic strength through a protein 
synthesis independent mechanism, as our previous findings in Chapter 3 showed that 
the translational inhibitor anisomycin has no significant effect on the magnitude of 
mGluR-dependent LTD. Therefore, in additional to U0126 normalising protein 
synthesis rates to WT levels, it is also targeting an alternative mechanism that is 
independent of new protein synthesis and facilitates AMPA receptor insertion at the 
PSD. This is plausible considering the numerous substrates of ERK1/2 (Roskoski 




Although not demonstrated in this thesis, it is reported that lovastatin corrects 
elevated mGluR-dependent LTD in Fmr1 KO mice to WT levels (Osterweil et al. 
2013). Similarly to U0126, lovastatin must be mediating its affects via a mechanism 
that is independent of new protein synthesis as mGluR-dependent LTD in Fmr1 KO 
mice is insensitive to translational inhibitors. 
 
Furthermore electrophysiological investigations revealed that rapamycin corrects 
elevated mGluR-dependent LTD to WT levels. Inhibition of mTOR also restores the 
protein synthesis dependency of this form of LTD, as the residual LTD expression is 
inhibited by anisomycin. This is an important finding, as it has not been previously 
shown whether any of the pharmacological strategies used in the treatment of FXS or 
TSC actually restore this core phenotype. As stated above, because the translational 
inhibitor anisomycin has no significant effect on the magnitude of LTD in Syngap 
heterozygous mice, rapamycin is also reducing mGluR-dependent LTD via a 
mechanism that is independent of mRNA translation. Intriguingly, inhibition of 
mTOR signalling reverts mGluR-dependent LTD to a state where it is reliant on the 
synthesis of new proteins in order to be sustained.  
 
In the Fmr1 KO brain, enhanced mGluR-dependent LTD occurs independently of 
new protein synthesis (Huber et al. 2002). This thought to arise from an 
overabundance of “LTD proteins” under steady state conditions, which are sufficient 
to maintain decreases in cell surface AMPA receptor expression following an LTD 
stimulus. In support of this hypothesis, the expression levels of proteins synthesized 
in response to mGlu1/5 receptor activation are increased and no longer regulated in an 
activity dependent manner in Fmr1 KO mice (Todd et al. 2003).  
 
If “LTD proteins” were overabundant in Syngap heterozygous mice, then one 
possible mechanism that U0126 and rapamycin may be inhibiting mGluR-dependent 
LTD is by facilitating the degradation of “LTD proteins” at postsynaptic sites in 
response to mGlu1/5 activation. Loss of these proteins would now revert mGluR-
dependent LTD back to a state where it is dependent on new protein synthesis in 
order to maintain the persistent removal of AMPA receptors. One potential way to 
 219 
access the effects of U0126 and rapamycin on protein degradation would be to 
induce mGluR-dependent LTD in the presence of U0126/rapamycin and a 
proteasome inhibitor, such as MG-132. If U0126 and mTOR were eliciting their 
effects via this pathway then in the presence of MG-132 they would no longer inhibit 
mGluR-dependent LTD at CA1 synapses.   
 
5.4.6 Pharmacological intervention following phenotypic onset restores mGlu5 
receptor function in the hippocampus of Syngap heterozygous mice 
Together these findings in Syngap heterozygous mice are consistent with those 
obtained in Fmr1 KO mice. Downregulation of constitutive mGlu5-Ras mediated 
signalling rescues the hippocampal disruptions in the mouse model of Syngap1 
haploinsufficiency providing further support to our initial hypothesis that mutations 
in Syngap1 and Fmr1 converge on a common pathophysiological axis. Thus this 
study has identified key therapeutic targets for the treatment of the hippocampal 
pathophysiology associated with Syngap1 haploinsufficiency, which include mGlu5, 
Ras, ERK1/2 and mTOR. This study also raises the intriguing possibility that current 
therapeutics undergoing clinical trials for the treatment of FXS, such as mGlu5 
antagonists and lovastatin, may be beneficial in treating patients with mutations in 
SYNGAP1. Although treatment of Syngap1 haploinsufficiency pharmacologically is 
unlikely to replace the function of protein expression, it may compensate and reduce 
phenotypic expression of a subset of cognitive symptoms. 
 
Furthermore the data presented in this chapter reveal that acute pharmacological 
interventions in vitro, which follow phenotypic onset in young adult mice, restore 
synaptic dysfunction in the Syngap heterozygous mice. Thus certain phenotypes 
associated with Syngap1 haploinsufficiency are reversible in the Syngap 
heterozygous brain. This is in agreement with several other studies that have 
observed phenotypic reversal in mouse models of neurodevelopmental disorders in 
adulthood, after commencement of phenotypic manifestations, including in FXS 
(Dölen et al. 2007; Osterweil et al. 2013; Henderson et al. 2012), NF1 (Costa et al. 
2002; Li et al. 2005), TSC (Ehninger & Silva 2011; Meikle et al. 2008; Zeng et al. 
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2007), Angelman syndrome (van Woerden et al. 2007) and Rett syndrome (Guy et al. 
2007).  
 
In addition, data in this chapter challenges a recent paper by Clement et al. (2012) 
that suggests phenotypic rescue is limited to critical period (~P14), as complete 
restoration of gene function in adult mutants failed to correct behaviour or cognitive 
endophenotypes in Syngap heterozygous mice, confining Syngap1 haploinsufficiency 
to being a disorder of neurodevelopment. However, this thesis demonstrates that 
synaptic dysfunction in the adult brain are restored by reducing the activity of 
SynGAP’s downstream effectors suggesting that SynGAP plays a role in regulating 
synaptic plasticity at the mature synapse. This means Syngap1 haploinsufficiency 
may not strictly be a neurodevelopmental disease but also a disorder of 































































6.1 Final Discussion and Future Experiments  
SYNGAP1 haploinsufficiency is a debilitating neurodevelopmental disorder caused 
by autosomal de novo mutations in the SYNGAP1 gene leading to the loss of one 
functional copy of SYNGAP1. Genetic screening of small cohorts of ID patients have 
revealed that the prevalence of SYNGAP1 mutations in the ID population could be as 
high as 4%, which would make SYNGAP1 haploinsufficiency one of the most 
common causes of sporadic and non-syndromic ID (Hamdan et al. 2011). Clinical 
examination of patients with SYNGAP1 mutations has revealed that this disorder is 
characterised by moderate to severe ID with a high incidence of other comorbidities 
including epilepsy and ASD (Klitten et al. 2011; Vissers et al. 2010; Berryer et al. 
2012; Carvill et al. 2013; Pinto et al. 2010).  
 
At present current therapeutic strategies used in the treatment of ID do not target the 
underling cause of the disorder, rather specific behavioural symptoms, such as 
hyperactivity, attention deficits, anxiety and irritable/aggressive behaviours (Berry-
Kravis 2014). To treat the core deficits that underlie ID targeted pharmacotherapies 
need to be developed.  This requires a greater understanding of the molecular 
mechanisms that underlie the learning and behavioural deficits associated with 
mutations in ID-related genes. Thus the generation of mouse models of ID have 
provided a valuable neurobiological tool to characterise protein function and the 
consequence of its loss in the mammalian brain.   
 
So far this has led to great advancements in the study of FXS with the identification 
of key cellular processes that are disrupted in the Fmr1 KO brain. Furthermore key 
intracellular mechanisms that are responsible for synaptic dysfunction have been 
identified, thus providing potential targets for therapeutic intervention in FXS. 
However, it remains unclear how Syngap1 haploinsufficiency impacts key synaptic 
events that underlie cognitive function in the mammalian brain. In this thesis it was 
hypothesized that the hyperactivity of Ras mitogen protein kinase signalling pathway 
in Syngap heterozygous mice may disrupt cellular mechanisms that underlie learning 
and memory deficits associated with Syngap1 haploinsufficiency.  
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Based on the evidence from the mouse model of FXS that abnormalities in mGlu1/5 
receptor mediated synaptic plasticity and protein synthesis lie downstream of Ras-
ERK1/2-MAPK signalling cascade, we hypothesized that Syngap heterozygous mice 
might share similar pathophysiological deficits in the hippocampus.  Using 
electrophysiological and biochemical techniques, it was shown in this thesis that 
mGluR-dependent LTD and basal protein synthesis rates were disrupted in young 
adult Syngap heterozygous mice, consistent with the mouse model of FXS. In 
addition it was directly shown that mutations in Syngap1 and Fmr1 converge on a 
common pathophysiological axis that appears to trigger hippocampal abnormalities 
in the mouse model of FXS and Syngap1 haploinsufficiency. Furthermore, it was 
found that pharmacological tools used in the treatment of FXS restore hippocampal 
function in Syngap heterozygous mice. 
 
The Role of Syngap1 in the Developing Brain 
There is now a convergence of findings that have begun to elucidate the function of 
SynGAP in the mammalian brain. It appears that during development, SynGAP has a 
profound effect on postsynaptic function at glutamateric synapses. At early ages 
SynGAP modulates a critical period of synapse maturation, limiting excitatory gain 
by restricting AMPA receptor insertion at immature synapses (Clement et al. 2012). 
Similarly, at this time point LTP is impaired, likely the consequence of saturated 
AMPA receptor accumulation at synapses, which prevents further increases in 
synaptic strength (Ozkan et al. 2014).  
 
Although by juvenile ages basal synaptic transmission stabilizes and is consistent 
between both WT and Syngap heterozygous mice, our data suggests that SynGAP 
plays a pivotal role in repressing basal mRNA translational rates that underlie long-
lasting forms of synaptic plasticity. It appears that in the post-adolescent brain 
Syngap heterozygous mice display enhanced Gp1 mGluR-dependent LTD at CA1 




At the PSD SynGAP is bound to scaffolding proteins PSD-95 and SAP-102 and 
interacts with the GluN2B subunit of the NMDA receptor, so is ideally positioned to 
relay synaptic activity to intracellular events (Chen et al. 1998; Kim et al. 1998). It is 
likely that SynGAP is mediating its effects at glutamatergic synapses via its synaptic 
GAP activity. Upon activation by CAMKII, SynGAP binds and inactivates several 
small G-proteins including Ras, Rap1, Rap2 and Rab5 (Oh et al. 2004; Tomoda et al. 
2004; Ye & Carew 2010). The Ras mitogen protein kinases initiate transcription, 
translation and phosphorylation of synaptic proteins, which play a pivotal role in 
synaptic plasticity and are crucial for cognitive function (Krab et al. 2008; Ye & 
Carew 2010). Thus, genetic mutations in components of Ras signalling, known as 
RASopathies are linked to ID (Cesarini et al. 2009). 
 
In the Syngap heterozygous brain, where SynGAP expression is dramatically 
reduced, phenotypic manifestations may arise from derepression of basal levels of 
Ras and its downstream substrates that include ERK1/2-MAPK and PI3K-mTOR-
Akt. Together the hyperactivation of these signalling cascades lead to the initiation 
of cellular processes that would normally lie dormant under steady-state conditions. 
In agreement, it appears that the genetic reduction of Syngap expression leads to the 
derepression of ERK1/2, Akt and S6 at rest. These proteins are components of 
cascades that mediate the initiation of mRNA translation through various effectors 
and it seems likely that overactivation of these proteins underlies the excessive 
translational rates in the hippocampus of Syngap heterozygous mice. In support of 
this hypothesis, inhibitors of Ras and MEK1/2 activity significantly reduced the 
activation state of ERK1/2 and S6, normalising protein synthesis rates in the 
hippocampus of Syngap heterozygous mice.  
 
Furthermore protein synthesis rates were saturated and were no longer regulated in 
an activity-dependent by mGlu1/5 receptor activation the Syngap heterozygous brain. 
Consequently, it appears that there may be a downregulation of mGlu1/5 receptor 
expression in hippocampal synaptoneurosomes from Syngap heterozygous mutants, 
perhaps a compensatory effect to counteract exaggerated mGluR-dependent 
signalling. Interestingly, increased basal protein synthesis rates in the hippocampus 
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of Syngap heterozygous mice did not appear to have a functional affect at the 
synapse until mGlu1/5 receptors were activated. However upon mGlu1/5 activation 
there was a disproportionate level of synaptic depression likely mediated by the 
excessive removal of AMPA receptors from the postsynaptic surface. In addition, 
our findings suggest that ERK and mTOR signalling may have dual functionality at 
the synapse mediating translation rates as well as AMPA receptor removal.  
 
To elucidate the exact mechanisms underlying excessive translational rates and 
AMPA receptor endocytosis in the hippocampus of Syngap heterozygous mutants, 
the activation states of a greater number of ERK1/2 and PI3K substrates need to be 
quantified under steady-state conditions, which was beyond the scope of this thesis. 
Furthermore, although in this study there were no detectable differences in 
expression levels of a subset of “LTD proteins”, this needs to be re-examined in 
hippocampal slices that have undergone the same experimental conditions which 
revealed the electrophysiological and biochemical phenotypes associated with 
Syngap1 haploinsufficiency.  
 
Basal protein synthesis rates: a potential biomarker for intellectual disability 
This thesis has also shown that increased protein synthesis rates are consistently 
reproducible in vitro in Syngap heterozygotes and Fmr1 KO mice and this phenotype 
also translates to the rat model of FXS.  Furthermore in vivo measurements have 
revealed that there is a global increase in protein synthesis in the Fmr1 KO brain 
(Qin et al. 2005a). This raises the intriguing possibility that measurements of cerebral 
protein synthesis in human patients could be used as a reliable biomarker for the 
disease (Bishu et al. 2009).  
 
This is of particular importance as certain genetic causes of ID share striking similar 
behavioural manifestations yet have opposing biochemical and cellular phenotypes 
(e.g. Fmr1 KO versus TSC heterozygotes; Auerbach et al. 2011). These findings 
have emphasized the need for optimal levels of synaptic protein synthesis. 
Furthermore, depending on where the mutation lies on the pathophysiological axis of 
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ID will determine treatment outcome i.e. PAM of mGlu5/mTOR inhibitors or NAM 
of mGlu5/Ras-ERK1/2 inhibitors. For example, therapeutic strategies that are 
beneficial for FXS could potentially exacerbate symptoms in the TSC heterozygous 
mutants and vice versa because protein synthesis rates lie on opposite ends of the 
spectrum. Thus it is important to establish how ID-related mutations affects synaptic 
plasticity and protein synthesis in order to establish the most effective therapeutic 
intervention i.e. PAM or NAM of mGlu5 (Auerbach et al. 2011). However 




Therapeutic targets in the mouse model of Syngap haploinsufficiency 
The identification of cellular processes that are dysfunctional in the Syngap 
heterozygous brain, which can be partially/fully restored in vitro following 
phenotypic onset in young adult mice have elucidated potential therapeutic targets 
for the treatment of Syngap1 haploinsufficiency. These targets include mGlu5, Ras, 
ERK1/2 and mTOR. Downregulation of mGlu5, Ras and ERK1/2 signalling rescued 
elevated protein synthesis rates in the hippocampus of Syngap heterozygotes, whilst 
enhanced and protein synthesis independent mGluR-dependent LTD was restored by 
an inhibitor mTOR. It appears that ERK1/2 also plays an important role in the 
expression and maintenance of mGluR-dependent LTD at CA1 synapses. However 
in order to determine whether it can restore mGluR-dependent LTD to WT levels 
perhaps a more subtle reduction in ERK1/2 signalling is required, which might be 
achieved by using an inhibitor of Ras, such as lovastatin.  
 
It will be interesting to see whether the chronic application of these compounds in 
vivo correct similar phenotypic manifestations. NAMs of mGlu5 receptors, lovastatin 
and rapamycin can be administered early on in developmental through subcutaneous 
injections (Michalon et al. 2012). In addition lovastatin can be administered orally, 
post-weaning, through specially formulated rodent chow (Osterweil et al. 2010). It 
will also be important to establish whether the pharmacological rescue of molecular 
and cellular deficits in hippocampus of Syngap heterozygous mice extends to 
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correcting impairments in hippocampal-dependent learning and memory tasks, such 
as water maze, radial arm maze and elevated T-maze. This will clarify whether the 
hyperactivity of Ras-mediated signalling is the root cause of the behavioural 
abnormalities associated with Syngap1 haploinsufficiency. Furthermore it will 
determine whether the pharmacological reduction of Ras signalling can restore 
cognitive function in the mouse model of Syngap1 haploinsufficiency.  
 
Promising findings from studies in the NF1 heterozygous mouse have revealed that 
lovastatin treatment was successful at rescuing impairments in LTP and spatial 
learning as well as attention deficits (Li et al. 2005). Furthermore administration of 
lovastatin to NF1 patients rescued similar abnormalities (Mainberger et al. 2013). In 
Fmr1 KO mice, both oral and acute injection of lovastatin has been shown to restore 
enhanced mGluR-dependent LTD, elevated basal protein synthesis rates and 
epileptogenesis in vitro and in vivo (Osterweil et al. 2013). Moreover an open-label 
trial in FXS patients revealed that the compound was well tolerated and had minimal 
side effects with patients showing a significant improvement in general ID 
behaviours and those specifically associated with FXS (Caku et al. 2014). As Syngap 
heterozygous mice closely phenocopy both Fmr1 KOs and NF1 heterozygotes, it is 
tempting to speculate that lovastatin may also successively treat similar phenotypes 
reported in Syngap heterozygous mice and patients with SYNGAP1 mutations. This 
compound is already approved for use in children to treat hypercholesterolemia and 




Genetic Rescue of Syngap haploinsufficiency  
Recently, another novel approach to rescuing the pathology associated with Syngap1 
has been proposed. This involves increasing SynGAP expression during the 
developmental period of synaptogenesis by targeting transcription factors that 
regulate the transcription of SynGAP mRNA at excitatory synapses (Aceti et al. 
2014). One potential target is the myocyte enhancer factor 2 (MEF2) family of 
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transcription factors. These transcription factors are highly abundant in the brain 
where they regulate gene transcription in an activity dependent manner.  
 
Activation of MEF2 family members, in response to neuronal depolarisation or 
synaptic activity, leads to the transcription of MEF2 target genes that appear to 
restrict the number of excitatory synapses during development (Flavell et al. 2006; 
Barbosa et al. 2008; Pfeiffer et al. 2010; Tsai et al. 2012). Importantly recent studies 
suggest that MEF2 induced gene transcription and synapse elimination may be 
critical for learning and memory behaviours (Barbosa et al. 2008). Several MEF2-
generated transcripts have been identified and include Arc, PCDH10 (photocadherin 
10), Ube3A (E3 ubiquitin-protein ligase) and Syngap (Tsai et al. 2012; Flavell et al. 
2006; Flavell et al. 2008). Thus, their aim is to determine whether there are any 
pharmacological agents that will activate MEF2-dependent transcription during early 
development in order the increase SynGAP expression at excitatory synapses in the 
Syngap heterozygous mice in the hope of restoring cognitive function. 
 
Previous attempts at genetic reversal of Syngap1 haploinsufficiency have identified a 
critical period in which Syngap must be reintroduced in order to successfully restore 
behavioural phenotypes (Clement et al. 2012; Ozkan et al. 2014; Aceti et al. 2014). 
In these studies they observed that the efficacy of postnatal rescue decreased by P21, 
whilst no improvement was observed in adulthood. Thus, at later stages of 
development perhaps a pharmacological rescue will be a crucial therapeutic strategy 
to restore synaptic dysfunction.  
Pharmacological rescue of epileptogenesis in the mouse model of Syngap 
haploinsufficiency 
From the list of therapeutic targets identified in this study, it is now important to 
establish whether they are effective at correcting other phenotypes associated with 
Syngap1 haploinsufficiency. Of particular interest to our laboratory is how 
SYNGAP1/Syngap1 mutations confer an increased susceptibility to epileptogenesis in 
both human patients and the mouse model of this disorder. Human patients appear 
particularly vulnerable to epileptic episodes that begin early on in childhood (Berryer 
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et al. 2012). It is reported that these patients have abnormal EEG patterns that reflect 
the presence of generalised seizures, which can be recapitulated in rodent models in 
vivo by exposure to high intensity auditory stimuli. Here it has been observed that 
Syngap heterozygous mice have a lower induction threshold for chemically-induced 
and audiogenic seizures (Guo et al. 2009; Clement et al. 2012).  
 
Previous studies has shown that a lasting consequence of mGlu5- and ERK1/2- 
mediated protein synthesis is the generation of epileptiform activity in CA3 of the 
hippocampus (Zhao et al. 2004). Fmr1 KO mice are also sensitive to epileptogenesis 
and it has been shown that lovastatin prevents the emergence of epileptiform activity 
in vitro and reduces susceptibility to AGS in vivo (Osterweil et al. 2013). To assess 
generalized epilepsy in our mouse model of SYNGAP1 haploinsufficiency, AGS 
equipment was set-up according to Osterweil et al. (2010). Based on existing data 
that Syngap heterozygous mice exhibit an increased susceptibility to AGS seizures 
and from our current findings that mGlu5-Ras-ERK signalling plays an important 
role in the pathogenesis of Syngap1 haploinsufficiency, we wanted to determine 
whether reducing Ras-ERK1/2 mediated signalling through oral administration of 
lovastatin could prevent the emergence of epileptic seizures (Guo et al. 2009; 
Clement et al. 2012). Unfortunately due to problems with animal breeding we were 
unable to demonstrate a pharmacological rescue in vivo. However experimental 
conditions were optimised using a small cohort of Syngap heterozygous and WT 
mice. Thus, it will soon be determined whether mGlu5-Ras signalling is also the 
predominant pathological mechanism underlying the generalised epilepsy associated 
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